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Abstract 
Exposure of murine skin to carcinogens such as 7,12- 
dimethylbenz[a]anthracene (DMBA) or ultraviolet light B (UVB) irradiation 
depletes the epidermal Langerhans cells (LC) and alters the local 
environment such that antigen applied through the treated skin causes the 
development of antigen specific immunosuppression. This ability to induce 
suppression was used as a strategy to downregulate an established immune 
response in mice sensitised to a contact sensitiser or mice with a utoimmune 
disease. 
Mice immune to picryl chloride or 2,4,6-trinitrochlorobenzene (TNCB) were 
treated with either DMBA or UVB irradiation which was then followed by 
TNCB through the treated skin. The DMBA followed by TNCB treatment 
downregulated both contact hypersensitivity (CHS) and antibody production 
in an antigen specific manner, whereas UVB followed by TNCB treatment 
could only downregulate the CHS response. When spleen cells were 
transferred from TNCB tolerant mice (i.e. naive mice treated with DMBA 
followed by TNCB) to TNCB-immune mice, both an established CHS and an 
established antibody response were downregulated in an antigen specific 
manner. Although there was significant downregulation, the reduction was 
not complete as it did not reach the background level. 
The ability to downregulate an established immune response provided an 
opportunity to treat autoimmune disease. A suitable model was 
experimental autoimmune gastritis (AIG) which develops following 
thymectomy 3 days after birth (3dnTx). Prior to evaluating these mice it was 
necessary to determine their immune function and to confirm that they 
could also develop antigen specific suppression. The 3dnTx mice had a 
reduced number of CD4+ and CD8+ T cells, a reduced lymphocyte 
proliferative response to PHA but a normal contact sensitivity response to 
TNCB. After treatment of the skin with DMBA these mice failed to develop 
contact sensitivity to TNCB. Adoptive transfer of splenocytes from these 
mice to naive mice transferred antigen-specific suppression, irrespective of 
whether the 3dnTx mice had developed autoimmune gastritis. Despite 
thymectomy the capacity of BALB/c mice to generate antigen-specific 
peripheral tolerance to TNCB was retained. These results suggest that 
precursor T cells which mediate suppression to antigens such as TNCB are 
present in 3dnTx mice and that these cells are likely to have developed in 
the thymus and exported to the periphery before 3 days after birth. 
When 3dnTx mice with established autoimmune gastritis were treated with 
DMBA, followed by the proton pump autoantigen or its epitope a reduced 
disease severity was observed but DMBA alone caused similar effects. By 
replacing DMBA with TNCB, which could also deplete LC from the 
epidermis, and applying autoantigens through the TNCB treated skin failed 
to induce antigen specific suppression to AIG and consequently established 
disease was not downregulated. At the preventative phase the results were 
more encouraging. When 3dnTx mice were treated on day 4 following birth 
with a combination of TNCB and the autoantigen peptide, peptide 19, none 
of these mice developed disease. 
The key findings in this thesis were that the application of a contact 
sensitiser through skin depleted of normal LC can downregulate an 
established CHS response. When this approach was applied to an 
autoimmune disease, the application of autoantigen through skin depleted 
of LC did not reduce an established autoimmunity but application of 
autoantigen through neonatal skin was completely sufficient in preventing 
autoimmune gastritis development. Modified LC may therefore provide a 
basis for a potential vaccine against autoimmune disease. 
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Foreword 
Langerhans cells reside in the skin and belong to a population of 
professional antigen-presenting cells known as dendritic cells. These cells 
are crucial to the immune system as the initiation and direction of an 
immune response relies on the interaction of antigen-presenting cells with 
naive T cells. Under most circumstances a response is generated that results 
in immunity and elimination of the foreign antigen. However, when skin is 
treated with chemical or physical agents the Langerhans cells in the skin are 
depleted and the morphology of residual cells is altered in such a way that 
when antigen is applied through the treated skin an immunosuppressive 
response results. This ability of such a modified skin environment to induce 
suppressive immunity offers the opportunity to target disease conditions 
where the immune response can cause tissue damage eg. autoimmune 
disease. 
The initial experiments in this thesis evaluated the ability of a modified skin 
environment to downregulate an established disease. For this aspect of the 
thesis the ability to downregulate an established contact sensitivity response 
was evaluated. Mice were made immune to TNCB and these TNCB-
immune mice were then treated with DMBA or UVB irradiation which was 
then followed by TNCB. The results from these experiments would 
determine if established immunity could be manipulated. 
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Following these experiments, an autoimmune model of m u rine 
autoimmune gastritis was evaluated. As this model required neonatal mice 
to be thymectomised it was necessary to establish baseline immunological 
data and to determine if these thymectomised could also generate a 
population of regulatory cells, similar to the population of regulatory cells in 
normal mice, that could prevent induction of immune response. 
The final aspect of this thesis was to utilise the neonatal thymectomy model 
of autoimmune gastritis and to treat these mice by applying autoantigen 
through skin, which contained a population of modified Langerhans cells. 
These experiments were designed to determine if immunisation of 
autoantigen through a modified Langerhans cell environment could 
provide a potential strategy to treat autoimmune disease at either the 
prevention or treatment levels. 
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Chapter One 
Literature Review 
Introduction 
The skin acts as a primary barrier against potentially harmful insults 
suffered by animals, but the overall structure and function of the skin is far 
more complicated than that of a mere physical barrier. In addition to its 
physical aspect, the skin also produces various substances and chemical 
components as well as containing different cell populations that react 
against stimulation by environmental agents. Of these environmental 
agents, chemical carcinogens and ultraviolet light are of particular interest as 
these two agents are able to induce a level of immune tolerance which may 
provide a potential strategy to regulate deleterious immune responses, 
including autoimmune disease. The following overview will examine the 
concept of the skin as an immune system and evaluate tolerance and 
autoimmune diseases with potential approaches for the treatment of 
autoimmune disease. 
1.1 Skin immune system 
The concept that the skin is an immune system is now well accepted. 
This is because the skin contains immune and non-immune cells which 
form an efficient network in response to a variety of environmental 
encounters. The term skin immune system (SIS) was first coined by Bos in 
1986 and is now in widespread use, providing an accurate description of the 
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role of this large and major organ. The SIS is a dynamic structure and can be 
subdivided into cellular and humoral components. These include resident, 
recruited, and recirculating cell populations (Bos, 1997), the most important 
of these are the Langerhans cells. Other cells of SIS are keratinocytes, 
macrophages, and T cells, including af3 T cells as well as 7.5 T cells which are 
particularly unique to murine strains. Interaction of these immune cells is 
also vital for the effective function of SIS. Those cells which contribute to 
immunological events will be discussed here. 
1.1.1 Langerhans cells 
1.1.1.1 Background 
The most remarkable of the skin immune cells are the Langerhans 
cells (LC) which are bone marrow-derived dendritic cells (Tamaki et al., 
1980) featuring unique intracellular organelles, Birbeck Granules (BG) 
(Birbeck et al., 1961). They also express the distinctive cell markers of Cluster 
of Differentiation (CD) la (Murphy et al., 1981; Moulon et al., 1991) and CD1c 
(Schmitt et al., 1986) in humans. CD1a and Cdlc are not identified in murine 
skin, however, LC also express various other important cell markers 
including ATPase, CD45, the CD11 family, the ICAM family and the B7 
molecules. Over 40 different cell markers have been found on normal or 
treated forms of LC (Teunissen et al., 1997) as listed in Table 1.1. With the 
exception of the Birbeck Granules there is no phenotypic marker that 
uniquely identifies LC. The expression of cell markers depends on where 
and, in what conditions, LC reside. 
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CD35 
CD21 
CD11B 
CD11c 
CD18 
++ CD11a 
CD58 
CD54 
CD102 
CD50 
CD80 
CD86 
CD49a 
CD49b 
CD49c 
-(+)c CD49d 
CD49e 
CD49f 
CD29 b 
CR1 
CD2 
CR3; C3biR 
gp150/95 
b chain of CD 11a,b,c 
LFA-1 
LFA-3 
ICAM-1 
ICAM-2 
ICAM-3 
B7-1 
B7-2 
VLA-1 
VLA-2 
VLA-3 
VLA-4 
VLA-5 
VLA-6 
chain of VLA antigens 
E-cadherin 
CD15 
HECA-452 
sialy-Lewisx 
-  
-  
+ 
Marker 
LC-specific 
"Lag" antigen 
Presence 	 Marker 	Presence 
Receptors & Adhesion Molecules 
FcyRI 
MHC molecules 	 FcyRII 
Class I 	HLA-ABC 	 FcyRIII 
b2-microglobulin 	 FcERI 
Class II 	HLA-DR 	 FcERI I 
Class II 	HLA-DP 
Class II 	HLA-DQ 
CD 74 	invariant chain 
RFD1 DQ-like 
T cell makers 
CD1a 
CD1b 
CD1c 
CD2 
CD3 
CD4 
CD5 
CD7 
CD8 
abT cell receptor 
rd T cell receptor 
B cell markers 
CD10 
CD19 
CD20 
CD22 
CD24 
CD40 +d 
Monocyte/macrophage markers 
CD15 	LeuM1 	-(+)e 
LeuM2 
CD14 
	
LEUM3 	-/+ 
CD33 
CD68 	 -(+)F 
OKM5 
+b 	 IL-2R CD25 
CD64 
CD32 
CD16 
CD23 
eBP 
other 
S100 
CD45 
CD45RA 
CD45RB 
CD45R0 
CD69 
CD83 
Markers 
pan-leukocyte 
Table 1.1 	LC makers. (From Marcel et al., 1997) 
The most significant cell marker expressed by LC is the high level of major 
histocompatibility complex (MHC) class II. In normal epidermis, MHC II is 
only expressed by LC (Katz et al., 1985). It is through MHC II that LC provide 
a powerful stimulatory function to activate naive T cells (Green et al., 1980; 
Enk and Katz, 1995). Thus LC are now identified as major antigen-presenting 
cells (APCs) (Kapsenberg et al., 1995). As such their in vivo role includes the 
characteristic skin reaction of a contact hypersensitivity (CHS), and type IV 
delayed hypersensitivity (DTH) (Teunissen et al., 1997). It also been suggested 
that LC are essential in the immunosurveillance against skin tumours 
(Halliday and Muller, 1984). In addition, LC have been implicated in the 
induction of tolerance (Halliday and Muller, 1986; Halliday and Muller, 
1987b; Cruz and Bergstresser, 1990; Simon et al., 1991). Understanding the 
role of LC is necessary to potentially manipulate the skin immune system. 
1.1.1.2 Role in CHS and DTH reactions 
Definitive evidence of LC as highly efficient antigen-presenting cells 
comes from studies of CHS reactions, particularly at the sensitisation stage. 
Contact hypersensitivity is a delayed type of hypersensitivity response 
specifically induced by a small antigen or hapten. When a hapten such as 
2,4,6-trinitrochlorobenzenesulfonic acid (TNCB) is applied to the skin, it 
binds to a carrier protein in the epidermis . This protein-hapten complex is 
processed by LC which migrate to the draining lymph node where the 
processed antigen in association with MHC-II is presented to naive T cells, 
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which are then activated. In addition, the MHC II of LC can also be directly 
bound by a hapten (Silberberg et al., 1976; Shelley and Juhlin, 1977). 
A successful CHS response depends on LC density. The application of a 
hapten through normal dorsal or ventral skin, which has a high LC density, 
induces a strong CHS response. However, when a hapten is applied, through 
a depleted LC density an effective CHS response is impaired. This is evident 
by studies of mice exposed to ultraviolet light B (UVB) or chemical 
carcinogens, both of which have the ability to deplete epidermal LC. The 
initial experiments were performed in 1976 by Silberberg and colleagues who 
showed that UVB irradiation depleted epidermal LC. When antigen was 
applied through this LC-depleted skin there was a failure to induce CHS 
response (Lynch et al., 1981; Gurish et al., 1983). This was further supported 
by Toews et al. (1980) who demonstrated that LC numbers in the epidermis 
were important in the induction of immune suppression using UV B 
radiation. Halliday and colleagues (1986) showed that chemical carcinogens 
could deplete LC and that this correlated with the failure to induce a CHS 
response when antigen was applied through this depleted skin. More 
recently it has been shown that contact antigens can deplete LC, and when 
another antigen was applied through this skin, CHS failed to generate 
(Woods et al., 1996). This later study also demonstrated that the induction of 
immune suppression is associated with the extent of LC depletion in the 
skin, higher doses of TNCB reduced LC numbers significantly. In addition, 
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mice tail skin which normally has a low LC density fails to generate a CHS 
response (Streilein et al., 1983). 
As previously mentioned, LC migrate to the draining lymph node. It is 
within the lymph node following exposure to a hapten, such as fluorescein 5 
isothiocyanate (FITC), where these antigen-bearing LC present antigens to 
specific CD4+ T cells and trigger a primary immune response (Hill et al., 
1993). The trigger for this migration occurs after exposure to antigen, 
although there is a low background level of migration occurring 
continuously (Dandie et al., 1992). The mechanisms involved in this 
migration are unclear, although some aspects have been partly revealed. 
When considering the mechanisms involved in migration it is necessary to 
conceptualize the structure of the skin and the location of the LC within this 
structure. 
The LC are located in the epidermis which is separated by a basement 
membrane. This structure consists of a variety of extracellular matrices, e.g. 
type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin 
(Laurie et al., 1982). The travelling LC bearing the antigen must pass through 
the basement membrane to reach lymphatic vessels. A study by Le Varlet et 
al. (1991) suggested that the expression of integrins of the p 1 subfamily on 
LC may be important in this process. Production of cytokines by 
keratinocytes and LC upon hapten application also increases the mobility of 
LC (Enk and Katz, 1992). In fact two cytokines, IL-113 and TNF-a, have been 
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demonstrated to stimulate LC migration (Enk et al., 1993; Cumberbatch and 
Kimber, 1992). In addition, in vivo hapten application such as TNCB or FITC 
enhanced LC migration, however, sodium lauryl sulfate , which is an 
inhibitor of the extracellular matrix reduced the LC migration. Thus, 
haptens play an important role in LC mobility (Kobayashi et al., 1994). 
Another study showed that application of a hapten to the skin would 
stimulate the LC to produce the matrix metalloproteinases which are 
important factors for degrading gelatin and collagen (Kobayashi, 1997). The 
activation of protein kinase C (PKC) also has been identified as critical in the 
migration of LC to the draining lymph as the inhibition of PKC activity can 
stop the LC migration (Halliday and Lucas, 1993). Thus, it is through this 
complex series of events that LC migrate and present antigen after 
encountering a contact sensitiser. 
The response of CHS to LC is antigen specific. When hapten-bearing LC 
migrate to a draining lymph node, they activate naive T cells. After this 
event the specific T cells expand and memory T cells are generated. The 
activated T cells produce interferon-gamma (IFN-y) and interferon-alpha 
(IFN-a), and travel back to the skin to induce a CHS immune response 
(Luger et al., 1997). 
1.1.1.3 Role in skin immunosurveillance 
The concept of immunosurveillance was first proposed by Macfarlane 
Burnet (Burnet, 1970). He postulated that immune cells have the ability to 
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survey the body for abnormal cells (eg. damaged or cancer cells) and to 
eliminate them. The relevance of this concept has been supported by the 
increased risk of skin cancers in patients using immunosuppressive drugs 
(Pritzker et al., 1970). It has been reported by Marshall (1973)who showed that 
transplant patients have an increased incidence of skin tumors (from 8% to 
17%) over a 4 years period. Further study by Shell and co-workers found that 
in 10 years time, transplant patients had a 57% higher risk of skin tumours 
than normal individuals (Shell et al., 1979). Those skin tumours found in 
patients treated with immunosuppressive drugs include squamous cell 
carcinoma, basal cell carcinoma, Kaposi's sarcoma, malignant melanoma, 
and Bowen's disease (Penn, 1980; Penn, 1994). 
Skin tumors also increased in patients with psoriasis, which is likely to be a 
consequence of their requirement for ultraviolet light treatment. This is 
because the ultraviolet light treatment can disturb the normal skin function. 
Patients with AIDS disease also have an increased risk of skin tumors as a 
result of reduced T cell function. With the AIDS viruses destroying CD4+ T 
cells there is reduced immunosurveillance and the risk of aberrant cells 
escaping detection is increased, hence the increased incidence of Kaposi's 
sarcoma (Dalgleish et al., 1984; Santucci et al., 1988; Chachoua et al., 1989). 
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At the experimental level, skin tumors develop following carcinogens 
treatment. This is due to the carcinogens altering the skin immune 
function, especially the LC in the skin, thus allowing abnormal tumour cells 
to occur (Qu et al., 1997). 
1.1.1.4 Role in tolerance induction 
It has been well documented that the induction of immunological 
tolerance can be achieved by application of a hapten through LC-depleted 
skin. Methods used to deplete LC in the skin have included chemical 
carcinogens (Muller et al., 1985), UVB irradiation (Toews et al., 1980), and 
tape stripping (Streilein et al., 1982). The tolerance that develops in this 
situation is antigen specific and appears to be related to the presence of 
suppressor cells (Muller et al., 1992). On the other hand, upregulation of LC 
numbers increases the ability of LC to activate T-cells (Meunier et al., 1994). 
The reduction of LC density is not the only explanation for the induction of 
tolerance, as the function of the residual cells must be activated to induce 
immunosuppression. This has been demonstrated by Ragg et al. (1995) in a 
sheep model where afferent LC (ie. veiled cells) were collected as they 
migrated away from carcinogen treated skin. Following application of 
DMBA the LC displayed a reduced ability to process and present soluble 
antigen in an in vitro proliferation assay. 
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Tolerance induced by LC depletion was also found after UVB irradiation. 
Epidermal cells from UVB irradiated skin depleted of LC from C57BL/6 mice 
incubated with a hapten suppressed the induction of CHS response (Dai and 
Streilein, 1995). Study of human epidermal LC found that LC antigen-
presenting function to T cells was impaired by UVB irradiation in the mixed 
epidermal cell-lymphocyte reaction experiment (Rattis et al., 1995). 
Consequently, when skin is depleted of LC by exposure to chemical 
carcinogens or UVB irradiation, one explanation for the failure to induce an 
immune response is that the dendritic cells are functionally impaired. 
1.1.2 Other skin dendritic cells 
The epidermis of the skin contains another population of dendritic 
cells termed indeterminate dendritic cells (IDC) which express CD1 and 
MHC II molecules, but lack Birbeck Granules in humans (Rowden et al., 
1979). Since IDC can only be distinguished from LC by the absence of BG 
they may be the precursor of LC (Breathnach, 1975). Indeed, a study by Hsiao 
(1989) of IDC in rats using immunoelectron microscopic showed that IDC 
belong to the lineage of LC. Recently, it has been suggested that IDC are true 
LC (Teunissen et al., 1997). 
The dermis also contains different populations of dendritic cells. These 
include LC that migrate into and out of the epidermis, and skin dermal 
dendritic cells, termed dermal dendrocytes (DD). The LC population in the 
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dermis is the precursor of epidermal LC and migrating LC, which carry 
antigens from the epidermis to the lymphoid organs. The dermal 
dendrocytes are the residential dendritic cells of the dermis. Although they 
have a dendritic shape the function of DD is largely different to that of the 
LC of epidermis. The phenotype of DD may closely resemble macrophages as 
many DDs express CD45, HLA-DR, Factor Ma, CD11b and CD14 (Cerio et al., 
1989; Weber Matthiesen and Sterry, 1990; Rowden, 1997). Unlike LC, with a 
main function of antigen presentation, the main functions of DD are 
involved in inflammation, wound healing, and immunity. The immune 
functions relating to DD include the production of IL-2, IL-8, and TNF-a 
which has been shown in psoriasis in humans (Nickoloff et al., 1991; Nestle 
et al., 1994). However, DD have also been hypothesised to be involved in 
antigen presentation (Lappin et al., 1996). 
1.1.3 Keratinocytes 
Keratinocytes are the major cell type and structure of the epidermis. 
They form the physical barrier in animals. However there is increasing 
evidence that keratinocytes are involved in skin immunity as they are able 
to express MI-IC II molecules, accessory molecules, produce various 
cytokines and play a role in the induction of tolerance (Chu and Morris, 
1997). 
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1.1.3.1 MHC II expression 
Keratinocytes have the ability to express MHC II in a variety of clinical 
conditions including graft vs. host disease (Lampert et al., 1981), psoriasis 
(Morhenn et al., 1982) and contact dermatitis (MacKie and Turbitt, 1983). All 
of these conditions are characterised by T cell infiltration, thus implicating 
keratinocytes in potential T cell activation. It has been determined that the T 
cell cytokine INF-7 is capable of inducing MHC ll expression of keratinocyte 
in vitro (Basham et al., 1985; Nickoloff et al., 1985), and in vivo (Aiba et al., 
1984). Consequently a model can be proposed whereby an inflammatory 
response is generated following exposure to antigens when the T cell in the 
infiltrate would modulate IFN-y, thereby up-regulating MHC II in 
keratinocytes which in turn can contribute to the maintenance of the 
immune response. It is not known whether keratinocytes can induce a 
primary immune response rather than maintain an established response. In 
fact there is evidence that MHC II bearing keratinocyte can anergise naive T 
cells (Gaspari et al., 1988), possibly due to a lack of adequate costimulatory 
signaling, although in some instances accessory molecules have been 
expressed. In mice, application of the contact sensitiser TNCB induces Ia 
expression of keratinocyte within 3 days (Germain, 1981). 
1.1.3.2 Accessory moleculars expression 
Keratinocytes can express both adhesion and costimulatory molecules. 
They express intercellular adhesion molecule-1 (ICAM-1/CD54) which is 
vital for the initiation and evolution of localized inflammatory processes in 
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the skin and serve as a specific ligand for lymphocyte function-associated 
antigen-1 (LFA-1/CD18), a cell-surface protein expressed on all leukocytes 
(Wright Caughman et al., 1992). Another important accessory molecule 
expressed by keratinocyte is LFA-3 (CD58) which is the ligand/receptor pair 
of LFA-3 (CD58)/LFA-2 (CD2) and is important for T cell activation (Chu and 
Morris, 1997). 
With regard to costimulatory molecules, keratinocytes express BB1, a 
member of the B7 family, B7-1, B7-2. BB1 serves as the ligand for CD28 (Chu 
et al., 1987). B7-1 and B7-2 are critical for T cell activation as the blockage of 
these two molecules by antibodies results in T cell anergy. However, the 
function of BB1 expressed on keratinocytes is not clear. BB1/CD28 blockage 
by monoclonal antibody did not have significant effect on keratinocyte 
induced T cell activation (Nickoloff and Turka, 1994). 
1.1.3.3 Cytokine production by keratinocytes 
Within the skin immune system the most important function of 
keratinocyte is to produce a vast array of cytokines with inflammatory and 
immunological activities. The effective nature of the cytokine profile can be 
seen in Table 1.2. It should be noted that resting keratinocytes produce a 
number of cytokines but following activation this range is dramatically 
expanded. It should also be noted that the activation of these cytokines 
encompasses a broad range of immunological and pathological activities. 
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Resting keratinocytes 	IL-1a, IL-6, IL-11, IL-15 
TNFa 
GM-CSF, G-CSF 
TGFP 
Activated keratinocytes 
(UV, endotoxin, phorbol ester, IL-a/P, IL-6, IL-7, IL-10, IL-11, IL-12, 
cytokines) 	 IL-13, IL-15, IL-1RA, 
TNF a 
IL-8, Gro-a,P,y, ENA-78, IP-10, 
MIP-2, MCP-1, RANTES 
IL-3, G-CSF, M-CSF, GM-CSF, SCF 
IFNa, IFNP 
TGFa, TGFP, PDGF, bFGF 
Note: IL, interleukin; TNF, Tumor necrosis factor; GM-CSF, granulocyte- 
macrophage colony-stimulating factor; G-CSF, granulocyte colony 
stimulating factor; transforming growth factor; Gro, growth regulated 
oncogene; ENA-78, epthelial neutrophil-activating protein-78; IF-b, 'y -
interferon-inducible protein-10; MIP- 2, macrophage inflammatory protein-2; 
MCP-1, microbial cationic protein-1; RANTES, regulated upon activation, 
normal T expressed, and presumably secreted; M-CSF, macrophage colony-
stimulating factor; SCF, stem cell factor; IFN, interferon; PDGF, platelet-
derived growth factor; bFGF, basic fibroblast growth factor. 
Table. 1.2 	Cytokine production by keratinocytes 
(From Thomas et al., 1997) 
Amongst these cytokines, IL-1 is critical in the activation of T cells. 
Keratinocytes secrete a low level of IL-1 in normal conditions but are 
upregulated when activated. TNFa is another important cytokine secreted 
by keratinocytes which increases following activation. This cytokine is 
involved in the inflammatory response and increases IL-1a production. 
Other important cytokine produced by keratinocytes involved in T cell 
activation include IL-12 and IL-15. IL-12 plays an important role in the 
induction phase of a CHS response as the topical application of allergens to 
skin in humans results in the induction of IL-12 within the epidermis 
(Muller et al., 1995). It also regulates TGF-13 production (Marth et al., 1997). 
IL-15 has similar biological effects to IL-12, as IL-15 can enhance the 
proliferation and activation of T cells (Luger et al., 1997). 
Other important cytokines produced by keratinocytes include IL-6, M-7 and 
IL-10. IL-6 is an important mediator of inflammation as the serum levels of 
IL-6 are elevated in patients with inflammatory or autoimmune diseases 
(Akira et al., 1993). Keratinocyte derived IL-7 is a growth factor for the 
epidemal dendritic T cells as the cultured dendritic epidermal T cell (DETC) 
line, 7-17, and freshly isolated DETC exhibited dose- and time-dependent 
proliferative responses to the IL-7 receptor and these responses were blocked 
completely by anti-IL-7 antibodies (Matsue et al., 1993). With keratinocytes 
irradiated by UVB the M-7 production is inhibited (Takashima, 1995) also 
implicating IL-7 in UVB-induced immune suppression. IL-10 is important 
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in the regulation of immunosuppression and will be discussed in the next 
section. 
1.1.3.4 Induction of immune tolerance 
Antigen presentation by professional APC results in a positive 
immune response. However, antigen presented by non-APC such as 
keratinocytes which lack costimulator factors can result in a state of immune 
suppression (Bal et al., 1990). Immunosuppression induced by these 
keratinocytes is antigen specific. It has been shown in vitro that hapten-
modified Ia+ keratinocytes specifically downregulate a contact allergen 
induced immune response to a Th1 cell clone (Gaspari et al., 1988); in vivo 
hapten-modified la+ keratinocytes also showed specific suppressive ability 
for a CHS response (Gaspari and Katz, 1991). 
The ability of keratinocytes to induce immune suppression is related to 
suppressive cytokine production. IL-10 for example, a powerful 
immunosuppressive cytokine, is secreted by keratinocytes (Taga et al., 1993). 
Enk and colleagues (1994) documented that IL-10 is directly involved in the 
induction of hapten-specific tolerance. IL-10 is also directly involved in the 
downregulation of contact sensitivity (Ferguson et al., 1994; Niizeki and 
Streilein, 1997). Studies with IL-10 knockout mice demonstrated that 
without IL-10 these mice mounted an exaggerated contact sensitivity 
response to hapten application, and also an increased magnitude and 
duration of a contact sensitivity response when compared with wild type 
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mice (Berg et al., 1995). Keratinocyte derived IL-10 also mediate systemic 
immunosuppressive effects from animals exposed to UVB irradiation. 
Ullrich and associates showed that UVB exposed PAM 212 keratinocytes 
which were neutralized with anti-IL-10 prior to injection into mice 
abrogated the suppressive effects of mediators on induction of delayed type 
hypersensitivity to subcutaneouly injected protein antigens which occurred 
with the PAM 212 keratinocytes (Ullrich, 1995a). This was also demonstrated 
when the mice were injected with antibodies to IL-10 and exposed to UVB 
irradiation (Ullrich, 1995b). Consequently the suppressive effect appear to be 
mediated by IL-10. 
In skin, the production of keratinocyte IL-10 is increased after haptenization 
of the cells and after UVB irradiation. IL-10 is the product of Th2 cells and is 
able to suppress proliferation of Th1 cells. In the situation of induction of 
immunosuppression after UVB irradiation, it has been postulated that 
keratinocyte derived IL-10 converts LC as inducer APCs of contact sensitivity 
to tolerogenic APCs (Enk and Katz, 1995). 
1.1.4 T Cells 
T lymphocytes express a13 or TS antigen receptors in humans and 
rodents. In the circulation the majority of T lymphocytes express oci3 antigen 
receptors. However, in the cutaneous epidermis T lymphocytes populations 
are different between humans and rodents. In humans, the epidermis 
17 
contains few ail T cells with a minor 78 T cell population. The function of 
these T cells is most likely to boost the immune response as most of the T 
cells are CD45R0+ memory population (Bos et al., 1993). Further studies 
from Davis et al. showed that these T cells are in an activated state as they 
express HLA-DR or CD25 molecules (Davis et al., 1988). 
On the other hand, the murine epidermis contains a unique T lymphocyte 
population referred to as dendritic epidermal T cells (DETCs). The c43 T cells 
of the epidermis participate in normal immune activation, while DETC are 
involved in a number of immune activities. 
DETC are dendritic cells but belong to the T cell population because they 
express Thy-1, and CD3 antigens. DETC are derived from bone marrow 
(Breathnach and Katz, 1984). Because of their location, it has been proposed 
that DETC are part of a first line of defense (Asarnow et al., 1988). Nixon 
Fulton et al. (Nixon Fulton et al., 1986) demonstrated that the proliferation 
ability of DETC increased when incubated with concanavalin A and IL-2. 
DETC can also be activated in vivo by contact allergens (Kaminski et al., 
1993a). DETC have the capacity to kill tumour cells when stimulated by IL-2 
(Okamoto et al., 1988; Kaminski et al., 1993b). Recently, Schuhmachers et al. 
(1995) suggested that the tumor killing ability of DETC may be mediated by 
2B4 antigen. 
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DETC may serve as a regulatory population of cells as they are able to induce 
hapten-specific tolerance in vivo when DETC incubated with hapten are 
injected into mice (Welsh and Kripke, 1990). The capacity to cause tolerance 
may be due to an ability to inhibit activated T cells to proliferate (Welsh et 
al., 1992) or to act as cytotoxic cells (Love Schimenti and Kripke, 1994). 
Studies by Cruz and co-workers demonstrated that DETC had an 
immunosuppressive function after low dose UVB irradiation (Cruz et al., 
1989). Intravenous injection of DETC derivatised with hapten can initiate 
down-regulation of the CHS response (Sullivan et al., 1986). 
1.1.5 Macrophages 
Skin macrophages are related to LC and both are bone marrow-
derived (Austyn, 1987). They can be found in various compartments of the 
skin but primarily in the superfical or papillary dermis (Weber Matthiesen 
and Sterry, 1990). The expression by macrophages of CD11b, CD14, and CD68 
distinguishes macrophages from LC. Although CD11b is also expressed on 
LC the level of CD11b is significantly lower than that of macrophages. 
The functions of dermal macrophages include anti-microbial defense in 
inflammation, contribution to repair in wound healing, antigen 
presentation, and immune suppression. Macrophages are phagocytes; they 
engulf microbial organisms and destroy them through oxidative and 
nonoxidative mechanisms. Macrophages participate in wound healing by 
producing growth factors for fibroblasts. Macrophages are also involved in 
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immune responses where they may act as the primary APC during 
induction of an immune response (Moller, 1978). Skin macrophages can 
downregulate or suppress an immune response. It has been shown by 
Cooper and associates that in human skin irradiated with ultraviolet light 
the numbers of CD36+ CD11b+ CD1" macrophage increase dramatically 
(Cooper et al., 1986; Meunier et al., 1995). Application of hapten through this 
macrophage enriched skin can lead to immune tolerance to the antigen 
(Hammerberg et al., 1994). UV-induced tolerance could be reversed by anti-
CD11b monoclonal antibody treatment, which further support the concept 
that macrophages are involved in UV-induced immune suppression 
(Hammerberg et al., 1996). 
1.1.6 Other skin immune cells 
The skin contains other cells with immunological functions. Mast 
cells mediate immediate hypersensitivity and have a role in delayed-type 
hypersensitivity immune responses. They release histamine and serotonin 
following crosslinking of their IgE receptors. Vascular endothelial cells can 
act as APCs to activate T lymphocytes via MHC II antigen on their surface. 
They also secrete immunological cytokines such as IL-1, TNF and IFNa/13 to 
increase the expression of adhesion molecules on epidermal cells (Pasyk et 
al., 1997). 
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Merkel cells are also involved in the regulation of the skin immune 
function. They secrete vasoactive intestinal polypeptides (Hartschuh et al., 
1983) and serotonin (Garcia Caballero et al., 1989) which are involved in 
inflammation. They also secrete calcitonin gene-related peptide (Alvarez et 
al., 1988) which has been shown to regulate LC (Hosoi et al., 1993) and 
macrophage function (Nong et al., 1989). 
1.1.7 Summary 
The skin contains a complete and complex immune system which is 
not only a barrier to microbial invaders but provides for a range of immune 
responses including responses involved in anti-tumour immunity, 
autoimmunity, and transplantation reactions. 
1.2 Tolerance 
Tolerance is a specific absence of an immune response to an antigen 
and is essential as animals tolerate their own antigens. This is critical for the 
animal's survival as failure of tolerance results in autoimmune disease. As 
the immune system must also eliminate potentially harmful foreign 
antigens, mechanisms must exist whereby these antigens are eliminated and 
self antigens remain unaltered. Tolerance therefore is a consequence of how 
the immune system discriminates between harmless 'self' antigen and 
harmful 'non-self' antigens. 
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Induction and maintainance of tolerance is one of central themes in 
immunology. The main targets for tolerance are T and B cells with several 
mechanisms suggested to induce tolerance in T and B cells which include 
clonal deletion, clonal anergy, and suppressor cells. 
1.2.1 Clonal deletion 
Clonal deletion is the elimination of self-reactive lymphocytes (T and 
B cells). Although the mechanism of clonal deletion involves many cells, 
discussion here is centred on T and B cells. 
1.2.1.1 T cell clonal deletion 
The primary place for T cell deletion is the thymus. In the thymus 
clonal deletion occurs in two waves, one of positive selection, the second 
negative selection. T cells that recognise self-MHC molecules are selected for 
positive selection whereas the T cells that fail to bind with self-MHC are 
clonally deleted. The second wave of clonal deletion occurs when T cells 
bind to dendritic cells or macrophages via self antigen. As these cells are 
potentially self reactive lymphocytes they are deleted. 
Kappler and associates used a monoclonal antibody against the product of 
V1317a (a variable region gene segment of the p chain of the T cell receptor) 
to follow the fate of T cells expressing this Vi317a (Kappler et al., 1987). They 
found that in mice which expressed the E molecule of the MHC class II, the 
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Vr317a bearing T cells were eliminated. In the thymus the first stage of 
immature T cells are CD4+8+ phenotypes and at this stage the thymus 
contains a proportion of VI317a bearing T cells. In a more mature stage the 
VI317a bearing T cells were depleted. This depletion of Vi317a T cells is 
complete as no VI:117a mRNA can be detected in the mature T cells. 
Cells involved in deleting T cells are probably antigen-presenting cells. 
Experiments using T cell receptor transgenic mice demonstrate that splenic 
antigen-presenting cells (SAPC) could induce deletion of CD4+8+ T cells 
when these SAPC are incubated with thymocyte suspensions from TCR 
transgenic mice (Swat et al., 1991). Thymic dendritic cells express MHC 
molecules. T cells that recognise the self-peptide/MHC complex with 
dendritic cells are deleted. Thus, tolerance could be maintained in T cells by 
clonal deletion. 
However, the deletion mechanism in the thymus does not eliminate all the 
harmful autoimmune reactive T cells. Many self peptides and MHC 
complexes are not generated or can not be seen by T cells in the thymus. 
Thus, T cell clones specific for such peptide/MHC complexes would not be 
deleted. These T cells can be activated if spleen cells from the animals are 
stimulated with synthetic peptides of this type (Schild et al., 1990). 
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1.2.1.2 B cell clonal deletion 
Clonal deletion also occurs with B cells. Studies using transgenic mice 
have shown that transgenic mice of M1-IC' background which expressed an 
IgM B cell receptor specific for MHC class I molecules K k and Dk, contained 
25-50% splenic B cells expressing this receptor (Nemazee and Burki, 1989). 
When crossed with MHC k mice all B cells expressing the IgM receptor 
disappeared. No transgenic receptor-bearing cells were detected in the spleen 
but a very low to undetectable amount was detected in the bone marrow. 
Thus B cell clonal deletion occurs in bone marrow. 
1.2.2 Clonal anergy 
Another mechanism that silences auto-reactive T and B lymphocytes 
is clonal anergy. As not all the self-reactive lymphocytes were eliminated 
from the primary lymphoid organs (ie. thymus, bone marrow), the escaped 
self-reactive lymphocytes must be suppressed in the periphery. This 
functional inactivation is termed clonal anergy. 
1.2.2.1 T cell anergy 
T cell anergy has been demonstrated in in vivo and in vitro models. 
In in vivo study Jacobsson and colleagues (Jacobsson et al., 1976) found an 
intravenous injection of Mtv-r spleen cells into MHC-compatible Mtv-T 
mice prevented a subsequent mixed lymphocyte response to these spleen 
cells. This study was further developed by Rammensee et al. (1989). They 
used an antibody to V136+, a T cell antigen that can interact with and be 
24 
stimulated by the Mtv-7 antigen, to follow the track of V06+ T cells after 
intravenously injection. They reported that CD4+ V136+ T cells survived, 
however, these T cells could not proliferate when stimulated with spleen 
cells expressing Mtv-7. These T cells also failed to make IL-2. Thus T cell 
anergy was induced in vivo. In the in vitro model, Lamb and co-workers 
(Lamb and Feldmann, 1984) found that a normal CD4+ T cell clone, when 
stimulated with high concentration of a peptide fragment from the 
influenza virus haemagglutination, for which it was specific, failed to 
respond to restimulation by that antigen in the presence of antigen-
presenting cells. The cells were alive but not functional. Those anergised T 
cells could be restimulated with the introdution of IL-2. Importantly, this 
reversal was achieved in all the anergic cells (Beverly et al., 1992). 
One of the mechanisms of anergy induction in T cells is the two signal 
model. Since a successful immune response require the peptide/MHC 
complex and a second signal such as CD28/B7 ligation, the absence of this 
second signal can lead to the T cell anergy. For example, cultures of T-cell 
clones in the presence of submitogenic doses of anti-CD3 without competent 
APC resulted in anergy, which could be prevented if anti-CD28 antibody was 
incorporated (Harding et al., 1992; Lenschow et al., 1996). In in vivo study, 
blockade of the B7-CD28 pathway has been demonstrated to result in long 
lasting tolerance to human xenoantigen in mice (Lenschow et al., 1992). 
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1.2.2.2 B cell anergy 
The induction of B cell anergy has been found in the two signal 
model. In B cell activation, two elements are required, the first is that the Ig 
receptor of the B cell must interact with the antigen. The second signal 
involves the peptide/MHC complex and CD40 /CD40 ligand. If B cells receive 
the first signal but not the second signal, the B cells are anergic. The reversal 
of B cell anergy can be achieved by lipopolysaccharides or strong T cell help. 
1.2.3 Suppressor T cells and self-tolerance 
Existence of suppressor T cells has been sought as a population of 
regulatory cells with an important role in fail-safe mechanisms to prevent 
an overeactive immune response and to contain self-reactive cells. Early 
evidence for the existance of suppressor T cells came from Gershon's study 
who showed that spleen cells can suppress the activation of normal T cells 
in an antigen specific manner (Gershon and kondo, 1971). In their study, 
immunological tolerance of sheep red blood cells could be transferred from 
one mouse to another. This was attributed to a subset of CD8+ T cells and was 
termed suppressor cells. One of the major limitations to the acceptance of 
suppressor T cells has been the inability to isolate and characterise these 
cells. This is due to the absence of reliable phenotypic markers of suppressor 
cells. Nonetheless, many experimental models have demonstrated the 
phenomena of suppressor T cells and indicated possible markers of these 
cells. 
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In humans, a subset of CD4+ T cells expressing glycoprotein 2H4, a member 
of the CD45 group of leukocyte common antigens, has been shown to induce 
suppressor cell activity in an in vitro study (Baadsgaard et al., 1987). These 
cells are CD4+CD45RA+ suppressor-inducer cells which have been shown to 
increase their numbers after UV irradiation, depending on the dose 
(Baadsgaard et al., 1987). These CD4+CD45RA+ suppressor cells have also been 
shown to have a reduced number in patients with SLE disease indicating 
CD4+CD45RA+ cells indeed play a role in the induction of 
immunosuppression (Morimoto et al., 1987). 
In mice, suppressor cells have been proposed as the IJ-restricted T cells. In 
this proposed system, suppressor cells are induced by various suppressive 
factors (Figure 1.1) . In this scheme, I-J+ antigen specific CD4+ or CD8+ cells 
contain a dominant cross-reactive idiotype. These cells, termed Ts1, produce 
the T suppressor cells factor TsFl. With the help of TsF1 and antigen 
stimulation, Ts2 cells are generated which are CDS' . I-J+ cells and produce 
TsF2. The interaction of primed antigen and TsF2 generate Ts3 cells which 
secrete nonspecific factors that are final mediators of suppression (Gershon 
et al., 1981). 
Elimination of functional T cells can also be achieved by veto cells. The T 
cell that recognises an antigen on the surface of the veto cell is rendered 
nonfunctional as a result of that interaction; the cell that becomes 
unresponsive determines the specificity of this type of unresponsiveness, 
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Antigen 
Thy 1+ 
Primed Antigen 
Suppression 
CD8 + 
I-J+ 
Figure 1.1 Interaction of proposed T suppressor cell subsets 
(Graph modified from Weiner et al., 1988) 
Ts F2 
and self is defined by antigens expressed on the veto cell surface (Fink et al., 
1988). 
Another demonstration of the existence of suppressor cells is that organ 
specific autoimmune disease can be induced in thymectomised mice (more 
detail in section 1.3.2). For example, autoimmune thyroiditis was found to 
occur without immunisation in thymectomised and X-ray irradiated rats 
(Volpe, 1994). However, reconstruction of these rats with lymph node cells 
will prevent the thyroiditis. 
1.3 Autoimmunity 
An intact immune system must tolerate self-antigens. When this fails 
autoimmunity results. In general, autoimmune disease can be defined as 
organ-specific eg. thyroiditis or non-organ specific eg. systemic lupus 
erythematosus. Although it is convenient to use such a classification, many 
autoimmune diseases appear to be both eg. multiple sclerosis. Another 
classification of autoimmune disease is either MHC class II associated or 
MHC class I associated autoimmune diseases (Sinha et al., 1990). 
It remains unclear how autoimmune diseases are initiated. However, 
studies from animals have revealed different mechanisms leading to the 
induction process. For example, certain strains of mice spontaneously 
develop autoimmune diseases, eg. non-obese diabetic mice (Gill and 
Haskins, 1993); antigen or chemical injection may induce autoimmune 
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diseases, eg. collagen-induced arthritis (Wilder, 1989) ; exposure to foreign 
antigens which are similar to self determinants eg. mycobacterial extract 
induced arthritis (Roitt et al., 1992) ; and 3 day neonatal thymectomy also 
result in autoimmune diseases, eg. autoimmune gastritis (Fukuma et al., 
1988). 
The study of animal models with autoimmune disease provide the 
opportunity to understand the autoimmune diseases. Here some important 
animal models will be discussed. 
1.3.1 Animal models of autoimmune diseases 
An important challenge for the study of autoimmune disease is to 
develop animal models that realistically reflect similar autoimmune 
diseases in humans. Several autoimmune diseases have been induced in 
animals similar to that of human autoimmune disease. Examples include: 
(1) Neonatal thymectomy causing autoimmune gastritis in BALB/c mice 
which is analogous to pernicious anaemia in humans (Toh et al., 1993). (2) 
Non-obese diabetic (NOD) mice or BB rats spontaneously develop diabetes 
with similar symptoms to insulin-dependent diabetes mellitus (Murase et 
al., 1990; Georgiou and Mandel, 1995). (3) Experimental autoimmune 
encephalomyelitis (EAE) can be induced following immunisation with 
myelin basic protein which produces a disease similar to multiple sclerosis 
(Swierkosz and Swanborg, 1977). (4) Collagen type II or mycobacterial extracts 
induce arthritis which is akin to rheumatoid arthritis (Stuart et al., 1984). (5) 
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New Zealand Black mice spontaneously develop systemic lupus 
erythematosus similar to SLE of humans (Howie and Helyer, 1968). (6) 
Nephritis in rats occurs following exposure to HgC12 in the drinking water 
and is analogous to glomerulonephritis in humans (Karp et al., 1991). Such 
models provide useful starting points to the mechanisms of autoimmune 
disease. 
1.3.2 Experimental autoimmune gastritis 
Autoimmune gastritis (AIG) can be induced in BALB/c mice by 
thymectomising these mice in the neonatal period (Nishizuka, 1982). The 
best time to induce autoimmune gastritis by thymectomy in mice is 2-4 days 
after birth. The disease can not be induced at day 0 or day 7 post birth 
(Taguchi et al., 1990). Thymectomising mice 3 days after birth is the most 
common method to induce autoimmune gastritis and is termed 3dnTx 
mice. Transferring spleen cells from autoimmune gastritis diseased mice to 
nude syngenic mice induces the disease (Taguchi and Nishizuka, 1987). 
Further studies have shown that CD4+ T cells of diseased mice are the key 
cellular element to induce autoimmune gastritis, as transfer of adult CD4+ 
but not CD8+ T cells to 3dnTx mice prevents 3dnTx mice from developing 
autoimmune gastritis (Fukuma et al., 1988). The pathological changes 
include lymphocytic infiltration of the gastric mucosa, destruction of 
parietal and chief cells and the production of autoantibodies to parietal cells 
(Kojima et al., 1980). These changes are also found in human pernicious 
anaemia. 
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Autoantibodies are directed towards the parietal cells, which are polarised 
epithelial cells, with the basal membranes oriented towards the lamina 
propria and the apical membranes facing the lumen of the gastric gland (Toh 
et al., 1997). These parietal cells are specialised cells that secrete hydrochloric 
acid into the stomach. This acid secretion is performed by a membrane-
bound enzyme termed gastric FIVIC-ATPase (also called proton pump) 
(Gleeson and Toh, 1991; Morley et al., 1992). The 1-1+/K+-ATPase consists of 
two major gastric membrane antigens, a 95 kDa protein, also defined as a-
subunit and a 60-90 kDa glycoprotein, also defined as 13-subunit (Toh et al., 
1990; Gleeson and Toh, 1991; Toh et al., 1992). Transgenic mice that express 
the 13-subunit of the HVIC-ATPase in thymus fail to develop anti-parietal 
cell autoantibodies when mice are thymectomised 3 days after birth, thus 
providing evidence that FIVIC-ATPase is the autoantigen (Alderuccio et al., 
1993). Furthermore, immunisation of mice with FIVIc-ATPase dissolved in 
adjuvant results in the short term induction of autoimmune gastritis 
further supporting that FIVIC-ATPase is indeed the autoantigen of 
autoimmune gastritis (Scarff et al., 1997). Prevention of AIG has been 
achieved by adoptive transfer of spleen cells from normal mice (Taguchi and 
Nishizuka, 1987) or intra-thymic injection of parietal cells (Nishio et al., 
1995). 
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1.3.3 Experimental diabetes 
Type 1 diabetes mellitus is an autoimmune disease caused by 
autoantibodies against islet cells of pancreas and has been proposed to be 
mediated by Th1-like CD4+ T cell immunity (Bradley et al., 1992). Two stains 
of murine, the Bio-Breeding (BB) rat and nonobese diabetic (NOD) mouse, 
can develop this disease spontaneously. BB rats develop the type 1 diabetes 
with insulitis and autoantibodies against 64-kD 3-cell antigen of the islet. 
Preventing BB rats from developing the disease can be achieved by 
treatment with anti-T-cell antibodies (Rossini et al., 1985). 
NOD mice begin to develop insulitis at the age of 5 to 8 weeks. At 6 to 7 
months, 70% of females and 40% of males become diabetic (Rossini et al., 
1985). The disease can also be induced by transfering T cells from diabetic 
mice to newborn NOD mice (Bendelac et al., 1989). Prevention and 
treatment of diabetes in NOD mice has been approached from two 
directions: non islet antigen-specific therapies and islet antigen-specific 
therapies. In the non-islet antigen-specific therapies, BCG vaccination to 
NOD mice (Harada et al., 1990) or injection of complete Freund's adjuvant 
in NOD mice (Sadelain et al., 1990) is efficient to prevent the onset of 
diabetes in NOD mice. In the islet antigen-specific therapies, complete 
prevention of diabetes is achieved by injecting syngeneic islets into the 
thymus of NOD mice at birth (Charlton et al., 1994). Oral feeding of porcine 
insulin to nonobese mice can prevent the disease (Zhang et al., 1991) as can 
intranasal administration of insulin peptide B: 9-23 (Daniel and Wegmann, 
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1996a; Daniel and Wegmann, 1996b) or glutamic acid decarboxylase (Schloot 
et al., 1996). 
1.3.4 Experimental allergic encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is an 
inflammatory disease of the central nervous system induced in laboratory 
animals by the injection of brain or spinal cord tissue, containing myelin 
basic protein (MBP) and proteolipid protein (PLP), with adjuvant. Paralysis 
begins 2-3 weeks after the hind legs are challenged with brain tissue. 
Injection of either MBP or PLP in normal mice is sufficient to induce EAE. 
Induction of EAE can also be achieved by transfering MBP-specific CD4+ T 
cells into normal recipients (McDonald and Swanborg, 1988). MBP is a 
complex protein and contains many epitopes. Some of these epitopes are 
pathogenic, depending on the animals. For instance, human MBP peptide 
residues 114-122 are pathogenic to guinea pigs but not to rabbits (Samson and 
Smilek, 1995). Prevention and treatment of EAE has been reported in many 
ways. Oral feeding of PLP 139-151 peptide (Karpus et al., 1996) or MBP (Brod 
et al., 1991) prevent the EAE disease. Nasal administration of MBP also 
prevents the relapsing of EAE (Bai et al., 1997). Suppression of EAE after 
clinical signs has also been reported by Racke and co-workers who showed 
that intraveneous injection of MBP twice daily, three times over 5 days, can 
suppress passively induced EAE (Racke et al., 1994). Brocke and colleague 
used altered peptide of MBP injected intraperitoneally to EAE diseased 
animals and were able to suppress the disease (Brocke et al., 1996). 
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1.3.5 Experimental arthritis 
Induction of experimental arthritis can be achieved by immunising 
mice with collagen or adjuvant. In collagen-induced arthritis, 
immunisation of mice with native type II collagen induces an inflammatory 
polyarthritis within 20 days (Goldschmidt et al., 1992). The disease can be 
induced in mice with a cocktail of monoclonal anticollagen antibodies. 
Further, the disease can be transferred from mice with collagen-induced to 
syngenic mice via their serum (Stuart et al., 1984). In adjuvant arthritis, an 
injection of Mycobacterium tuberculosis in oil (complete Freund's adjuvant) 
causes transient inflammation of the joints. The main pathologic finding in 
the joints is granuloma formation. The lesion can be transferred to 
syngeneic animals by T cells from rats with the disease. Prevention of 
collagen-induced arthritis can be achieved by oral feeding of collagen II 
(Trentham et al., 1993) or i.v. injection of its protein (Myers et al., 1989) or 
peptide (Samson and Smilek, 1995). 
1.3.6 Other experimental autoimmune diseases 
Experimental nephritis can be induced by repeated injections of 
Brown Norway rats with mercuric chloride (Hinglais et al., 1979). Repeated 
immunisation of mice with rat red blood cells results in the production of 
erythrocyte autoantibodies (Young and Hooper, 1993). Mice immunised with 
retinal antigen interphotoreceptor retinoid-binding protein induces 
experiment autoimmune uveoretinitis (Rizzo et al., 1994). Experimental 
autoimmune neuritis can be induced in rats by treatment of bovine spinal 
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root myelin or neuritogenic P2-specific T cells (Gehrmann et al., 1992). In 
addition, injection of viable syngenetic testicular germ cells can induce 
experimental autoimmune orchitis (Tokunaga et al., 1993). Mice infected 
with cardiotropic virus coxsackievirus B3 lead to autoimmune myocarditis 
(Neumann et al., 1994). 
1.3.7 Summary 
Experimental induced autoimmune diseases provide an ideal tool to 
look at the inside story of similar diseases in humans. The treatment 
method used in treating autoimmune diseased animals may be useful for 
applying to human treatments. However, different autoimmune diseases 
require different approaches for the treatment of autoimmune diseases. 
Some of the disease can be prevented before onset. The following section 
will discuss a possible new method, skin-induced tolerance, for applying to 
the treatment of autoimmune disease. 
1.4. Skin and cutaneous tolerance 
It has long been understood that immune tolerance can be induced 
via the skin. Application of antigen through chemical or physical light 
treated skin results in immunosuppression. Whether this skin-induced 
immunosuppression is suitable for the treatment of autoimmune disease 
requires answers. However, many facts which will be discussed below, may 
provide clues for the use of cutaneous tolerance induction as a possible 
treatment strategy for autoimmune disease. 
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1.4.1. Chemical substances and cutaneous tolerance 
Chemical substances such as carcinogens and allergens can alter the 
skin environment. Application of carcinogens such as 7,12- 
dimethylbenz[a]anthracene (DMBA) can reduce the LC number in the skin 
as can contact allergens such as TNCB, FITC and 2,4-dinitrofluorobenzene 
(DNFB) (Woods et al., 1996). Application of antigen through DMBA or 
TNCB-treated and LC-depleted skin results in immunological tolerance 
(Halliday and Muller, 1986; Halliday and Muller, 1987a; Halliday and Muller, 
1987b; Woods et al., 1996). More importantly the tolerance is transferable as 
spleen cells transferred from mice treated with DMBA/antigen or 
TNCB/antigen to syngeneic mice, induced tolerance in the recipient mice. 
The cutaneous tolerance generated is antigen specific as responses to 
different antigens remain unaltered. The induction of DMBA-induced 
cutaneous tolerance which acts on both cellular and humoral immunity; 
this has been demonstrated by Halliday and co-workers showing contact 
sensitivity and antibody production are both reduced (Halliday and Muller, 
1986; Halliday and Muller, 1987b). Further, the specific tolerance induced by 
DMBA/antigen treatment is long lasting (Halliday and Muller, 1987b). 
Possible mechanisms underlying the development of specific immune 
tolerance induced in DMBA/antigen treated mice have been studied. 
Halliday et al. (Halliday et al., 1988) demonstrated that activation of 
suppressor cells may be the key element in DMBA/antigen induced 
tolerance. Cells that mediate the induction of suppressor cells in DMBA- 
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treated mice have been indicated as the DMBA-resistant, Ia-positive, Thy-1 -, 
U-restricted epidermal cell (Halliday et al., 1990). When antigen is applied 
through normal skin containing LC a positive immune response resulted, 
whereas antigen applied through LC-depleted skin containing the DMBA-
resistant, Ia-positive, Thy-1 -, U-restricted epidermal cell immunosuppression 
resulted. Thus LC depletion is an important indication of whether immune 
response results in activation or suppression. 
DMBA treatment of the skin not only depletes LC but also affects their 
function. Study in sheep found that dendritic cells migrating after DMBA 
treatment had a reduced antigen-presenting function (Ragg et al., 1995). 
Study in mice found that cluster formation between CD4 4- T cells and 
dendritic cells were reduced in DMBA-treated mice compared with normal 
controls (Chilcott, 1994). Analysis of the ability of DMBA-treated dendritic 
cells to induce apoptosis in T cells showed no changes between DMBA-DC 
incubated with normal T cells and Normal-DC incubated with T cells 
(Grzegorczyk, 1994). However, an in vivo study showed DMBA-DC could 
induce apoptosis to T cells indicating tolerance induction by DMBA 
treatment may in part be through apoptosis (Reed, 1996). 
Further study on DMBA-treated mice revealed that DMBA did not alter IL- 
12 production of LC when compared with normal control (Malley, 1996). 
However, a decreased IL-113 production of draining dendritic cells after 
DMBA treatment has been observed in sheep (Ragg et al., 1997). 
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Other chemicals can also induce an immunosuppressive effect when 
applied to the skin. The LC depletion remains the important indication of 
whether suppression results. The tumour promoter, 12-0- 
tetradecanoylphorbol-13-acetate (TPA) can deplete LC from the epidermis 
which leads to an impaired immune response whereas urethane, a tumour 
initiator does not impair LC numbers and function, and the immune 
response remains intact (Halliday et al., 1987). 
1.4.2 Ultraviolet light and cutaneous tolerance 
Ultraviolet (UV) radiation is part of sunlight and is divided into three 
regions: UVA (320-400 nm), UVB (290-320 nm), and UVC (200-290 nm). UVB 
in particular has been directly implicated in the cause of human skin cancer. 
One of the reasons why skin tumours are induced by UVB irradiation is the 
association with an impaired skin immune function. In classical 
experiments, Kripke demonstrated that UVB-induced tumours grafted to 
syngenic normal mice were rejected. However, when these tumours were 
grafted to UVB irradiated syngeneic mice the tumour survived (Fisher and 
Kripke, 1976; Kripke, 1977; Kripke and Fisher, 1977). This indicated that 
UVB not only initiates skin tumours but has the ability to suppress immune 
functions. 
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Further assessment of UVB-induced immune suppression revealed that 
UVB irradiation could suppress contact hypersensitivity (CHS) and delayed-
type hypersensitivity (Dill) responses and in some cases a humoral 
immune response. In clinical terms CHS is a common skin disease, 
presenting as allergic contact dermatitis. Contact hypersensitivity is a 
prototype of DTH which is a T-cell mediated reaction. However CHS and 
DTH are not exactly the same. CHS can be mediated by MHC class I-restricted 
CD8+ cells and class II-restricted CD4+ cells whereas DTH only can be 
mediated by MHC class H-restricted CD4+ cells (Gocinski and Tigelaar, 1990). 
When mice are treated on the skin with UVB irradiation and then hapten is 
applied through this UVB-treated skin, CHS is not induced. These animals 
become specifically unresponsive to the chemical contact, and are unable to 
mount effective hypersensitivity reactions if presented subsequently with an 
immunogenic regimen (Streilein et al., 1980; Toews et al., 1980; Kripke and 
Morison, 1985). In addition, the murine CHS response can be suppressed by 
spleen cells or draining lymph node cells from UVB and hapten-treated 
mice. This suppression is due to the hapten-specific suppressor cells as 
transfer of UVB and other hapten-treated spleen cells could not suppress the 
normal CHS response (Elmets et al., 1983). 
Similar to CHS, the DTH response can also be impaired using the UVB 
regimen. When mice were irradiated and sensitised with large antigens such 
as sheep red blood cells (SRBC) or bovine serum albumin (BSA), the DTH 
responses were suppressed on subsequent challenge (Ullrich et al., 1986a). 
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This was due to antigen-specific suppressor cells as spleen cells of immune 
suppressed mice transferred to recipients suppress the DTH response on 
subsequent antigen application (Ullrich et al., 1986a). 
Most of the evidence indicates that UVB irradiation selectively suppresses 
the cell-medicated part of the immune response (Brissert and Granstein, 
1997). However, there are some reports suggesting that humoral immunity 
can also be suppressed. Spellman and co-workers showed that in naive mice, 
application of human immunoglobulin G (HIg) through UVB irradiated 
skin failed to reduce anti-HIg antibodies whereas in H[g immunised mice, a 
normal humoral immune response was evident (Spellman et al., 1984). In 
addition, it has been shown that when mice were treated with UVB 
irradiation followed by hapten application, plaque-forming cells to the 
hapten were significantly reduced (Ullrich et al., 1986b). Recently, Brown and 
colleagues showed that the reduction of antibody production by UVB 
irradiated is selective. They found that Borrelia burgdorferi immunization 
to UVB irradiated mice reduced IgG2a and IgG2b antibody production but 
not IgG1 antibody production (Brown et al., 1995). 
The relationship of the dose of UVB and the volume of hapten applied to 
the UVB irradiated skin is critical in the induction of tolerance. A study 
using C3H/HeN mice showed that UVB-induced local immune suppression 
was related to the dose of UVB, the divided exposure of UVB, the hapten 
concentration, the volume of the hapten, and the time course of UVB 
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irradiation in the suppression of CHS (Miyauchi and Horio, 1995). The strain 
of mice used in the experiment also effects the degree of UV-induced 
tolerance (Streilein and Bergstresser, 1988). 
Mechanisms involved in UV-induced immune suppression are complex. 
For example, in mice, UV radiation is able to convert LC from potent 
antigen-presenting cells to suppressive antigen-presenting cells (Simon et 
al., 1991), Thy-1+ epidermal cells have been documented as involved in the 
induction of UV-induced immunosuppression (Sullivan et al., 1986), 
Epidermal IT, la+ and Thy-1 - cells have been suggested as the important cells 
in the UV-induced suppressor T cell generation (Granstein, 1985), CD4+ T 
cells have also been demonstrated as the suppressor cells induced after UV B 
irradiation followed by hapten application. These CD4+ T cells belong to the 
Th2 subset (Elmets et al., 1983; Simon et al., 1990). In humans, Granstein et 
al. showed that after UV irradiation the CD4+CD45RA+ suppressor-inducer T 
cells were responsible for the induction of immunologic tolerance and this 
only occurred when human skin was irradiated with UVB or UVC (Cooper 
et al., 1985; Baadsgaard et al., 1987). 
The chemical mediators of UVB-induced tolerance include cytokines, cis-
urocanic and histamine, and other agents. The most studied cytokine in 
UVB-induced cutaneous tolerance is IL-10. It has been shown that in vivo 
hapten-specific tolerance induced by UVB is mediated by IL-10 (Enk et al., 
1994) and this is due to the inhibition of LC antigen-presenting function 
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(Enk et al., 1993). TNFa has also been shown to play a role in the UVB 
irradiation-induced immune suppression (Rivas and Ullrich, 1994). 
Injection of TNF-a intradermally mimicked the effects of UVB irradiation 
in regulating immune responses against contact sensitisers in mice. TNF-a 
is reported to facilitate LC migration and thus neutralizing the production of 
TNF-a results in immune suppression (Moodycliffe et al., 1994). IL-4 is 
another cytokine participating in the UVB-induced suppression. When 
transferring suppressor cells of UVB irradiated mice in combination with 
antibodies to IL-4, all immunosuppressive activity was abrogated (Rivas and 
Ullrich, 1994). It has been suggested that because the cytokines produced after 
UVB irradiation were Th2 cytokines the suppressor cells may be Th2-like 
cells (Ullrich, 1995b). As IL-12 is critical in the induction of immune 
response, UV irradiation can reduce the production of IL-12 indicating UV-
induced suppression may be due to insufficient IL-12 production (Schwarz et 
al., 1996). IL-la and IL-113 are also critical in the activation of the immune 
response; reduction of these cytokine also leads to immune suppression 
(Enk et al., 1993; Grabbe et al., 1994). 
Urocanic acid is another molecule that takes part in UVB-induced 
immunosuppression. It is a product of histidine and is abundant in the 
upper layer of the epidermis. Histidine is the precusor of both trans-urocanic 
acid and histamine. Irradiation of the skin with UVB causes isomerisation 
of trans-urocanic acid to cis-urocanic acid. The cis-urocanic acid is 
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immunosuppressive (De Fabo and Noonan, 1983; Noonan and De Fabo, 
1992). This can be demonstrated by local injection of cis-urocanic acid to the 
epidermis which decreases the number of LC (Kurimoto and Streilein, 1992) 
when mice are treated with cis-urocanic acid their splenic antigen-
presenting cells function are affected (Noonan et al., 1988). Injection of cis-
urocanic acid has also been shown to extend the acceptance of heart grafted 
animal (Noonan and De Fabo, 1992). Histamine, another product of 
histidine in the epidermis also behaves like cis-urocanic acid to inhibit CHS 
responses (Hart et al., 1997). Investigation of how cis-urocanic acid or 
histamine induce immune suppression revealed that both molecules can 
induce PGE 2 production suggesting the PGE 2 plays a role in the cis-urocanic 
acid induced immunosuppression (Jaksic et al., 1995). Studies by Kurimoto 
and Streilein found that cis-urocanic acid can increase TNF-a secretion from 
the epidermis, therefore, preventing LC migration and resulting in 
immunosuppression (Kurimoto and Streilein, 1992). 
Other agents are also involved in the mediation of UV-induced 
immunsuppression. UVB has the ability to directly mutate DNA to form 
pyrimidine dimers. This leads to the concept that DNA damage may be the 
result of UVB-induced tolerance. Study by Kripke and colleagues 
domonstrated that pyrimidine dimers in DNA were involved in the 
initiation of systemic immunosuppression in UV-irradiated mice as 
application of liposomes which repair DNA damage, together with U V B 
irradiation prevents the induction of immunosuppression (Kripke et al., 
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1992). Aloe barbadensis gel extract also prevents UVB irradiation-induced 
immunosuppression but this prevention is not due to the repair of DNA 
damage (Strickland et al., 1994). Serum from UVB irradiated mice is also 
reported to have the ability to induce immunosuppression (Harriott Smith 
and Halliday, 1988). Supernatants from irradiated keratinocyte cell line also 
contain immunosuppressive ability and this has since been identified as IL-
10 (Ullrich, 1995a) 
1.5 Methods of tolerance induction 
Other methods to induce experimental tolerance can be achieved by 
oral, respiratory, eye chamber, and intrathymic or intravenious injection of 
antigens or antibodies. Such methods have been reported to treat established 
or autoimmune responses (Kosiewicz et al., 1994; Liblau et al., 1997; Weiner, 
1997a). However, one thing in common with cutaneous tolerance is all the 
methods used to induce specific tolerance require specific antigen and 
involve participation of antigen-presenting cells. For example, oral feeding 
of antigen can induce antigen specific immunosuppression. This tolerance 
induction involves antigen and APC as demonstrated by Liu et al. (1993) 
who showed that intestinal dendritic cells can process and present antigen 
from intestinally fed antigen leading to tolerance. Respiratory tolerance is 
another form of experimental tolerance which utilises inhalation or nasal 
challenge of antigen to generate specific tolerance. It has been demonstrated 
that antigen-presenting alveolar macrophages are responsible for the 
induction of tolerance in animals (Thepen et al., 1991). Nasal challenge of 
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antigen can also lead to tolerance via Th2 cytokine production and this may 
be related to the nasal mucosa dendritic cell (Tian et a/., 1996). 
Induction of tolerance via the anterior chamber of the eye has been shown 
to suppress the immune response if soluble antigen is applied through the 
eye chamber before (Williamson and Streilein, 1989) and after antigen 
application (Kosiewicz et al., 1994). This method of induced tolerance also 
appears to involve APC. To support this view Steptoe and colleague, 
showed that MHC II-positive dendritic cells migrated from the eye chamber 
after antigen treatment (Steptoe and Thomson, 1996). Suppressor cells have 
been isolated after this treatment (Wilbanks and Streilein, 1990) suggesting a 
strong link between APC and suppressor cells in eye tolerance. 
Induction of tolerance can be achieved via intrathymic injection (Staples et 
al., 1966; Ellison and Waksman, 1970). Oluwole and co-workers 
demonstrated that the mechanism of this tolerance was associated with 
thymic DC (Oluwole et al., 1995). Intraveneous injection of antigen can also 
induce tolerance and this form of immunosuppression has been suggested 
to involve blood dendritic cells (Liblau et al., 1996; Liblau et al., 1997). 
1.6 Summary 
An immune response driven by antigen towards a full immune 
response or a suppressed immunity is dependant on the quantity and quality 
of antigen application as well as where the antigen is applied. Utilizing skin 
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as the tolerance-driven organ, requires deletion of LC in the epidermis. This 
has been demonstrated in chemically and UVB manipulated skin. Other 
methods of induced tolerance also require certain conditions in the treated 
organ. 
Cutaneous tolerance has been used mainly for allegic dermatitis, unlike 
other forms of tolerance induction which have been used to treat established 
immunity as well as autoimmune diseases. It is of interest that cutaneous 
tolerance may be an effective method for the treatment of unwanted 
immune response. So far cutaneous tolerance has been shown to prevent 
induction of contact sensitivity however the use of cutaneous tolerance to 
suppress established immunity has yet to be fully examined. This thesis will 
examine the ability of cutaneous tolerance to downregulate established 
immunity as a possible treatment for autoimmune disease. 
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Chapter Two 
Materials and Methods 
2.1 Animals 
BALB/c mice were obtained from the Central Animal House, 
University of Tasmania. All mice were used with the approval of the 
Animal Ethics Committee of the University of Tasmania (permit number 
94049). BALB/c mice were housed in the Animal House, Division of 
Pathology with free access to water and food. The nu/nu BALB/c mice were 
purchased from Animal Resources Centre, Western Australia and housed 
in special designed cages (Model AS 980, Able Scientific, West Australia) in 
the Division of Pathology with free access to sterilised water and food. 
2.2 Reagents 
2.2.1 Solutions 
	
2.2.1.1 	Phosphate Buffered Saline (PBS) 
16.00g NaC1 
7.30g Na2PO412H20 
0.40g KH2PO4 
0.40g KC1 
Dissolved in 2 litres of Milli-Q water and autoclaved. 
2.2.1.2 	Glucose-Phosphate Buffer Saline (G -PBS) 
I) 1.0 M Phosphate Saline 
a). 1.0 M KH2PO4: 136.1 g/liter 
b). 1.0 M Na2HPO4.2H20: 156.01g/liter. 
Combine 910 ml of 1.0 M Na2HPO4.2H20 and 90 ml of 1.0 
M KH2PO4. 
II) Saline and Glucose 
a). 0.14 M NaCl: 8.2g/litre--1000 ml 
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b). D-Form Glucose--10g 
Combine (a) and (b). 
All solutions were prepared in Milli-Q water. 
10 ml of solution (I) was added to 1 litre of solution (II) 
and sterilised by filtration through 0.22 1.tm millipore 
filters. 
	
2.2.1.3 	10% FCS in G -PBS 
10m1 of fetal calf serum (FCS Commonwealth Serum 
laboratories, Australia) was added to 90m1 G-PBS. 
2.2.1.4 	0.28 M Cacodylate Buffer pH 6.9 
39g cacodylic acid sodium (C2H6AsO2Na) (Sigma, U.S.A.) 
was dissolve in 900 ml distilled water. pH was adjusted to 
6.9 with 2 M HC1 (73g/liter). Volume adjusted to 1000 ml 
with Milli-Q water and sterilised through 0.22 g m 
millipore filters. 
2.2.1.5 	EDTA/PBS/0.001% trypsin 
7.2g EDTA Na4 salt 
0.001g trypsin (BDH, Product 39041, Australia) 
Volume made to 1 litre 
2.2.1.6 	0.25% trypsin 
0.25g of trypsin was added to 100m1 G-PBS. 
2.2.1.7 	RPMI medium 
104g of RPMI powder (ICN Biomedicals, INC., U.S.A. Cat. 
Number 10-601-22) was added to 10 litres of Milli-Q water 
and sterilised through 0.22 gm millipore filters. 
2.2.1.8 	10%FCS/RPMI 
100m1 Fetal Calf Serum (FCS Commonwealth Serum 
Laboratories, Australia) was added to 1 litre RPMI 
medium. 
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100m1 100X Vitamins (Flow Laboratories) and 100mg L-
Glutamine (Sigma, U.S.A.) was added to 1 litre RPMI 
medium. 
	
2.2.1.9 	PBS + 2`YoBSA + 0.2% Azide 
1 litre PBS 
20g crude bovine serum albumin (BSA) (Commonwealth 
Serum Laboratories) 
2g NaN3 (BDH, Australia) 
20g of BSA and 2g of NaN 3 was floated on the top of PBS 
(1 litre) and allowed to gently settle into solution until all 
the BSA dissolved and sterilised through 0.22 la m 
Millipore filters. This solution could not be shaken or 
stirred as this would result in the formation of large sticky 
lumps of BSA. 
2.2.1.10 	FACS Fixative 
500m1 PBS 
10g glucose (Ajax Chemicals) 
1.09m1 15% NaN 3 
13ml 40% formaldehyde 
Add above together 
2.2.1.11 	Glycerin Jelly 
10g gelatin 
60m1 Milli-Q water 
70m1 glycerin 
0.25g phenol 
Dissolve the gelatin in distilled water using gentle heat. 
Add the glycerin and phenol, mix well. For use, melt in 
water bath at 56-60 ° C, avoid shaking to speed this process 
otherwise mountant will be full of air bubbles. 
2.2.1.12 	Trypan Blue 
0.25g Trypan blue powder (Chroma-Gesellschaft, Schmid 
& Co. German) was added to 100m1 of Milli-Q water and 
sterilised through 0.22 1.1m millipore filters. 
49 
2.2.2 Contact sensitisers 
(1) Picryl Chloride or 2,4,6-trinitrochlorobenzene (TNCB): Tokyo-Kasei, 
Japan, Cat. Number CO307. 
(2) Picryl Sulfonic Acid Sodium Salt or 2,4,6-trinitrochlorobenzenesulfonic 
acid (TNBS): Tokyo-Kasei, Japan, Cat. Number FC005. 
(3) 2,4-dinitrofluorobenzene (DNFB): Sigma Chemical Company, 
U.S.A., Cat. Number F-7250. 
2.2.3 Antigens 
(1) Gastric H+/K+ ATPase (Proton Pump): The proton pump was 
provided by my collaborator Prof. Toh of Monash University 
Australia. Mouse and pig gastric RIK+ ATPase was purified 
from gastric membranes by tomato-lectin affinity 
chromatography (Callaghan et al., 1992). 
(2) Peptide 19: The peptide 19 of proton pump was purchased from Dr 
Cenk Suphioglu of the Melbourne University, Australia. 
Sequence: LLNVPKNMQVSIVCKILADHVTFNN 
2.2.3 Carcinogens 
(1) 7,12, dimethylbenz(a)anthracene (DMBA): Sigma Chemical 
Company, U.S.A., Cat. Number D-3254. 
2.2.4 Vehicle 
(1) Acetone: BDH, Australia. 
(2) Olive oil: Bertolli, Italy. 
2.2.5 Antibodies 
(1) TIB 120: Cultured hybridoma supernatant, anti-mouse I-A, I-E 
(American Type Culture Collection) (Davignon et al., 1981; 
Bhattacharya et al., 1981). 
(2) Goat anti - rat Ig - peroxidase conjugate: Southern Biotechnology 
Associates Inc., Birmingham, USA., Cat E295-W365D. 
(3) Anti-mouse immunoglobulin F(ab) 2 fraction affinity isolated 
fluorescein conjugated: Silenus Laboratories Victoria, Australia, 
Cat 5023DDAF0591. 
(4) Sheep anti-mouse immunoglobulin stabilised serum: Silenus 
Laboratories Victoria, Australia, Cat. Number 5034DS0591. 
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2.2.6 Others 
(1) Veet Hair Remover: Reckitt and Colman Pharmaceuticals, 
Australia 
(2) Diaminobenzidine tetrahydrochloride (DAB): Sigma Chemical 
Company, U.S.A., Cat. Number Ki390. 
2.3 General methods (methods used in two or more chapters) 
2.3.1 Sensitisation of mice 
Immune mice were prepared by immunising adult mice with 
two applications of the hapten 2,4,6-trinitrochlorobenzene (TNCB) 
(dissolved in a 4:1 solution of acetone: olive oil) at days 0 and 7 by 
applying 100g1 of 0.5% or 2%TNCB to the shaved dorsal trunk or 
abdominal skin. 
2.3.2 DMBA treatment 
Adult mice were treated with 100p.1 of 1% DMBA dissolved in 
acetone to the shaved dorsal skin. 
2.3.3 Assessment of contact sensitivity 
Contact sensitivity was elicited by applying 20 1.11 of sensitising agent 
(0.5% TNCB in 4:1 acetone-olive oil ) to the dorsal surface of the right ear, 5 
days following the final treatment (eg. TNCB applied through DMBA-
treated skin). The contact sensitivity to the TNCB appeared as an increase in 
ear thickness. The thickness of the challenged and unchallenged ears was 
measured 24 or 48 hr later with an engineer's spring-loaded micrometer. 
The contact sensitivity response was determined by measuring the increase 
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in ear thickness and expressed as a percentage increase as calculated by the 
formula: 
thickness of challenged ear - thickness of unchallenged ear 
X 1 00. 
thickness of unchallenged ear 
One exception of the measurement was the UVB study of chapter 4. In 
chapter 4, the ear thickness before and after challenge was measured. The 
contact sensitivity response was expressed as a percentage increase in ear 
thickness as calculated by the formula: 
ear thickness after ear challenge - ear thickness before ear challenge 
X 1 0 0. 
ear thickness before ear challenge 
2.3.4 Measurement of anti -TNP antibodies 
Two hours following ear measurement the mice were bled by cardiac 
puncture while under Halothane (Fluothane, ICI Pharmaceuticals, 
Melbourne, Australia) anaesthesia. The blood was allowed to clot for 1 hour 
at 37°C and left overnight at 4°C before the serum was separated and stored 
at -20°C. Specific anti-trinitrophenyl (anti-TNP) antibodies formed in 
response to sensitisation with TNCB were measured using an indirect 
haemagglutination technique based on procedures described by Mishell 
(1980). Trinitrophenylated derivatives of sheep red blood cells (SRBC) were 
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prepared by reacting SRBC with 2,4,6-trinitrobenzenesulfonic (TNBS). Fresh 
SRBC were washed in PBS and 300 111 was added to 2.1 ml TNBS-cacodylate 
buffer (pH 6.9) and incubated at room temperature for 30 minutes. The 
TNBS-cacodylate buffer was prepared by dissolving 0.075g TNBS in 4 m 1 
cacodylate buffer and centrifuging at 3000rpm for 15 minutes and the upper 
2.1 ml of TNBS-cacodylate buffer was collected. The SRBC and TNBS-
cacodylate buffer mixture was mixed for 30 minutes and washed 4 times in 
cold PBS buffer containing 2% w/v glucose. Finally, TNBS conjugated SRBC 
(TNP-SRBC) were resuspended at 2% in Phosphate Buffered Saline solution. 
At all times the tubes were wrapped in aluminum foil to prevent 
photodecomposition of TNBS. For indirect haemagglutination, 96 well 
round bottom plates were used and 251.11 serum samples were added in 
doubling dilution to the wells of a 96 well round bottom plate. A total of 25 
pa of 2% TNP-SRBC was then added to each well and the plate incubated at 
37°C for 45 minutes. Plates were washed once at 400g for 7 minutes. 
Unbound serum was removed by washing the well with 50111 PBS, the 
plates were centrifuged at 400g for 7 mins and the supernatant carefully 
removed. In each well 50 gl sheep anti-mouse IgG diluted 1:500 with PBS 
was added to the washed pellet and mixed by repeated pipetting. Plates were 
incubated overnight at room temperature. 
2.3.5 Spleen cell preparation and adoptive transfer 
Mice from the spleen cells transfer experiments were sacrificed by 
inhalation of Halothane anaesthesia and their spleens were removed. A 
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single cell suspension was prepared by gently teasing the spleen through 80 
mesh stainless-steel sieve into RPMI medium (HyClone U.S.A.). The cell 
suspension was collected into 10 ml centrifugation tubes and centrifuged at 
400g for 10 minutes, and the supernantant discarded. The cells were then 
washed twice in RPMI medium by centrifugation. The cell viability was 
estimated by their exclusion of trypan blue. The number of viable 
lymphocytes was counted using a haemocytometer. The concentration of 
the spleen cells was adjusted to 1 X 108 /ml. Approximately 5 X 10 7 viable 
cells were injected into tail vein of syngeneic host mice. 
2.3.6 Epidermal LC identification 
2.3.6.1 Preparation of epidermal sheets 
The dorsal area of the mice was shaved with animal clippers, and 
mice were then sacrificed by CO2 in air asphyxiation. The remaining hair 
was removed with a chemical depilitant containing thioglycollate (Veet Hair 
Remover). This was rubbed into the coat of the animal and left for 10 
minutes. The dorsal area was then washed in cold water and the skin rubbed 
dry. The keratin layer was removed by applying good quality cellotape to the 
shaved skin and then stripping it off until the skin glistened. A fresh strip of 
cellotape was applied to the shaved skin and the area dissected from the 
animal. 
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The skin/tape combination was then cut into approximately 1cm2 segments, 
placed with the dermis side down into wells containing 20mM 
EDTA/PBS/0.001°/0 trypsin and incubated at 37°C for 2 hours with slight 
agitation (Baker and Habowsky, 1983). The dermis was separated from the 
epidermis with fine forceps using a dissecting microscope. The epidermis 
was left attached to the sticky tape. The epidermal sheets were then fixed in 
acetone for 10 -15 minutes at room temperature. 
2.3.6.2 Identification of Langerhans Cells 
The sheets were washed three times in PBS with the shaking 
epidermis facing downward and then incubated with 200g1 of undiluted TIB 
120 hybridoma supernatant, to identify Ia + cells at 37°C with slight agitation 
for 2 hours and then incubated at 4°C overnight. The sheets were washed in 
PBS three times and incubated in goat anti - rat Ig - peroxidase conjugate 
(1/100) for two hours at 37°C. After washing three times with PBS staining 
was then visualised with diaminobenzidine tetrahydrochloride, by 
incubation at room temperature for 5 - 10 minutes. The sheets were then 
washed three times with MilliQ water and mounted in glycerin jelly on 
clean glass slides. The slides were stored at 4°C when not being used. 
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2.3.6.3 Dendritic cell count 
Cells were counted by means of an image analyser using the 
NIH Image 1.6 program on a Macintosh Power PC computer. Cell 
counts were calculated from epidermal sheets stained with the TIB 120 
monoclonal antibodies at 40 times magnification. Six fields were 
counted and the number of cells per mm 2 was then calculated. The 
mean count for each age group was then calculated. 
2.3.7 Detection of autoantibody production of autoimmune gastritis 
Normal BALB/c mice were sacrificed and their stomachs dissected. 
Approximately 1mm strips of the fundus of the stomachs were frozen by 
being placed on aluminum foil to float on a 2-Methyl butane (BDH 
Laboratory Supplies. Poole, England) and liquid nitrogen (Union Carbide, 
Australia) solution. Frozen sections of approximately 6[1,m thickness were 
then mounted on aquadhere slides. Serum was removed from the tail blood 
samples after spinning in a microcentrifuge at 12,000 rpm for 30 seconds. 
The tail blood serum was then double diluted in PBS commencing with a 
1/8 dilution to a 1/ 2024 dilution. Serum dilutions (101.11 per section) were 
then incubated on the stomach section slides for thirty minutes at room 
temperature. The slides were then gently washed twice with PBS and 
slightly agitated with PBS on the slide for five minutes after each wash. 
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10111 of anti-mouse immunoglobulin conjugated with fluorescein 
isothiocyanate (1 : 80) was added to each slide and incubated for 30 minutes 
at room temperature. The slides were washed as previously with PBS. Slides 
were then viewed using a fluorescence microscope and the degree of 
fluorescence was assessed and scored when compared with positive and 
negative controls, strongly positive (score of three) and negative (score of 0). 
The titre was then determined as the last dilution at which a positive 
reaction could be scored. 
2.3.8 Histological assessment 
After the end point of each experiment, the mice were sacrificed and 
their stomachs dissected. The fundus of each stomach had a strip of 
approximately 1mm removed, which was fixed in formalin solution. 
Sections of this part of the stomach were mounted on clean glass slides and 
stained by means of H&E staining and sectioned to determine the 
histological presence of disease. The sections were viewed at 10X and 20X 
magnification and were allocated a score for the degree of atrophy and 
inflammatory cellular infiltration present in each section. A score of 3 was 
given to those stomachs with the greatest degree of gastric atrophy (loss of 
parietal cells) and inflammatory cellular infiltration and a score of 0 to those 
stomachs with normal gastric mucosa and minimal cellular infiltration. 
The stomach of each mouse was scored according to the extent of the 
presence or absence of these parameters. 
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2.3.9 Neonatal thymectomy 
Normal BALB/c (H-2 d) mice were thymectomised on day 3 (day of 
birth designated as day 0) (3dnTx) under cold anaesthesia. The sternum was 
opened at the midline and after exposing the thymus, each lobe was 
aspirated with a Pasteur pipette attached to a vacuum. These mice were 
checked for the remaining thymus using the fine forceps. If any residual 
thymus was detected it was removed by forceps. Mice were then warmed 
with a 60 watt lamp and returned to their mother. 
2.3.10 Statistical analysis 
An unpaired Student's t-test was performed to analyse 
experimental data. Macintosh computer Statview (Version 1.1 Abacus 
Concepts, Inc.) program was used for this analysis. 
2.4 Specific methods (methods used only in one chapter 
indicated) 
2.4.1 Methods used in chapter 3 
2.4.1.1 Downregulation of established contact response 
TNCB immune mice were treated with 100111 1% DMBA on shaved 
dorsal skin. Five days later, 100111 of 0.5% TNCB was applied to the DMBA-
treated dorsal trunk of each mouse. For testing the specificity of immune 
suppression, the same procedure was carried out using 0.5% DNFB. A 
further 5 days later the mice were ear challenged and contact sensitivity was 
determined. 
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2.4.1.2 Spleen cell transfer 
1% DMBA or acetone was applied onto the dorsal trunk of naive 
adult mice and a further 5 days later, 100111 of 0.5% TNCB was applied to the 
same site. Five days later, spleens of these mice were removed and 
adoptively transferred via the tail vein to TNCB immune mice. For 
examining the specificity of immunosuppression, 0.5% DNFB was used 
instead of 0.5% TNCB. 
2.4.1.3 Epidermal cell preparation 
The dorsal skin of the mice was shaved using an electric clipper and 
the remaining fur removed by chemical depilitant (Veet; Ricketts and 
Colman Ltd, U.K.). The keratin layer was removed by repeated attachment 
and removal of cellophane until the skin was shiny. Treated skin was 
excised and floated dermal side down in 0.25% trypsin dissolved in G-PBS 
for 18 hours at 4° C. After 18 hours, fetal calf serum (FCS; Commonwealth 
Serum Laboratories, Melbourne, Australia) was added (final concentration 
of 10%) to neutralise the trypsin. Epidermal cells were obtained by using a 
glass rod to vigorously rub the skin surface. The epidermal cells removed by 
this method were washed once in G-PBS containing 10% FCS and once in G-
PBS by centrifugation at 400g for 7 minutes. The viability was assessed by 
trypan blue exclusion. 
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2.4.1.4 Conjugation of epidermal cells with TNCB 
ECs were incubated at 37° C in a fully humidified atmosphere with 
5% CO2 in air. One hour later the cells were washed twice in G-PBS. These 
epidermal cells were mixed with to an equal volume 20mM 2,4,6- 
trinitrobenzenesulphonic acid for 15 minutes at 37° C. Cells were then 
washed twice in G-PBS with 10% FCS. The final concentrations of ECs was 
adjusted to 1 x 105 /m1 or 1 x 107/ml. 
Cells prepared by both these methods were subsequently injected into 
immunised mice. No less than 1 x10 4 cells was subcutaneously injected into 
each mouse or 1 x10 6 cells was intravenously injected into each mouse. 
2.4.1.5 Transfer of epidermal cells treated with DMBA followed by TNCB 
ECs from mice treated with either 100111 1% DMBA followed by TNCB 
or either 100111 acetone followed by TNCB were prepared (section 2.4.1.3). 
The final concentrations of ECs was adjusted to 1 x 10 5 /m1 or 1 x 107/ml. 
Cells prepared by both these methods were subsequently injected into 
immunised mice. No less than 1 x10 4 cells was subcutaneously injected 
into each mouse or 1 x106 cells was intravenously injected into each 
mouse. 
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2.4.2 Methods used in chapter 4 
2.4.2.1 UVB irradiation protocols 
For treatment with UVB, the dorsal trunk was shaved and the 
mice were anaesthetised by intraperitoneal injection of 600pg 
pentobarbital sodium (Nembutal, Boehringer Ingelheim, Australia) 
diluted 1: 10 in 0.9% sodium chloride. Irradiation was carried out using 
a bank of six FS40 sun lamps (UVS Ultraviolet, Scoresby, Victoria, 
Australia) with high efficiency silverlux reflective film (3M Australia 
Pty Ltd) behind the lamps. Lamps were prewarmed for at least fifteen 
minutes to stabilise output. The UV light emitted by these lamps was 
within the range of 280 nm to 400 nm with a major emission peak at 
313 nm. UVB (280 nm to 320 nm) output was 22.4 watts/m 2 
representing approximately 64% of total UV light emission. UV dose 
was measured using a IL-1700 research radiometer (International Light, 
Newburyport M.A., U.S.A.). Mice were irradiated at a distance of 15 cm 
from the light source and were exposed to either 1, 3, 7 or 13 kJ/m 2 of 
UVB irradiation. In the study of LC density, the TNCB immune mice 
were exposed to 3, 7, 10 or 13 kJ/m 2. In multi exposure experiments, 
mice were exposed to three doses of 7 kJ/m2. In all irradiation 
protocols the ears of the mice were protected from the UVB source by 
shielding with aluminum foil. 
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2.4.3 Methods used in chapter 5 
2.4.3.1 Lymphocyte proliferation assay 
Lymph node (axillary, brachial and inguinal) cell suspensions were 
prepared by pressing the lymph nodes through nylon mesh. The cells were 
washed twice in RPMI culture medium (HyClone, U.S.A.), resuspended at 
1x106 cell/ml in complete RPMI medium containing 10% fetal calf serum, 
Gentamicin (150n/m1), L-glutamine (2mM) (CSL, Melbourne, Australia), 2- 
mercaptoethanol (SERVA, New York) and placed into 96-well round-bottom 
microtitre plates (Sarstedt-Group, Adelaide, Australia) in a final volume of 
200g1 which contained doubling dilutions of PHA from 50pg/m1 to 1p.g/ml. 
The cultures were incubated for 3 days at 37 °C, 5% CO2 and 1[1Ci/well of 
methyl [H] thymidine (specific activity 2 Ci/mMol; Amersham Life 
Sciences, Australia) was added for the last 6 hours. Cultures were set up in 
triplicate and harvested on an automatic cell harvester (Skatron) and 
cellular incorporation of [31-I] thymidine counted using a liquid scintillation 
counter (LKB Wallac) and expressed as counts per minute (c.p.m). 
2.4.3.2 Flow cytometry 
Lymphocytes (1 X 106) from lymph nodes of 3dnTx mice, at 6-8 weeks 
of age, were incubated on ice for 30 minutes with either biotinylated anti-
mouse CD4 (Clone RM4-5, PharMingen), biotinylated anti-mouse CD8 
(Clone 53-6.7, PharMingen) for T cell identification or phycoerythrin 
conjugated anti-mouse B220 (Clone RA3-6B2 , PharMingen) for B cell 
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identification. After washing, the B220 labeled cells were immediately 
prepared for flow cytometry whereas streptavidin-phycoerythrin (Code No. 
R0438, DAKO A/S, Denmark) was added to the biotinylated CD4 and CD8 
preparations and incubated on ice for a further 30 minutes. Cells were 
analysed on a Coulter EPICS Elite ESP flow cytometer equipped with a 
Coherent Innova 90 argon ion laser and analysed with the ELITE 
workstation software. 
2.4.3.3 Induction of immunosuppression in 3dnTx mice and nu/nu mice 
Groups of age matched 3dnTx mice (TNCB immune or non-immune) 
or nu/nu adult mice were treated on the dorsal skin with 100g1 1% DMBA. 
Five days later 100g1 2% TNCB was applied through DMBA-treated skin. 
The control groups were treated with acetone instead of DMBA. For antigen 
specificity test, DNFB was used instead of TNCB in the DMBA-treated group. 
Groups of 3dnTx mice were separated into autoimmune gastritis positive 
and negative groups. 
2.4.3.4 Adoptive transfer of spleen cells from thymectomised and nu/nu 
mice 
Thymectomised or nu/nu mice were shaved and treated with 1% 
DMBA in acetone. Five days later, 2% TNCB was applied through the 
DMBA-treated skin. A further five d4s later, spleens from the DMBA-
TNCB-treated mice were removed and a single cell suspension prepared in 
RPMI medium containing 10% FCS. These cells were washed 3 times with 
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RPMI and 5 x 107 viable cells, as determined by trypan blue exclusion, were 
injected into naive mice. Control mice received spleen cells from acetone-
TNCB-treated mice. For the antigen specific control 2,4- 
dinitrofluorobenzene (DNFB), instead of TNCB, was applied through the 
treated skin and the spleen cells were transferred as above. Suppressor 
spleen cells were detected by their ability, following adoptive transfer, to 
suppress the host response to TNCB sensitisation. 
2.4.4 Methods used in chapter 6 
2.4.4.1 Treatment of autoimmune gastritis (AIG) 
Mice thymectomised 3 days with AIG (12-15 weeks old) were treated 
with 1% DMBA followed by 1-11C-ATPase (50gg per mouse) or peptide 19 
(501.tg per mouse) dissolved in PBS applied through the DMBA-treated area. 
Control groups were treated with DMBA alone or Acetone followed by WIC-
ATPase (501.1g per mouse). Mice were bleed at day 35, and 50. For one 
experiment the DMBA was replaced by 2% TNCB followed by peptide 19 
application. 
2.4.4.2 Prevention of autoimmune gastritis (AIG) 
Four day old 3dnTx mice were treated with peptide 19 (10g per mouse) 
dissolved in 2% TNCB. Control groups were 2% TNCB alone. The solvent 
alone (acetone) and peptide 19 (10p.g per mouse) dissolved in acetone groups 
were also assessed. 
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Chapter Three 
Downregulation of Established Immune 
Response by Chemical Carcinogen 
3.1 Introduction 
Skin antigen-presenting cells, the Langerhans cells (LC), play an 
important role in the activation of naive T cells (Silberberg et al., 1976). Loss 
of LC from the skin impairs the skin immune system's ability to mount an 
immune response against contact sensitisers and to detect unwanted cells 
such as tumour cells (Muller et al., 1997). Further, the application of hapten 
or antigen through LC-depleted skin results in the induction of antigen 
specific tolerance (Spellman et al., 1984; Halliday and Muller, 1986). For 
example, the chemical carcinogen 7, 12-dimethylbenz(a)anthracene (DMBA), 
which has been shown to deplete LC in the epidermis, establishes an 
environment in which the application of a contact sensitiser through the 
treated skin results in the induction of immunosuppression to the contact 
sensitiser (Halliday and Muller, 1986). High concentrations of 2,4,6- 
trinitrochlorobenzene (TNCB) also deplete LC from the skin. As with 
DMBA-mediated LC depletion, when haptens, such as DNFB, are applied 
through TNCB-treated skin, tolerance rather than immunity to DNFB is 
induced (Woods et al., 1996). The tolerance induced by applying antigen 
through LC-depleted skin is antigen specific. 
It has been proposed that this antigen specific suppression was due to 
antigen specific suppressor cells, as the transfer of spleen cells from hapten 
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tolerant mice to naive mice suppressed the development of an immune 
response when the naive mice were subsequently challenged with the same 
hapten (Halliday and Muller, 1987b). It would appear that the spleen 
contained antigen specific cells that were important 'effector' cells, that is, 
they were able to prevent the induction of an immune response at the 
effector stage. Further analysis at the inducer stage of tolerance induction 
revealed that the residual antigen-presenting cells were unable to induce 
immunity as naive mice immunised with epidermal cells harvested from 
DMBA-treated skin and pulsed with hapten failed to generate an immune 
response to the same hapten (Halliday et al., 1988). These cells induced 
antigen specific suppression as the immune response to other antigens was 
unaffected. Consequently, antigen specific tolerance can be divided into the 
induction phase, which is due to antigen presentation by aberrant epidermal 
cells and at the effect phase, due to antigen specific cells present in the 
spleen. 
The prevention of contact sensitivity development by pretreatment of 
murine skin with an LC-depleting agent such as DMBA has been clearly 
established. However the work so far has concentrated on prevention, rather 
than reversal of an established contact sensitivity response. The ability to 
downregulate an established, and deleterious immune response has obvious 
important clinical implications. Consequently this chapter evaluates the 
potential for manipulating the skin immune system to downregulate an 
established contact sensitivity response. 
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3.2 Results 
3.2.1 Langerhans cell density after DMBA treatment 
In normal mice, depletion of LC from the epidermis following 
exposure to DMBA is central to the development Of antigen specific 
tolerance. These LC-depletion studies were determined using naive mice 
and as this chapter is evaluating the ability to downregulate an established 
contact sensitivity response, immune mice rather than naive mice were 
examined to ascertain that LC depletion was also observed. All the mice in 
these experiments had been immunised with the contact sensitiser and 
immunisation was performed through ventral skin. The evaluation of 
DMBA-mediated LC depletion was performed by treating these immune 
mice with DMBA through dorsal skin, because this was the site that was to 
be treated for the downregulation experiments. 
Application of 1% DMBA to TNCB-immune mice depleted LC from the skin 
when compared with the acetone treated control (Figure 3.1). The epidermis 
of DMBA-treated TNCB-immune mice contained approximately 100 LC per 
mm 2 whereas the acetone treated (control) group contained approximately 
1300 LC per mm 2 . Consequently, DMBA not only depleted epidermal LC in 
normal mice but had the ability to deplete epidermal LC in immune mice. 
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Figure 3.1 Number of LC residing in the epidermis five days after 
DMBA (test) or acetone treatment (control). 
Results represent the mean ± standard deviation from at 
least 6 mice. P value was determined by Student's 
unpaired t-test. 
3.2.2. DMBA/TNCB treatment reduced contact sensitivity and antibody 
production in TNCB-immune mice 
When the antigen TNCB was applied through the DMBA-treated skin 
of TNCB-immune mice, there was a significant reduction in the level of 
contact sensitivity and antibody production to TNCB (Figure 3.2). Although 
this reduction was significant, it was not a complete reduction as both 
contact sensitivity and antibody levels to TNCB were higher than the 
control group (group 1), which had not been exposed to TNCB until they 
were ear challenged. It can be concluded that the application of TNCB 
through DMBA-treated skin causes a significant, but not complete reduction, 
of both cell mediated and humoral immunities. 
3.2.3 Reduction of contact sensitivity and antibody production in TNCB- 
immune mice by DMBA/TNCB treatment was antigen specific 
To determine if the reduction of contact sensitivity and antibody 
production was antigen specific the non-cross reactive antigen DNFB was 
applied through the DMBA-treated skin of TNCB-immune mice to render the 
mice tolerant to DNFB. When these mice were assessed for contact sensitivity 
to TNCB there was no significant reduction compared to the control TNCB-
immune mice that were treated with acetone followed by DNFB (Figure 3.3). 
Consequently, applying DNFB through DMBA-treated skin did not reduce 
established contact sensitivity to TNCB. 
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Treatment 
Sen. 
Group 
1 st  2nd 
Treat. Resen. 
TNCB TNCB Acetone TNCB 
P < 0.05 	 1 P <0.01 .  TNCB TNCB DMBA TNCB 
40 	80 	0 	16 	256 
% increase in ear thickness 	Titre of anti-TNCB antibodies 
Sen. = Sensitisation 
Treat. = Treatment 
Resen. = Resensitisation 
Figure 3.2 Reduction of established contact sensitivity and antibody 
response following DMBA/TNCB treatment. 
TNCB-immune mice were sensitised by immunising through 
the skin with two separate applications (1st, 2nd) of 0.5% TNCB. 
These mice were then treated with acetone (group 2) or 1% 
DMBA (group 3) and five days later they were resensitised 
through the treated skin with 100111 of 0.5% TNCB. A further 5 
days later contact sensitivity was assessed by ear challenge and 
increase in ear thickness was determined (left panel) and anti-
TNCB antibody levels were assessed by indirect 
haemagglutination (right panel). Naive mice (group 1) were 
untreated throughout but were ear challenged with TNCB. 
Results represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 2 and 3 
using Student's unpaired t-test. 
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Treat. Resen 
1 TNCB TNCB Acetone DNFB 
2 TNCB TNCB DMBA DNFB 
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% increase in ear thickness 
Sen. = Sensitisation 
Treat. = Treatment 
Resen. = Resensitisation 
NS = No significant difference 
Figure 3.3 Downregulation of established immune response by 
DMBA/TNCB is antigen specific. 
TNCB-immune mice were sensitised by immunising 
through the skin with two separate applications (1st, 
2nd) of 0.5% TNCB. These mice were then treated 
either with acetone (group 1) or 1% DMBA (group 2) 
and five days later they were resensitised through the 
treated skin with 10411 of 0.5% DNFB. A further 5 days 
later, contact sensitivity to TNCB was assessed by ear 
challenge and increase in ear thickness was 
determined. Results represent the mean ± standard 
deviation from at least 6 mice. P value was determined 
with Student's unpaired t-test. 
3.2.4 Reduction of contact sensitivity and antibody production in TNCB-
immune mice following adoptive transfer of spleen cells from TNCB-
tolerant mice 
Suppression can be transferred by spleen cells. To determine whether 
spleen cells from TNCB-tolerant mice (i.e. naive mice) treated with DMBA and 
TNCB could also downregulate cell mediated and humoral immune responses 
of TNCB-immune mice, spleen cells were transferred from TNCB-tolerant 
mice to TNCB-immune mice and contact sensitivity and antibody levels to 
TNCB were evaluated. As shown in Figure 3.4, the transfer of spleen cells from 
TNCB-tolerant mice (group 2) to TNCB-immune mice caused a significant 
reduction in both contact sensitivity and antibody responses to TNCB. This 
reduction was antigen specific as spleen cells transferred from DNFB-tolerant 
mice (group 2) to TNCB-immune mice did not reduce either contact sensitivity 
or antibody levels to TNCB. Consequently the transfer of spleen cells from 
TNCB-tolerant mice to TNCB-immune mice caused an antigen specific 
reduction in both cell mediated and humoral immunity. 
3.2.5 Effect of contact sensitivity and antibody production in TNCB-immune 
mice following adoptive transfer of epidermal cells after DMBA 
followed by TNCB treatment 
Downregulation of an established contact sensitivity response can be 
achieved by the transfer of spleen cells from tolerant mice. The next phase of 
this study was to determine if downregulation could be achieved at the 
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Figure 3.4 Downregulation of established immune response by spleen cells 
generated from DMBA/TNCB treated mice. 
Recipent TNCB-immune mice were sensitised by immunising 
through the skin with two separate applications (1st, 2nd) of 
0.5% TNCB. These mice received spleen cells from donor mice 
treated either with acetone followed 5 days later by 0.5% TNCB 
(group 1 - control), 1% DMBA followed 5 days later by 0.5% 
TNCB (group 2 - TNCB tolerant), or 1% DMBA followed 5 days 
later by 0.5% DNFB (group 3 - DNFB tolerant). A further 5 days 
following spleen cell transfer contact sensitivity was assessed by 
ear challenge and increase in ear thickness was determined (left 
panel) and antibody levels were assessed by indirect 
haemagglutination (right panel). Results represent the mean ± 
standard deviation from at least 6 mice. P values were 
determined by comparing group 1 with group 2 and group 1 
with group 3 using Student's unpaired t-test. 
inducer phase. To investigate this possibility epidermal cells from DMBA-
TNCB-treated mice were transferred to TNCB-immune mice. 
Figure 3.5 shows that epidermal cells from DMBA/TNCB-treated donors did 
not cause a downregulation of either contact sensitivity or antibody 
production following either a subcutaneous (sc) injection of 1 x 104 
epidermal cells or an intravenous (iv) injection of 1 X 10 6 epidermal cells. 
This indicates that after DMBA/TNCB treatment epidermal cells could not 
transfer a suppressive signal strong enough to reduce the response in TNCB-
immune mice. 
3.2.6 Effect upon contact sensitivity and antibody production in TNCB-
immune mice following adoptive transfer of TNP coupled epidermal 
cells from DMBA-treated mice 
Epidermal cells obtained from treated with DMBA and incubated in 
vitro with hapten results in the suppression of CHS in naive mice. The next 
aspect of this study was to determine if an established immune response 
could be suppressed by DMBA-treated and TNP-coupled epidermal cells. 
Figure 3.6 shows that neither subcutaneous injection nor intravenous 
injection of DMBA-treated and TNP-coupled epidermal cells could 
downregulate the subsequent TNCB challenge induced immune responses. 
Neither contact sensitivity nor anti-TNCB antibody production was 
downregulated. 
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Figure 3.5 Failure to downregulate an established immune response by 
transfer of epidermal cells from DMBA followed by TNCB treated 
mice. 
Recipent TNCB-immune mice were sensitised by immunising 
through the skin with two separate applications (1st, 2nd) of 
0.5% TNCB. These mice received epidermal cells by s.c or i.v. 
routes from donor mice treated either with acetone followed 5 
days later by 0.5% TNCB (group land 3 - control), or 1% DMBA 
followed 5 days later by 0.5% TNCB (group 2 and 4- test). A 
further 5 days following epidermal cell transfer contact sensitivity 
was assessed by ear challenge and increase in ear thickness 
was determined (left panel) and antibody levels were assessed 
by indirect haemagglutination (right panel). Results represent 
the mean ± standard deviation from at least 6 mice. P values 
were determined by comparing group 1 with group 2 and group 
3 with group 4 using Student's unpaired t-test. 
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Figure 3.6 Epidermal cells from DMBA treated mice coupled with TNBS 
could not suppress an established immune response. 
Recipent TNCB-immune mice were sensitised by immunising 
through the skin with two separate applications (1st, 2nd) of 
0.5% TNCB. These mice received epidermal cells by s.c or i.v. 
routes from donor mice treated with either acetone (group land 
3 - control), or 1% DMBA (group 2 and 4- test) and coupled 
with TNBS. A further 5 days following epidermal cell transfer 
contact sensitivity was assessed by ear challenge and increase in 
ear thickness was determined (left panel) and antibody levels 
were assessed by indirect haemagglutination (right panel). 
Results represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 1 with 
group 2 and group 3 with group 4 using Student's unpaired t-
test. 
3.3 Discussion 
One of the first steps, leading to the development of antigen specific 
immunosuppression is the depletion of LC from the epidermis. Halliday 
and Muller have clearly shown that DMBA has the ability to deplete LC 
from the skin and application of a contact sensitiser through this skin result 
in antigen specific suppression (Halliday and Muller, 1986). Adapting this 
procedure to downregulate an established immune response required 
confirmation that DMBA caused LC depletion in mice that have previously 
been immunised through the skin with a contact sensitiser. LC depletion is 
not a unique phenomenon to carcinogen as the application of this contact 
sensitisers TNCB or DNFB on its own can cause significant LC depletion 
(Woods et al., 1996) and there is evidence showing that when an animal is 
treated with contact sensitiser the LC migrate from the skin to the draining 
lymph (Woods et al., 1996). This is the same result with DMBA treatment of 
the skin which induced LC migration (Dandie et al., 1992; Dandie et al., 
1994). The consequence of the pretreatment of TNCB is unknown. However, 
the results in this thesis demonstrate that LC depletion from the epidermis 
of TNCB-immune mice occurred following exposure to DMBA, but it is 
important to note that the DMBA application was applied to a different site 
than the original site of TNCB immunisation. This was undertaken as a 
deliberate measure to mimic as closely as possible the situation in naive 
mice that had not been exposed to antigen. 
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In both naive and immune mice, the same treatment resulted in a 
downregulation of established immunity suggesting that similar 
mechanisms that caused antigen specific suppression in naive mice also 
triggered immune suppression in immune mice. However in immune 
mice, unlike naive mice, where the immune response was completely 
abolished to hapten, the downregulation did not reach the background level. 
It is possible that although similar suppressive factors or signals were 
generated in both naive and immune mice, these signals did not have the 
strength ability to completely reverse or to silence previously activated T 
lymphocytes, possibly due to the fact that secondary T cell responses are 
more intense than primary response. Consequently suppression of naive T 
cell activation is more effective than suppression of previously activated T 
cells. 
The ability to transfer suppression from tolerant mice to naive mice via 
spleen cells (Halliday and Muller, 198Th) indicates that the spleen contains a 
population which can prevent the induction of an immune response in an 
antigen specific manner. This population could also downregulate an 
established immune response and therefore provide further support for the 
concept that similar mechanisms of suppression operate at the cellular level 
in both naive and immune mice. However, in immune mice, these 
suppressive mechanism may not be as effective and as a result, an 
established immune response is only partially downregulated. 
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Coupling of hapten to DMBA-treated cells in vivo or in vitro did not 
suppress CHS or antibody production when these cells were transferred to 
immune mice. In contrast, the immune response of naive mice became 
tolerant when these mice received DMBA-treated hapten-coupled epidermal 
cells (Halliday et al., 1988). It is likely that inactivation of memory T cells 
requires suppressor effector cells rather than suppressor inducer cells. The 
suppressive signals generated by DMBA-treated epidermal cells may not be 
sufficiently strong enough to suppress memory T cells. Alternatively the 
number of DMBA-treated epidermal cells required to suppress an 
established immune response may be greater than the number required to 
prevent the induction of immune response in naive mice. This might be a 
consequence of the greater number of antigen specific cells present in 
immune mice following clonal expansion in response to antigen 
stimulation. 
It is concluded from this study that manipulation of the skin immune 
system by DMBA was able to reduce an established immune response either 
by in vivo treatment or by spleen cells transfer. This suppression has parallel 
outcomes for both cellular and humoral immune responses with a 
downregulation of both. However, modified epidermal cells did not have 
the ability to suppress an established immune response using current 
methods. These basic observation have clinical relevance for the treatment 
of autoimmune disease as the downregulation of established immunity may 
be sufficient to benefit over-reactive immunity. 
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Chapter Four 
Downregulation of Established Immune 
Response by Physical Carcinogen 
4.1 Introduction 
The previous chapter has shown that an established immune 
response can be downregulated by modifying epidermal LC by DMBA 
treatment. However, as DMBA is a toxic carcinogen it does not lend itself to 
the ultimate goal of human trials. Alternatively, a workable agent that has a 
similar ability to suppress the immune response through the skin treatment 
is ultraviolet light (UVB) irradiation. It has been well established that 
cutaneous exposure to UVB irradiation alters the immune response and 
leads to the suppression of CHS to haptens applied through the irradiated 
epidermis in mice (Toews et al., 1980) and in humans (Yoshikawa et al., 
1990). Since LC play a role in the induction of immunity and as LC are 
depleted from the skin by UVB irradiation, it has been suggested that the 
loss of LC contributes to the induction of tolerance (Stingl et al., 1981; Aberer 
et al., 1981). Various other factors are also involved in UVB-induced 
immune suppression. For example, isomerization of urocanic acid from 
trans to cis following UVB irradiation has been linked with the induction of 
immune tolerance (Noonan and De Fabo, 1992). An increase of Interleukin-
10 after UVB irradiation also been correlated with the induction of 
immunosuppression (Rivas and Ullrich, 1994). Macrophages have also been 
shown to be involved in UVB-induced immune suppression as there is an 
increase in their number in the draining lymph nodes and at the site of 
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UVB irradiation (Cooper et al., 1986; Duraiswamy et al., 1994). Consequently, 
UVB irradiation can induce immune suppression via a number of potential 
mechanisms, however, LC depletion is most likely to play a prominent role. 
This immune suppression is also antigen specific as spleen cells adoptively 
transferred from UVB and hapten-treated mice to naive syngeneic mice 
transfer antigen specific tolerance (Elmets et al., 1983; Simon et al., 1992). It 
has been proposed that hapten-specific suppressor cells may play a key role 
in the induction of tolerance (Greene et al., 1979; Ullrich, 1995b). The ability 
to induce antigen specific suppression by UVB and hapten treatment thus 
provides an alternative strategy to manipulate the immune system in an 
antigen-specific manner, such that inappropriate or deleterious immune 
responses including those associated with autoimmunity, could be 
modulated. 
Indeed UVB radiation has been used in the treatment of various immune 
disorders in humans. A combination therapy of psoralen and UVA has been 
well established for the treatment of psoriasis, atopic dermatitis, vitiligo, and 
T cell lymphoma (Ullrich et al., 1989). UVB combined with coal tar also has 
been shown to be effective in treating psoriasis (Stern et al., 1980). Narrow-
Band UVB wavelengths situated around 313 nm have been used to 
effectively treat atopic dermatitis (Green et al., 1988). Other beneficial effects 
of UVB therapy include reduction of prostaglandins which mediate 
inflammation (Katayama and Hori, 1984), increase of vitamin D synthesis 
(Staberg et al., 1988), and immunosuppression (Teunissen et al., 1993). 
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4.2 Results 
4.2.1 Effect of different UVB doses on LC depletion 
The study with DMBA showed that LC were depleted 5 days after 
DMBA treatment in TNCB-immune mice. To ascertain that UVB 
irradiation causes LC depletion in TNCB-immune mice rather in addition to 
naive mice and to determine its optimal dose the LC numbers of the dorsal 
skin were evaluated 5 days after different UVB doses. The results, showed 
that 5 days after UVB irradiation LC numbers were significantly reduced 
when the skin was exposed to doses of 7 kJ/m2 or higher (Figure 4.1). 
4.2.2 Time course of LC depletion following UVB-irradiation 
Unlike DMBA, maximum LC depletion may not occur 5 days after 
irradiation. Previous studies have shown a time dependent reduction in LC 
number following UVB irradiation, and the kinetics of this reduction was 
driven by the initial UVB dose (De Rie and Bos, 1997). Consequently it was 
important to determine the appropriate time after UVB-irradiation for 
maximum LC-depletion in TNCB-immune mice and therefore 
development of immunosuppression. As 7 and 13 kJ/m 2 caused significant 
LC depletion at 5 days post irradiation, these doses were utilized. The dose of 
7 kJ/m2 was the minimum dose that caused LC depletion whereas 13 kJ/m 2 
was the maximum dose that did not cause excessive erythema and 
discomfort for the mice (Doses of 20 kJ/m2 or higher were abandoned due to 
ethical constraints). As shown in Figure 4.2, both 7 and 13 kJ/m 2 UVB doses 
could significantly deplete LC numbers at 3 and 5 days after irradiation. The 
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Figure 4.1 Number of LC in the epidermis of TNCB-immune 
mice five days after UVB irradiation. 
Mice were sensitised by immunising through the 
skin with two separate application of TNCB, 5 days 
apart. The TNCB-immune mice were then treated 
with UVB irradiation and a further 5 days later the 
number of Ia+ cells was determined. Results 
represent the mean ± standard deviation from at 
least 6 mice. P values were determined by comparing 
the control group (0 kJ/m 2) and test groups using 
Student's unpaired t-test. 
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Figure 4.2 Number of LC in the epidermis of TNCB-immune mice 
at 1,3,5 or7 days following UVB irradiation. 
Mice were sensitised by immunising through the skin 
with two separate application of TNCB, 5 days apart. The 
TNCB-immune mice were then treated with UVB 
irradiation at 7 (0) or 13 kJ/m2 (•) and a further 1,3,5 or 7 
days later the number of MI - cells was determined. Results 
represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing control 
group (0 kJ/m 2) and test groups using Student's unpaired 
t-test. 
13 kJ/m 2 UVB reduced LC numbers from day 1 to day 7 after irradiation 
whereas 7 kJ/m2 UVB reduced LC numbers from day 3 to day 5 after 
irradiation. In current protocol, the most effective time of LC depletion for 
both doses was 3 days after irradiation. 
4.2.3 Application of TNCB three days after UVB irradiation did not reduce 
contact sensitivity or antibody production in TNCB immune mice 
As LC depletion was the most significant 3 days after UVB irradiation 
it was predicted that hapten application at this time would lead to antigen 
specific downregulation of an established immune response. As shown in 
Figure 4.3, when TNCB was applied through the skin of TNCB-immune 
mice 3 days after UVB irradiation there was no significant reduction in 
contact sensitivity. A slight, but not statistically significant reduction was 
seen following UVB doses 7 kJ/m 2 or higher. At all doses, antibody levels to 
TNCB were not affected (Figure 4.3). Hence, the established TNCB 
immunity, neither contact sensitivity nor antibody production was 
significantly downregulated if TNCB was applied to skin 3 day after UVB 
irradiation. 
4.2.4 Application of TNCB five days after UVB irradiation reduced contact 
sensitivity but not antibody production in TNCB immune mice 
Although 3 days after UVB irradiation caused maximum LC 
depletion, this time course did not cause significant immune suppression. 
Miyauchi and Horio (1995) reported similar findings in naive mice as 
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Figure 4.3 Unaffected contact hypersensitivity and antibody responses 
following UVB/TNCB treatment. 
Mice were sensitised by immunising through the skin with two 
separate applications (1st, 2nd) of 2% TNCB, 5 days apart. 
Control mice (group 1) were treated with acetone alone. TNCB-
immune mice were then treated with varying doses of UVB 
irradiation and three days later they were resensitised through 
the treated skin with 10011.1 of 2% TNCB. A further 5 days later 
contact sensitivity to TNCB was assessed by ear challenge and 
increase in ear thickness was determined (left panel) and 
antibody levels were assessed by indirect haemagglutination to 
TNCB (right panel). Naive mice (group 1) were untreated but 
were ear challenged with TNCB alone. Remaining groups (2-6) 
received 0,1,3,7 or 13 kJ/m2 UVB irradiation respectively. 
Results represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 2 with 
groups 3,4,5 and 6 using Student's unpaired t-test. 
maximal LC depletion did not generate suppression in UVB irradiated mice. 
In effect, a maximum suppression occurred 2 days after maximum LC 
depletion (Miyauchi and Horio, 1995). As application of TNCB 3 days 
following UVB irradiation did not downregulate an established immune 
response the next procedure was to increase this period to 5 days after UVB 
irradiation. As shown in Figure 4.4, when TNCB was applied through the 
UVB irradiated skin of TNCB-immune mice there was a dose dependent 
reduction in contact sensitivity to TNCB. When given as a single dose, at 
least 7 kJ/m 2 UVB irradiation was required to cause a significant reduction in 
contact sensitivity. However, at all doses, antibody levels to TNCB were not 
affected. Although the reduction in contact sensitivity was significant, it was 
not a complete reduction, as in all UVB doses tested the contact sensitivity 
was much higher than the control mice (group 1) that had not been exposed 
to TNCB until they were ear challenged. Therefore a single UVB dose of 7 
kJ/m2 or more, significantly downregulated cell mediated immunity but not 
humoral immunity in TNCB-immune mice. 
As 7 kJ/m 2 was the minimum dose that caused significant immune 
suppression, this dose was used throughout the remainder of this thesis. 
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Figure 4.4 Reduction of established contact sensitivity but not antibody 
response following UVB/TNCB treatment. 
Mice were sensitised by immunising through the skin with 
two separate applications (1st, 2nd) of 2% TNCB, 5 days apart. 
Control mice (group 1) were treated with acetone alone. TNCB-
immune mice were then treated with varying doses of UVB 
irradiation and three days later they were resensitised through 
the treated skin with 10011.1 of 2% TNCB.A further 5 days later 
contact sensitivity to TNCB was assessed by ear challenge and 
increase in ear thickness was determined (left panel) and 
antibody levels were assessed by indirect haemagglutination to 
TNCB (right panel). Naive mice (group 1) were untreated but 
were ear challenged with TNCB alone. Remaining groups (2-6) 
received 0,1,3,7 or 13 kJ/m 2 UVB irradiation respectively. 
Results represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 2 with 
groups 3,4,5 and 6 using Student's unpaired t-test. 
4.2.5 Three consecutive doses of UVB irradiation followed by TNCB reduced 
an established contact sensitivity response but not antibody 
production 
Although an established contact sensitivity response could be 
downregulated by application of antigen 5 days following UVB irradiation, 
this reduction did not reach the background level. The next aspect of this 
study was to increase the downregulation of an established immune 
response. Consecutive doses of UVB irradiation have a greater 
immunosuppressive effect on the induction of immunosuppression. TNCB 
application following 3 consecutive doses of 7 kJ/m 2 UVB irradiation to 
immune mice caused a significant reduction of contact sensitivity but 
antibody levels to TNCB remained unaffected (Figure 4.5). The reduction in 
contact sensitivity, although significant, still did not reach the background 
level. 
4.2.6 Three consecutive cycles of UVB irradiation followed by TNCB reduced 
an established contact sensitivity response but not antibody 
production 
In a further attempt to completely reduce contact sensitivity an 
alternative strategy was employed. Since the generation of suppressor cells 
came from the treatment of application of hapten through the LC-depleted 
skin, TNCB-immune mice were treated with 3 consecutive cycles of 7 kJ/m2 
UVB irradiation followed by TNCB. As shown in Figure 4.6 contact 
sensitivity was significantly reduced but antibody levels to TNCB remained 
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Figure 4.5 Reduction of established contact sensitivity but not antibody 
response following 3 consecutive doses of UVB. 
Mice were sensitised by immunising through the skin with 
two separate applications (1st, 2nd) of 2% TNCB, 5 days apart. 
Control mice (group 1) were treated with acetone alone. The 
TNCB-immune mice were either untreated (group 2) or treated 
with 3 consecutive doses of 7 kJ/m 2 UVB irradiation 2 days 
apart (group 3). Five days following the final UVB irradiation 
they were resensitised through the treated skin with 100111 of 
2% TNCB. A further 5 days later contact sensitivity to TNCB 
was assessed by ear challenge and increase in ear thickness was 
determined (left panel) and antibody levels to TNCB were 
assessed by indirect haemagglutination (right panel). Naive 
mice (group 1) were untreated but ear challenged with TNCB. 
Results represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 2 and 
group 3 using Student's unpaired Hest. 
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Figure 4.6 Reduction of established contact sensitivity but not antibody 
response following 3 consecutive UVB -TNCB treatments. 
Mice were sensitised by immunising through the skin with two 
separate applications (1st, 2nd) of 2% TNCB, 5 days apart. Control 
mice (group 1) were treated with acetone alone. The TNCB-
immune mice were then either treated with 2%TNCB alone 
(group 2) or with 3 consecutive cycles of 7 kJ/m 2 UVB followed 5 
days later with TNCB and the cycle repeated after another 5 days 
(group 3). Five days following the final TNCB treatment contact 
sensitivity to TNCB was assessed by ear challenge and increase in 
ear thickness was determined (left panel) and antibody levels to 
TNCB were assessed by indirect haemagglutination (right 
panel). Naive mice (group 1) were untreated but ear challenged 
with TNCB alone. Results represent the mean ± standard 
deviation from at least 6 mice. P values were determined by 
comparing group 2 and group 3 using Student's unpaired t-test. 
unaffected. Again, although the reduction in contact sensitivity was 
statistically significant, it did not reach background level. 
4.3 Discussion 
The ability to prevent the development of an immune response 
provides an opportunity to manipulate the immune system and avoid the 
induction of inappropriate immune responses including autoimmune 
diseases. When contact sensitisers were painted on UVB pre-treated skin, a 
state of immunosuppression was induced instead of a normal CHS 
response. This was due to the loss of skin dendritic cells, the LC. In the 
present study, the LC were depleted at day 3 or day 5 after UVB irradiation, 
when UVB doses of 7 kJ/m 2 or greater were given. In the situation of pre-
treatment with UVB, the degree of LC depletion often correlated with the 
degree of immunosuppression. Interestingly, in mice with an established 
immune response, when hapten was applied to the skin 3 days after a dose 
of UVB irradiation which resulted in the most severe loss of LC, 
suppression of CHS response was not achieved. However, suppression of an 
established immune response was obtained when the hapten was applied 
through skin that, 5 days before, had been irradiated with a high dose of 
UVB. This suggested that the stronger immune suppressive signals were 
generated after 5 days of UVB irradiation. 
The comparison between multiple doses in naive and immune mice 
showed a different result. It has been demonstrated that multiple doses of 
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UVB irradiation could lead to more effective tolerance induction compared 
to a single dose of UVB irradiation (Miyauchi and Horio, 1995). In the 
present study, multiple doses did not create a greater immune suppression, 
as the suppression was no greater than a single high UVB dose. There are 
few reports describing experiments designed to downregulate an established 
CHS response. One group that did evaluate contact sensitivity was Kosiewcz 
et al. (1994). They failed to detect a reduction in contact sensitivity when 
DNFB-immune mice were treated with 4 daily UVB doses of 0.4 kJ/m 2 
followed 1 hour after the final UVB dose with DNFB. This regime was able 
to induce suppression in naive mice but not in immune mice, thus 
contrasting with the present study. The apparent discrepancy may reflect the 
UV irradiation protocols and timing of antigen application. This thesis study 
found that a single dose of 7 kJ/m 2 was required to cause a significant 
downregulation of established immunity. This is substantially higher than 
the 4 consecutive doses of 0.4 kJ/m 2 undertaken by Kosiewcz and colleagues. 
Other differences may relate to the strains of mice (BALB/c compared to 
C3H) or the timing of antigen application. This thesis study found that 
application of antigen 3 days post-UVB exposure was not able to induce 
significant downregulation. At least 5 days post-UVB exposure was required 
to cause significant downregulation. As Kosiewcz et al. applied antigen 
immediately after the final UVB irradiation, the microenvironment in the 
skin may not have changed to the extent required for a suppressor signals to 
be generated. 
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The results presented here did not show complete downregulation of the 
immune response, even after repeated treatments with UVB irradiation. 
This may relate to the ability of UVB followed by hapten to stimulate 
memory T cells. The activation requirements of naive T cells include the 
appropriate antigen/TCR interaction as well as a range of costimulatory 
signals including the B7/CD28 system and soluble mediators such as the 
cytokines IL-1 (Simon et al., 1991) and IL-12 (Kang et al., 1996). Memory T 
cells can be restimulated via TCR ligation and a reduced requirement for 
costimulation (Katz, 1988; Van de Velde et al., 1993; Croft et al., 1994). It may 
therefore be possible that following UVB-treatment, some functional 
antigen-presenting cells remain in the skin, which induces the activation of 
the memory T cells. An alternative explanation may relate to the nature of 
the suppressor signal which prevents the activation of naive T cells more 
effectively than memory cells. 
UVB irradiation did not affect antibody production in most of the study 
involving in the use of naive mice (Kim et al., 1990). However, some reports 
may suggest that UVB irradiation may affect antibody production. Ullrich 
and colleagues (Ullrich et al., 1986b) showed in an in vivo study that 
suppressive cells generated by hapten applied through 40 kJ/m 2 UVB 
irradiated skin and transferred to naive mice could reduce the number of 
direct plaque-forming cells of the recipient against hapten. This was antigen 
specific as the plaque-forming cells against other antigens were not reduced. 
Another study by Spellman et al. documented that application of 
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immunoglobulin through the UVB irradiated skin did result in the 
suppression of antibody production (Spellman et al., 1984). The present 
study, used high doses of UVB radiation, both signal and multiple 
applications, were unable to suppress the antibody production in immune 
mice. It appears that tolerance induced by UVB had little effect on 
suppression of antibody production in immune mice. 
In comparison, both contact sensitivity and antibody production were 
downregulated in immune mice following DMBA treatment. However, 
contact sensitivity but not antibody mediated immunity was reduced when 
immune mice were treated with UVB followed by hapten. This difference in 
suppression by DMBA and UVB is consistent with the observed suppression 
in naive animals and reflects the ability of DMBA/TNCB treatment to 
prevent both Th1 and Th2 responses, whereas UVB irradiation is more 
likely to prevent Th1 responses, probably by inducing the production of Th2 
cytokines, including IL-4 and IL-10 (Rivas and Ullrich, 1992). Such a 
consistent response observed with both naive and immune animals 
indicates that a similar underlying mechanism of suppression was 
involved. 
These responses propose that suppressor cells were generated as the transfer 
of spleen cells from TNCB-tolerant mice to TNCB-immune mice also 
resulted in antigen specific suppression and reduced the immune response. 
The transfer of suppression to naive mice is due to antigen specific 
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suppressor cells which are induced after the application of antigen to LC-
depleted skin (Halliday et al., 1988). This cellular suppressor signal has the 
ability to prevent the induction of an immune response and as shown in 
this study is also able to significantly reduce an established response. 
The ability to reduce an established immune response in an antigen specific 
manner has important implications for the potential treatment of allergic 
and autoimmune diseases where the causative antigens have been 
identified. Although immunisation through carcinogen modified skin only 
partially suppressed an established immune response, this reduction may be 
sufficient to ameliorate the symptoms of an autoimmune disease. Future 
studies in this area could be directed at a greater reduction or ablation of an 
ongoing immune response. 
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Chapter Five 
Peripheral Tolerance Induction in 
Thymectomised Mice by Immunisation 
Through Chemical Carcinogen Altered Skin 
5.1 Introduction 
Following the demonstration that downregulation of an established 
immune response could be achieved by applying hapten through altered 
skin, the next step of this study was to evaluate whether an autoimmune 
disease could be modulated by a similar approach. The first consideration 
before such an undertaking was to determine an appropriate model. As the 
induction of antigen specific immunosuppression requires at least two 
components, modification of the skin and an antigen that could be applied 
through this modified environment, it was important to select a model of 
autoimmunity where the autoantigen had been well characterised. 
Furthermore, for effective monitoring of disease progression it was crucial 
that a measure of autoimmunity, such as levels of autoantibodies could be 
routinely performed. One such model is autoimmune gastritis (AIG). The 
identification of the autoantigens came from tests examining the specificity 
of parietal cell autoantibodies present in the circulation of animals with 
AIG. The autoantibodies are parietal cell specific and can be routinely 
monitored by immunofluorescence using serum samples on stomach 
sections (Fukuma et al., 1988). 
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The target of the autoantibodies in the parietal cells is the WIC -ATPase (also 
known as the proton pump), the enzyme responsible for acidification of 
gastric juice. More specifically the autoantigen is the 95 kDa a-subunit and 
more specifically the 60-90 kDa glycoprotein f3-subunit of the WIC -ATPase 
(Jones et al., 1991; Gleeson and Toh, 1991; Toh et al., 1992) and peptide 
mapping of this antigen has identified the active epitope (Toh et al., 1990). 
Experimentally, this disease can be induced by two main procedures. Firstly, 
immunisation of BALB/c mice with rat gastric parietal cells in Freund's 
complete adjuvant leads to the induction of gastritis and circulating 
antibodies to the WIC -ATPase (Kontani et al., 1992). Gastritis could be 
induced by immunising dogs with gastric mucosal extracts (Hennes et al., 
1962). Immunisation of rhesus monkeys with gastric mucosal extracts in 
Freund's complete adjuvant also resulted in gastritis (Andrada et al., 1969). 
More recently, normal BALB/c mice immunised with purified murine 
gastric WIC -ATPase emulsified in complete Freund's adjuvant developed 
autoimmune gastritis (Scarff et al., 1997). However this approach, requires 
continued immunisation with the gastric WIC -ATPase to maintain the 
disease. 
The second approach is to use mice thymectomised 3 days after birth 
(3dnTx). These mice generate autoimmune gastritis in approximately 60 
percent of animals (Kojima and Prehn, 1981; Murakami et al., 1993). The 
mice have similar pathological lesions to those in pernicious anaemia in 
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humans (Kojima and Prehn, 1981; Gleeson et al., 1996) and the disease is 
maintained throughout the life of the mouse without any further treatment 
(Kojima and Prehn, 1981). As with the immunisation model, the 
auto antigen is the gastric FrIC-ATPase and the disease can be monitored by 
screening for autoantibodies in the blood. As the 3dnTx immunisation 
model results in life-long disease and reflects an altered immunoregulation 
mechanism it was selected as the appropriate model to use in this 
investigation. 
It has been hypothesized that progenitor autoreactive T cells are present in 
the periphery (Bonomo et al., 1995a; Bonomo et al., 1995b), but appear to be 
in a state of anergy (Jones et al., 1990; Kruisbeek et al., 1992). Analysis of this 
hypothesis has lead to the proposal that following thymectomy, particularly 
at day 3 after birth, populations of immunoregulatory T cells lost. Analysis 
of the lymphocyte populations in these mice indicates that an absence of the 
regulatory T cells that control self-reactive cells was responsible for this 
autoimmune disease (Bonomo et al., 1995b). Evidence that these regulatory 
T cells exist in adult mice was provided by adoptive transfer of normal 
spleen cells (Taguchi and Nishizuka, 1987; Taguchi et al., 1990), particularly 
the CD4+ CD25+ T cells (Asano et al., 1996) from healthy adult mice to 3dnTx 
mice. This prevents the development of AIG implicating a role for these T 
cells in the maintenance of peripheral tolerance to the gastric antigens. 
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These background observations provide a number of interesting questions 
relating to immunoregulation and the fate of T cell subpopulations. Of 
particular interest to the studies in this thesis was the question of whether 
active suppression could be induced following application of antigen 
through LC-depleted skin in the 3dnTx mice. The ability to generate 
suppression via this approach would confirm the validity of this model and 
provide evidence that peripheral tolerance could still be induced thus 
providing a strategy for the treatment of autoimmune gastritis. 
Prior to undertaking the specific experiments to evaluate the potential of 
applying antigen through a modified skin environment to produce systemic 
antigen specific suppression it was important that the immune status of the 
3dnTx mice was evaluated. This chapter summarises the immunological 
status of 3dnTx mice assessed by enumeration of CDC and CD8+ T cells; the 
capacity of spleen cells from these mice to respond to the mitogen PHA; 
evaluation of contact hypersensitivity responses to TNCB, and 
determination of the ability of these mice to generate antigen specific 
suppressor cells to TNCB induced contact hypersensitivity and antibody 
production. As an extension of this study nude mice that respond to TNCB 
immunisation were also examined in a similar manner to determine the 
absolute requirement of the thymus for the generation of suppression. 
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5.2 Results 
5.2.1 Development of autoimmune gastritis 
Thymectomised mice developed autoimmune gastritis as assessed by 
autoantibody titres 32. AIG negative mice were defined by an autoantibody 
<8. Titres of 8 and 16 were classified as indeterminate and mice were not 
used. Mice with titres ?_. 32 comprised 50-60 percent of the 3dnTx mice; 10 
percent of 3dnTx mice were in the undetermined group and the rest were 
AIG negative mice. 
5.2.2 Proliferative responses of 3dnTx mice splenic lymphocytes pre and post 
DMBA treatment 
The splenic lymphocytes from the 3dnTx mice showed a reduced 
ability to respond to PHA (Figure 5.1). After cutaneous application of 1% 
DMBA there was a further reduction in the PHA-induced proliferation from 
3dnTx mice as well as a reduction in proliferation of cells from normal 
control mice (Figure 5.2). Thus thymectomy and/or topical application of 
DMBA reduced the ability of lymphocytes to proliferate in response to PHA. 
5.2.3 LC density in 3dnTx mice following DMBA-treatment 
As reduced LC density is a critical component for the induction of 
antigen specific tolerance, LC density in 3dnTx mice following DMBA 
application was examined. Results shown in Figure 5.3 demonstrate that 
application of DMBA caused a significant reduction in LC density compared 
to acetone treated controls. 
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Figure 5.1 PHA induced proliferation of lymphocytes from 3dnTx 
mice. 
Spleen cells from normal or 3dnTx mice at 10 5 /well 
were incubated with various concentrations of PHA for 
3 days at 37°C, 5%CO2 and proliferation was determined 
by [3H] thymidine incorporation. Results represent the 
mean ± standard deviation of triplicate cultures from a 
representative experiment. 
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Figure 5.2 PHA induced proliferation of lymphocytes from DMBA or 
acetone treated normal or 3dnTx mice. 
Spleen cells from DMBA or acetone treated normal or 
3dnTx mice at 105 /well were incubated with various 
concentrations of PHA for 3 days at 37°C, 5%CO2 and 
proliferation was determined by [ 3H] thymidine 
incorporation. Results represent the mean ± standard 
deviation of triplicate cultures from a representative 
experiment. 
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Figure 5.3 Number of LC residing in the epidermis five days 
after DMBA (test) or acetone treatment (control). 
Results represent the mean ± standard deviation 
from at least 6 3dnTx mice. P value was determined 
by Student's unpaired t-test. 
P <0.0001 
5.2.4 Lymphocyte numbers in 3dnTx mice 
There was overall reduction in the total number of lymphocytes from 
the spleen of 3 dnTx mice (Table 5.1). When the relative number of T and B 
cells was evaluated the percentage of B220+ B cells was found to be 
unchanged in the 3dnTx mice compared to normal mice whereas the 
percentages of CD4+ and CD8+ T cells were decreased (Figure 5.4). This was 
observed -with all thymectomised mice, irrespective of whether they 
developed autoimmune gastritis. As the relative proportion of CD4+ and 
CD8+ remained unchanged in the 3dnTx mice this indicates that 
thymectomy did not alter the balance of these cells. Following cutaneous 
exposure to DMBA the ratio of T and B cells was unaffected but the total 
number of spleen cells was further reduced (Table. 5.1). 
5.2.5 Induction of immunosuppression in 3dnTx mice 
As changes in lymphocyte population were observed with 3dnTx 
mice it was important to evaluate immune tolerance induction. When 
TNCB was applied through the DMBA-treated skin of thymectomised mice 
there was neither a contact sensitivity nor antibody response (Figure 5.5). 
This occurred with all the DMBA-treated thymectomised mice, irrespective 
of whether they developed AIG. 
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Mice Treatment Average numbers of spleen cell per mouse 
Normal mice 
Acetone 10.00 x 107 	± 	0.95 x 107 
DMBA 5.10 	x 107 	± 	0.41 x 107 
3dnTx mice 
(AIG positive) 
Acetone x 107 	± 	0.45 x 107 
DMBA 3.15 	x 107 	± 	0.13 x 107 
3dnTx mice 
(AIG negative) 
Acetone 4.05 	x 107 	± 	0.32 x 107 
DMBA 3.25 	x 107 	± 	0.16 x 107 
Table 5.1 Number of spleen cells from normal and 3dnTx mice. 
Mice treated with DMBA showed a reduced number of 
total spleen cells. Normal mice contained more spleen 
cells than 3dnTx mice. Result represent the mean± 
standard deviation from 6 mice per group. 
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Acetone treated 
normal mice Ji Y/X/* 
DMBA treated 
normal mice 1-1 =1-1 
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AIG- mice =11 
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Figure 5.4 Phenotypic analysis of lymphocytes from the spleen of 
normal and 3dnTx mice. 
Normal mice (upper panel), AIG- 3dnTx mice (middle 
panel), or AIG+ 3dnTx mice (lower panel ) were treated 
with either the acetone vehicle or DMBA and the spleen 
removed 5 days later. Results represent the mean ± 
standard deviation for each phenotypic marker from 
each group. 
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Figure 5.5 Induction of immunosuppression following DMBA/TNCB 
treatment of 3dnTx mice. 
Thymectomised mice were subdivided into mice with disease 
(AIG+; groups 1 and 2) and mice without disease (AIG-; groups 
3 and 4) and were treated with either 1% DMBA or acetone 
followed 5 days later with 2% TNCB. A further 5 days later 
contact sensitivity was assessed by ear challenge and increase in 
ear thickness was determined (left panel) and antibody levels 
were assessed by indirect haemagglutination (right panel). 
Control mice (group 5) received no treatment prior to ear 
challenge. Results represent mean ± standard deviation from at 
least 6 mice. P values were determined by comparing group 1 
with group 2 and group 3 with group 4 using Student's 
unpaired t-test; 
5.2.6 Induction of immunosuppression in 3dnTx mice by DMBA/TNCB 
treatment was antigen specific 
To determine if the reduction of cell mediated response was antigen 
specific the non-cross reactive antigen DNFB was applied through the DMBA-
treated skin of 3dnTx mice to render the mice tolerant to DNFB. When these 
mice were assessed for contact hypersensitivity to TNCB there was no 
significant reduction in cell mediated immunity compared to the control mice 
which were treated with acetone followed by DNFB (Figure 5.6). Consequently, 
applying DNFB through DMBA-treated skin did not induce tolerance to TNCB. 
5.2.7 Induction of immunosuppression in 3dnTx mice by DMBA treatment had 
a systemic effect 
Normal mice treated with DMBA develop antigen specific suppression 
when antigen is applied through the LC-depleted skin (Halliday and Muller, 
1986), but not when antigen is applied through normal untreated skin. Results 
shown in Figure 5.7 demonstrate that when antigen is applied through the 
abdominal skin of 3dnTx mice treated with DMBA on the dorsal skin there is a 
significant reduction in both contact sensitivity and in antibody production. 
Thus in 3dnTx mice DMBA-treatment resulted in a systemic effect on 
immunosuppression. 
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Figure 5.6 Induction of immunosuppression in 3dnTx mice is 
antigen specific. 
Groups of mice were treated with acetone or DMBA 
on shaved abdominal skin. Five days later, groups of 
mice were sensitised by applying TNCB to the treated 
(abdominal) skin and DNFB to the untreated (dorsal 
skin). A further 5 days later contact sensitivity to 
DNFB was assessed by ear challenge and increase in 
ear thickness was determined (CHS). Results 
represent the mean ± standard deviation from at 
least 6 mice. P value was determined by comparing 
group 1 with group 2 using Student's unpaired t-test. 
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Figure 5.7 Induction of immunosuppression in 3dnTx mice is local 
and systemic. 
Groups of mice were treated with acetone or DMBA on 
dorsal skin. Five days later, the mice were sensitised by 
applying TNCB to the treated (dorsal) skin or to the 
untreated (ventral) skin. A further 5 days later contact 
sensitivity to TNCB was assessed by ear challenge and 
increase in ear thickness was determined (CHS) and 
antibody levels were assessed by indirect 
haemagglutination to TNCB (Ab production). Results 
represent the mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 1 
with group 2 and group 1 with group 3 using Student's 
unpaired t-test. 
5.2.8 Generation of transferable suppression in 3dnTx mice 
The ability to induce immunosuppression in 3dnTx mice posed the 
question of the ability of these mice to produce antigen specific suppressor 
cells. Results illustrated in Figure 5.8 demonstrate that transferable 
suppression was induced by DMBA/TNCB treatment of 3dnTx mice. 
Adoptive transfer of the spleen cells from these mice transferred 
suppression as the ability of the recipient mice to respond to TNCB was 
significantly reduced when compared to the control mice which received 
normal spleen cells. This transfer of suppression was observed in all 3dnTx 
mice irrespective of whether they developed AIG, and both contact 
sensitivity and antibody production was suppressed. 
5.2.9 Generation of antigen specific suppressor cells in 3dnTx mice 
To determine whether spleen cells from TNCB-tolerant 3dnTx mice 
(i.e. 3dnTx mice treated with DMBA and TNCB) could also suppress cell 
mediated and humoral immune responses in an antigen specific manner, 
spleen cells were transferred from other hapten-tolerant 3dnTx mice to 
3dnTx mice. Spleen cells of DMBA alone treated 3dnTx mice were also 
transferred to 3dnTx mice to determine whether DMBA alone could 
generate suppressor cells. As shown in Figure 5.9, recipient mice that 
received spleen cells from 3dnTx mice treated with DMBA followed by the 
antigen DNFB, did not have any reduction in either contact sensitivity or 
antibody production to TNCB, whereas recipient normal mice that received 
spleen cells from 3dnTx mice treated with DMBA followed by TNCB had a 
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Figure 5.8 Adoptive transfer of immunosuppression. 
Spleen cells were transferred to naive mice from TNCB tolerant 
3dnTx mice which had been subdivided into mice with disease (AIG+: 
groups 1 and 2) and mice without disease (AIG-: groups 3 and 4) and 
were treated cutaneously with either 1% DMBA or acetone followed 5 
days later with 2% TNCB at the same site. Five days after transfer all 
mice (except group 5) were sensitized with 2% TNCB and a further 5 
days later contact sensitivity was assessed by ear challenge and increase 
in ear thickness was determined (left panel) and antibody levels were 
assessed by indirect haemagglutination (right panel). Control mice 
(group 5) received spleen cells from 3dnTx mice that received no 
treatment. Results represent mean ± standard deviation from at least 6 
mice. P values were determined by comparing group 1 with group 2 
and group 3 with group 4 using Student's unpaired t-test. 
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Figure 5.9 Adoptive transfer of antigen specific immunosuppression. 
Spleen cells were transferred from TNCB or DNFB tolerant 
3dnTx mice which had been treated cutaneously with either 
acetone or 1% DMBA followed 5 days later with 2% TNCB 
(group 1 and group 2), 1% DMBA followed 5 days later by 2% 
DNFB (group 3), 1% DMBA only (group 4). Five days after 
transfer all mice sensitized challenged with 2% TNCB and a 
further 5 days later contact sensitivity was assessed by ear 
challenge and increase in ear thickness was determined (left 
panel) and antibody levels were assessed by indirect 
haemagglutination (right panel). Control mice (group 5) received 
no treatment prior to ear challenge. Results represent mean ± 
standard deviation from at least 6 mice. P values were 
determined by comparing group 1 with group 2 and group 3 
with group 4 using Student's unpaired t-test. 
significantly reduced contact sensitivity and antibody response when 
challenged with TNCB thus indicating antigen specificity (Figure 5.9). To 
determine whether a single application of DMBA alone to the dorsal skin of 
3dnTx mice also had the ability to generate transferable suppressor cells, the 
spleen cells of these DMBA-treated mice were transferred to normal mice 
and no suppression was observed, thus DMBA treatment alone does not 
cause antigen-specific suppression. 
5.2.10 DMBA/TNCB treatment reduced contact sensitivity and antibody 
production in TNCB-immune 3dnTx mice 
To determine whether DMBA/TNCB treatment of 3dnTx mice could 
also suppress cell mediated and humoral immune responses of mice with 
an established immune response to TNCB, 3dnTx mice pre-immunised 
with TNCB were treated with DMBA followed by TNCB application. The 
control was acetone followed by TNCB. When the antigen TNCB was 
applied through the DMBA-treated skin of TNCB-immune 3dnTx mice 
there was a significant reduction in the level of contact sensitivity and 
antibody production to TNCB (Figure 5.10). Although this reduction was 
significant, it was not a complete reduction as both contact sensitivity and 
antibody levels to TNCB were higher than the control group (group 3), that 
had not been exposed to TNCB until they were ear challenged. 
Consequently, the application of TNCB through DMBA-treated skin causes a 
significant but not complete reduction of both cell mediated and humoral 
immunity in immune 3dnTx mice. 
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Figure 5.10 DMBA/TNCB treatment in 3dnTx mice reduces established contact 
sensitivity and antibody responses. 
TNCB-immune 3dnTx mice were sensitised by immunising 
through the skin with two separate applications (1st, 2nd) of 2% 
TNCB. These mice were then treated with acetone (group 2) or 1% 
DMBA (group 1) and five days later they were resensitised 
through the treated skin with 100111 of 2% TNCB. A further 5 days 
later contact sensitivity was assessed by ear challenge and increase 
in ear thickness was determined (left panel) and anti-TNCB 
antibody levels were assessed by indirect haemagglutination (right 
panel). Naive mice (group 1) were untreated throughout but were 
ear challenged with TNCB. Results represent the mean ± standard 
deviation from at least 6 mice. P values were determined by 
comparing group 2 and 3 using Student's unpaired t-test. 
5.2.11 Reduction of contact sensitivity and antibody production in TNCB-
immune mice following adoptive transfer of spleen cells from TNCB-
tolerant 3dnTx mice 
It was next determined if spleen cells from TNCB-tolerant mice could 
also downregulate cell mediated and humoral immune responses of TNCB-
immune mice. This was performed by transferring spleen cells from TNCB-
tolerant 3dnTx mice to TNCB-immune mice and contact sensitivity and 
antibody levels to TNCB were evaluated. As shown in Figure 5.11, the 
transfer of spleen cells from TNCB-tolerant 3dnTx mice (group 1) to TNCB-
immune mice caused a significant reduction in both contact sensitivity and 
antibody responses to TNCB. This reduction was antigen specific as spleen 
cells transferred from DNFB-tolerant 3dnTx mice (group 2) to TNCB-
immune mice did not reduce either contact sensitivity or antibody levels to 
TNCB. Consequently the transfer of spleen cells from TNCB-tolerant 3dnTx 
mice to TNCB-immune mice caused antigen specific reduction in both cell 
mediated and humoral immunity. 
5.2.12 LC density in nu/nu mice following DMBA -treatment 
As the induction of immunosuppression was observed in 3dnTx 
mice, the next logical step was to determine if the induction of 
immunosuppression could also be observed in athymic mice. For these 
experiment nu/nu BALB/c mice were used. Before examining this question, 
LC depletion following DMBA treatment was evaluated as LC depletion is 
an important indication of skin containing the ability to generate 
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Figure 5.11 Downregulation of established immune response by suppressor cells 
generated from DMBA/TNCB treated 3dnTx mice. 
Recipent TNCB-immune mice were sensitised by immunising 
through the skin with two separate applications (1st, 2nd) of 2% 
TNCB. These mice received spleen cells from donor mice treated 
either with acetone followed 5 days later by 2% TNCB (group 3 - 
control), 1% DMBA followed 5 days later by 2% TNCB (group 1 - 
TNCB tolerant), or 1% DMBA followed 5 days later by 0.5% DNFB 
(group 2 - DNFB tolerant). A further 5 days following spleen cell 
transfer contact sensitivity was assessed by ear challenge and increase 
in ear thickness was determined (left panel) and antibody levels 
were assessed by indirect haemagglutination (right panel). Results 
represent the mean ± standard deviation from at least 6 mice. P 
values were determined by comparing group 3 with group 1 and 
group 3 with group 2 using Student's unpaired t-test. 
DMBA - -I P < 0.0001 
Acetone 
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Figure 5.12 Number of LC residing in the epidermis of nu/nu 
mice five days after DMBA (test) or acetone 
treatment (control). 
Results represent the mean ± standard deviation 
from at least 6 mice. P value was determined by 
Student's unpaired t-test. 
immunosuppression. As with normal and 3dnTx mice, LC numbers were 
significant depleted in DMBA-treated nu/nu mice (Figure 5.12). 
5.2.13 Contact hypersensitivity and antibody production following 
DMBA/TNCB treatment in nu/nu mice 
When TNCB was applied through the DMBA-treated or vehicle 
treated skin of nu/nu mice there was neither a contact sensitivity nor 
antibody response (Figure 5.13). While this demonstrates that T cells have a 
critical role in the contact sensitivity response it does not provide any 
additional information on the generation of suppression. 
5.2.14 Contact hypersensitivity and antibody production of normal mice after 
transferring spleen cells from nu/nu mice following DMBA/TNCB 
A key element for the induction of tolerance in this study is the 
generation of suppressor cells. Spleen cells from nu/nu mice treated with 
DMBA or acetone followed by TNCB or DMBA alone were adoptively 
transferred to the normal naive mice. Results show that none of the three 
groups transferred tolerance indicating that thymic derived cells are 
important for the generation of antigen specific suppression (Figure 5.14). 
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Figure 5.13 Effect of DMBA/TNCB treatment on contact sensitivity 
in nu/nu mice. 
The nu/nu mice were treated with either 1% DMBA or 
acetone followed 5 days later with 2% TNCB. A further 
5 days later contact sensitivity was assessed by ear 
challenge and increase in ear thickness was determined 
(left panel) and antibody levels were assessed by 
indirect haemagglutination (right panel). Results 
represent mean ± standard deviation from at least 6 
mice. P values were determined using Student's 
unpaired t-test; 
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Figure 5.14 Adoptive transfer of immunosuppression following transfer of 
spleen cells to naive mice from nu/nu mice. 
Nu/nu mice were treated with either 1% DMBA or acetone 
followed 5 days later with 2% TNCB. Five days after transfer all 
mice (except group 1) were challenged with 2% TNCB and a 
further 5 days later contact sensitivity was assessed by ear 
challenge and increase in ear thickness was determined (left 
panel) and antibody levels were assessed by indirect 
haemagglutination (right panel). Results represent mean ± 
standard deviation from at least 6 mice. P values were 
determined by comparing group 1 with group 2 and group 1 
with group 3 using Student's unpaired t-test. 
5.3 Discussion 
When mice are treated with agents that deplete epidermal 
Langerhans cells an immunosuppressive environment is established such 
that any new antigen applied through the skin causes an antigen-specific 
immunosuppression (Halliday and Muller, 1986) that is transferable via 
spleen cells (Halliday and Muller, 1987b). In this study, we evaluated the 
capacity of 3dnTx mice to generate this form of antigen-specific suppression. 
As T cells develop into CD4+ and CD8+ T cells in the thymus, removal of 
the thymus in the neonatal period should not be expected to shift the 
balance of the T cell subpopulations which have already been exported to the 
periphery. However, it is not known whether neonatal thymectomy would 
remove the precursor T cells which mediate antigen-specific suppression. 
Further, as thymectomy 3 days after birth results in autoimmunity in more 
than half of these mice (Kojima and Prehn, 1981) and as autoimmunity can 
occur as a consequence of perturbations in maintenance of tolerance 
mechanisms the ability of 3dnTx mice to develop peripheral suppressor 
mechanisms by applying antigen through LC-depleted skin was evaluated. 
The 3dnTx mice had a reduced ability to respond to PHA, an observation 
which is consistent with that of Ward and colleagues (Ward et al., 1986). 
This is most likely a consequence of the reduced number of T cells while B 
cells remained unaltered, hence there was a relative increase in the 
proportion of B cells which would not respond effectively to PHA. The 
reduction of T cells was not due to a selective loss of a specific lymphocyte 
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population as both CD4+ and CD8+ T cells were present in the spleen at a 
normal ratio. 
In contrast to the reduced ability to respond to PHA stimulation, the 3dnTx 
mice displayed a relatively normal contact sensitivity response. This was an 
interesting observation and suggests that there exists a relatively large pool 
of precursor T cells that can respond to TNCB, which is normally coupled to 
proteins within the skin in order to be recognised. Further, PHA-
responsiveness relies on cell proliferation whereas the ability to generate a 
CHS relies not only on cell proliferation but inflammation and T cell 
infiltration, which are still functional in the 3dnTx mice. When TNCB was 
applied through DMBA-treated skin of 3dnTx mice there was a failure to 
induce humoral and cellular immunity in both the AIG÷ and AIG - groups 
of 3dnTx mice. This failure to induce immune responses was antigen 
specific as another hapten, DNFB, applied through DMBA untreated skin 
did not induce immunosuppression. However, a suprising result was TNCB 
applied through DMBA untreated skin also caused immune suppression in 
3dnTx mice. This was opposite to the results with normal mice treated with 
the same procedure and of 3dnTx mice treated with another hapten. As 
normal mice have more effective T cells available for activation than 3dnTx 
mice, normal mice can response to contact sensitisers more vigorously. 
While it has been shown that DMBA is a immunosuppressive agent 
(Thurmond et al., 1987; Thurmond et al., 1988; Ha et al., 1993) the induction 
of CHS in normal mice was not affected by DMBA treatment. In the 3dnTx 
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mice, DMBA suppressed most T cell activity thus systemic immune 
suppression appeared. As DNFB induced immunity through DMBA 
untreated skin, this may be explained by the 3dnTx mice receiving two 
strong haptens (TNCB and DNFB) together, and although T cells have been 
suppressed by DMBA, these two haptens could still revive the immune 
response. It is also possible that these two haptens stimulate different subset 
of T cell populations. Hence, DNFB may activate a T cell population that is 
not actively suppressed by DMBA. 
The present study found that antigen specific suppression was generated in 
both groups of thymectomised mice since adoptive transfer of spleen cells 
from these mice to naive mice also transferred antigen specific suppression. 
Confirmation that DMBA alone did not cause antigen specific suppression 
was obtained when transfer of spleen cells from mice treated with only 
DMBA did not transfer suppression. Thus 3dnTx mice can develop 
peripheral tolerance to the hapten TNCB and this developed regardless of 
whether the mice developed AIG. 
Reflection on the above results leads to the suggestion that induction of 
peripheral tolerance may be possible in athymic mice, as 
immunosuppression was generated in 3dnTx mice. Study on nu/nu mice 
demonstrated that suppressor cells could not be detected through DMBA 
modified skin. The most likely reason that no suppressor cells generated in 
nu/nu mice is that they lack of T cells from the beginning of their life. As 
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thymus is the place for T cell maturation and T cells are responsible for the 
generation of immunosuppression, that no suppressor cells generated in 
nu/nu mice is not surprising. 
While LC depletion was evident in the skin of nu/nu mice treated with 
DMBA, application of contact sensitiser through such skin did not induce 
comparable immune suppression. The incapability of nu/nu mice to 
generate suppressor cells may be due to the abnormal function of LC, as 
Grabbe and colleagues have demonstrated that LC of athymic nude mice 
have a deficient antigen-presenting function (Grabbe et a/.,. 1993). In the 
same study they also showed that transplantation of thymus can restore LC 
function suggesting the thymus is important for the complete function of 
LC. 
The demonstration in this chapter that the downregulation of TNCB 
established immune response can be achieved by the application of TNCB 
through DMBA modified skin. This is an important observation and 
provides support for the notion that the treatment of AIG disease could be 
achieved through a similar procedure. 
Recent investigations have provided important insights into the intriguing 
question as to why thymectomy should predispose to autoimmune gastritis. 
One proposition is that an alteration of homeostatic mechanisms will allow 
autoreactive T cells to be activated, rather than be suppressed, and that 
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autoimmmunity can be prevented following the restoration of homeostasis 
(Bonomo et al., 1995b). This is consistent with the early observations that 
the transfer of normal spleen cells to 3dnTx mice can prevent the induction 
of autoimmunity and that the population of regulatory spleen cells appeared 
to map to a T cell (Thy1.2+, Ig") population (Taguchi and Nishizuka, 1987; 
Taguchi et al., 1990). Further refinement by Sakaguchi and coworkers has 
identified a subpopulation of CD4 + T cells that regulate AIG induction 
(Sakaguchi et al., 1996). This subpopulation of CD4 + T cells is CD25+ and 
adoptive transfer of this specific population from normal adult mice to 
3dnTx mice prevents the development of AIG (Asano et al., 1996) suggesting 
that this cell population controls the function and expansion of pathogenic _ 
CD4+ T cells. It has been further proposed by Asano et al. (1996) that 
pathogenic autoimmune CD4+ T cells are produced before day 3 and that the 
immunoregulatory CD4 + CD25+ T cells are produced after day 3 following 
birth. This explains why thymectomy at day 3 allows the pathogenic, but not 
immunoregulatory T cells to develop, hence predisposing to autoimmunity. 
The actual role and function of these cells awaits further clarification. 
In contrast, the regulatory T cells involved in suppression of a contact 
sensitivity response following application of antigen through LC-depleted 
skin remain poorly defined. Our studies here suggest that within 3 days of 
birth precursor cells, that have the potential to develop into 
immunoregulatory cells against foreign antigens, such as TNCB, have 
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developed. From this information it is likely that these cells differ from the 
immunoregulatory CD4+ CD25+ T cells that control development of 
autoimmune gastritis. 	Nonetheless, preliminary results have also 
implicated a population of activated CD4+ T cells as suppressing the 
induction of contact sensitivity (Rist, personal communication, manuscript 
in preparation). This being the case, it suggests that suppression is 
analogous to the activated CD4 + CD25+ regulators in autoimmune gastritis, 
with a different timing of their thymic development. While it is unlikely 
that there is a direct link between developing autoimmune gastritis and 
developing antigen specific suppression by immunising through DMBA-
modified skin, the results from the present study indicate that peripheral 
tolerance can still be generated by the presentation of antigen by altered 
dendritic cells and as such all tolerance generating mechanisms were not 
abrogated in the 3dnTx mice that developed autoimmune gastritis. 
Moreover, despite the decline in lymphocyte numbers and the diminished 
PHA response, antigen-specific suppression was still retained. 
In summary, a reduction in LC numbers in the skin of BALB/c mice allows 
for the development of antigen specific suppression, despite removal of the 
thymus 3 days after birth. Therefore in these mice, although lymphocyte 
numbers are reduced and the lymphocytes show a diminished proliferative 
response to PHA, precursor cells that account for this type of active 
immunosuppression are retained. The retained immunosuppressive ability 
of the peripheral T cells is trasferrable and is antigen specific. This provides 
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an opportunity to develop a unique strategy for the treatment of 
autoimmune disease. 
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Chapter Six 
Treatment of Autoimmune Gastritis Through 
LC-depleted Skin 
6.1 Introduction 
Previous chapters have demonstrated that the application of a contact 
sensitiser through DMBA modified skin of either normal or thymectomised 
mice leads to the induction of antigen specific immunosuppression. Using 
this procedure both an established CHS and an antibody response were 
significantly downregulated. From these observations, and coupled to the 
fact that this suppression is long lived and systemic, it may be possible to 
regulate other immune responses by inducing tolerance through the skin. 
This is a particularly attractive proposal as it provides an opportunity to treat 
immune diseases, including autoimmunity. As antigen specific suppression 
was also observed with 3dnTx mice that were prone to autoimmune 
gastritis, the application of a defined antigen through LC-depleted skin in 
these mice could be exploited in order to downregulate autoimmune 
gastritis. 
The 3dnTx autoimmune gastritis model has been well characterised and was 
discussed in the previous chapter. The autoantigen in this model is the 
immunogenic H+/K+ ATPase (proton pump). Immunisation with W/K+ 
ATPase in Freund's complete adjuvant causes the development of AIG 
(Scarff et al., 1997). Induction of antigen specific immunosuppression is an 
immune response that also requires an immunogenic antigen to be applied 
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through LC-depleted skin. The fr/K+ ATPase antigen was an appropriate 
antigen for these studies. The Fr/IC ATPase consists of a and 13 subunits 
(Toh et al., 1990). Studies by Alderuccio et al. (1993) demonstrated that 
thymectomy-induced gastritis was prevented in transgenic mice when the 1:3 
subunit of the gastric Fr/K+ ATPase was expressed in the thymus. This 
suggested that the 13 subunit is a major autoantigen recognised by the 
pathogenic T cells. BALB/c mice which develop autoimmune gastritis 
following immunisation with murine gastric Fr/K+ ATPase react with 
1-1+/K+ ATPase in lymphocyte proliferation assays in vitro. Using a series of 
21-mer overlapping peptides, the immunogenic peptide reactive with these 
splenic T cells was identified and hereinafter will be referred to as "peptide 
19" which was located at the C-terminus of the 13 subunit of the 1-1+/K+ 
ATPase (B.H. Toh - personal communication). During the progress of this 
thesis peptide 19 became available and its soluble nature combined with an 
ability to stimulate T cells when appropriately presented, made it ideally 
suitable for use with skin applications. Although the 3dnTx mice had a 
reduced level of immunity they retained their capacity to generate a CHS 
response indicating that the skin contained functional LC and that there was 
a sufficient pool of naive T cells to be stimulated. More importantly, and by 
virtue of their ability to respond to contact sensitisers, these mice could also 
generate antigen specific suppression when treated with DMBA followed by 
the contact sensitiser. This antigen specific suppression could be adoptively 
transferred by spleen cells to normal mice, thus providing evidence that 
104 
3dnTx mice could generate antigen specific suppression. The selection of the 
3dnTx model of autoimmune gastritis was because this disease induced by 
thymectomy persists for a lifetime, can be routinely screened during 
experimental procedures without the need for a further challenge of antigen 
and it represents an alteration in immunoregulation which is likely to 
mimic the disease situation. As the immunisation model needs to be 
regularly immunised this model would not be as effective in analysing the 
down regulation experiments. 
In this chapter approaches to either down regulate autoimmune gastritis or 
to prevent development of disease were evaluated. In one series of 
experiments FIVIC ATPase or peptide 19 was applied through DMBA-treated 
skin to generate antigen specific suppression as an approach to treat 
established disease. In an alternative series of experiments, peptide 19 was 
applied through neonatal skin as an approach to prevent development of 
disease. 
6.2 Results 
6.2.1 Stomach histology in mice with AIG 
Histologically, the development of AIG in 3dnTx BALB/c mice was 
classified into three stages (Figure 6.1). Histology of normal stomach is 
shown in Figure 6.1A. In stage 1 (Figure 6.1B), mononuclear cells initially 
infiltrated along the subglandular region of the lamina propria and the 
parietal cells remain intact. In stage 2 (Figure 6.1C), these inflammatory cells 
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Figure 6.1 Histology of AIG in 3dnTx BALB/c mice. The normal 
(A), first (B) , second (C) and third (D) stage of AIG 
spontaneously developing in 3dnTx BALB/c mice. 
Arrow in panel A represents normal parietal cell. Arrow 
in panel B represents lymphocytes start to infiltrate. 
Arrow in panel C represents initial destruction of 
parietal and chief cells. Arrow in panel D represents 
parietal cells replaced by mucous neck cells. (Original 
magnification X100). 
Figure 6.2 Indirect immunofluorescence staining of the gastric mucosa 
of a normal mouse by 1:256 dilution of autoantibody from a 
3dnTx mouse in stage 3 of AIG. (Original magnification 
X100). 
expanded upwardly along the gland, coupled with the destruction of both 
parietal and chief cells. In stage 3, the gland became atrophic and was 
replaced by proliferating mucous neck cells (Figure 6.1D). In all mice 
showing histological features of AIG, autoantibodies against parietal cells 
were detected by immunofluorescence (Figure 6.2). The titres of 
autoantibodies generally correlated with the pathological changes observed 
with the different stages of AIG. The immunofluorescence titres were 
approximately 32 in stage 1, between 64 and 128 in stage 2, and 256 in the 
stage 3. However there was an occasional exception. 
6.2.2 Treatment of 3dnTx mice with established autoimmune gastritis 
Thymectomised mice with autoimmune gastritis and autoantibody 
titres 32 which were treated with DMBA followed 5 days later by Fl+/K+ 
ATPase or peptide 19 showed significantly decreased autoantibody titres 
compared to mice treated with acetone alone. This was observed at both 35 
and 50 days post treatment (Figure 6.3). However, a significantly reduced 
autoantibody titre was also observed with the group treated with DMBA 
alone. Consequently application of DMBA to the skin of 3dnTx mice with 
AIG caused a reduction in autoantibody titres. 
A summary of the histological changes following DMBA treatment is 
shown in Table 6.1. Of the 5 mice treated with DMBA followed by Fr/K+ 
ATPase (group 2), 4 mice had evidence for either stage 2 or stage 3 
pathological changes. Of the 5 mice treated with DMBA followed by peptide 
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1st 
Day 35 post treatment 
III Day 50 post treatment Group 2nd 
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H+/K+ 
ATPase P < 0.05 
iiiiaiiii_i Peptide 19 Acetone 
Peptide 19 	 N.S. 
< 0.05 
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DMBA 
P < 0.05 
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4 	16 	64 	256 	1024 
Autoantibody titres 
Figure 6.3 Autoantibody titres of AIG positive mice after treatment with 
DMBA followed by H+/K+ ATPase or peptide 19. 
The shaved dorsal trunk skin of 3dnTx mice with AIG was 
treated with either acetone followed by H+/K+ ATPase (group 1), 
DMBA followed by H+/K+ ATPase (group 2), acetone followed by 
peptide 19 (group 3), DMBA followed by peptide 19 (group 4), or 
DMBA alone (group 5). The open columns represent the 
autoantibody titres of the 3dnTx mice prior to treatment. The 
hatched columns represent autoantibody titres after 35 days since 
first treatment and the solid columns represent autoantibody 
titres tested after 50 days since first treatment. Results represent 
mean ± standard deviation from 5 mice per group. Comparisons 
were made between the different treatments at day 35 and day 50, 
group 1 was compared to group 2, group 3 was compared to group 
4, and group 5 was compared to group 1 or group 3, using 
Student's two-tailed, unpaired t-test. DMBA followed by H+/K+ 
ATPase or peptide 19 or DMBA alone appeared to reduce 
autoantibody titres. 
Treatment Pathology Autoantibody titre Number 
(Group 1; 5 mice) Normal 0 
Acetone followed 
by H+/K+ ATPase 
Stage 1 128 1 
Stage 2 128 1 
Stage 3 128 128 256 3 
(Group 2; 5 mice) Normal 0 
DMBA followed 
by H-F/K+ ATPase 
Stage 1 32 1 
Stage 2 64 64 2 
Stage 3 64 64 2 
(Group 3; 5 mice) Normal 0 
Acetone followed 
by peptide 19 
Stage 1 64 1 
Stage 2 256 256 2 
Stage 3 256 1024 2 
(Group 4; 5 mice) Normal 0 
DMBA followed 
by peptide 19 
Stage 1 32 1 
Stage 2 32 64 2 
Stage 3 64 128 2 
(Group 5; 5 mice) Normal 0 
DMBA alone Stage 1 32 1 
Stage 2 32 64 64 3 
Stage 3 64 1 
Table 6.1 Comparison of autoantibody titres and pathological changes 
of 3dnTx mice with autoimmune gastritis 50 days post 
treatment. 
19 (group 4), 4 mice had evidence for either stage 2 or stage 3 pathological 
changes. This was the same result for the DMBA alone treatment (group 5) 
and acetone followed by HVIC ATPase (group 1) or peptide 19 (group 3) 
treated group. Consequently, the evidence indicates that DMBA treatment 
may suppress autoantibody production but it does not affect lymphocyte 
infiltration towards the base of the glands and the destruction of both 
parietal and chief cells. 
6.2.3 Effect of spleen cell transfer from normal mice treated with DMBA and 
MK+ ATPase to 3dnTx mice with autoimmune gastritis 
Although DMBA followed by Fl+/K+ ATPase appeared to cause 
downregulation of autoantibody production it might still be possible that 
antigen specific suppressor cells were generated. To assess this possibility 
normal mice were treated with DMBA followed by I-1 4- /KE ATPase and the 
spleen cells were adoptively transferred to 3dnTx mice with established AIG. 
As there was no evidence for a reduction in autoantibody levels (Figure 6.4), 
it was unlikely that antigen specific suppressor cells were produced that 
could downregulate established autoimmune gastritis when the intact FIVIC 
ATPase was applied through DMBA-treated skin. Confirmation that 
adoptive spleen cell transfer did not suppress disease development can be 
seen from the histology (Table 6.2). All of the 5 mice that received spleen 
cells from donor mice treated with DMBA followed by Fr/K+ ATPase had 
evidence for stage 2 and stage 3 pathological changes. This is the same result 
for DMBA alone and acetone followed by I-r/K+ ATPase treatment. 
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El Pre treatment 
Treatment 
Donor 
(normal mice) 
Recipient 
(MG mice) 
Day 35 post treatment 
Group Treatment. 1st 	2nd 
Intravenous 
injection 
III Day 50 post treatment 
H+/K+ 
ATPase 
5 X107 
Spleen cells 
Acetone 
DMBA H+/K+ 
ATPase 
5X107 
Spleen cells N.S. 
N.S. 
N.S. 
N.S. 
	I N.S. 
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4 
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Autoantibody titres 
Figure 6.4 Autoantibody titres of AIG mice after receiving spleen cells from 
normal mice treated with DMBA followed by H+/K+ ATPase. 
Shaved dorsal trunk skin of 3dnTx mice with AIG was treated 
with either acetone followed by H+/K+ ATPase (group 1) DMBA 
followed by H+/K+ ATPase (group 2), or DMBA alone (group 3). 
The spleen cells from these were adoptively transferred to 3dnTx 
mice with AIG. The open columns represent the autoantibody 
titres of the 3dnTx mice that were selected prior to treatment. The 
hatched columns represent autoantibody titres after 35 days since 
spleen cells transfer and the solid columns represent 
autoantibody titres tested after 50 days since spleen cells transfer. 
Results represent mean ± standard deviation from 5 mice per 
group. Comparisons were made between the different treatments 
at day 35 and day 50, group 1 was compared to group 2 and to 
group 3 using Student's two-tailed, unpaired t-test. DMBA 
followed by H+/K+ ATPase or DMBA alone did not appeare to 
reduce autoantibody titres. 
5X107 
Spleen cells 
Treatment Pathology Autoantibody titre Number 
(Group 1; 5 mice) 
AIG mice received 
spleen cells from 
Acetone followed 
by H-F/K+ ATPase 
treated mice 
Normal 
Stage 1 
Stage 2 
Stage 3 
16 
64 64 512 1024 
0 
0 
1 
4 
(Group 2; 5 mice) 
AIG mice received 
spleen cells from 
DMBA followed 
by Hi-/K+ ATPase 
treated mice 
Normal 
Stage 1 
Stage 2 
Stage 3 
32 
64 
32 
64 128 
0 
0 
2 
3 
(Group 3; 5 mice) 
AIG mice received 
spleen cells from 
DMBA alone treated 
mice 
Normal 
Stage 1 
Stage 2 
Stage 3 
16 
32 
32 
256 
64 
0 
0 
3 
2 
Table 6.2 Comparison of autoantibody titres and pathological 
changes of 3dnTx mice with autoimmune gastritis 50 days 
after receiving spleen cells. 
Consequently, the evidence indicates that DMBA treatment does not induce 
suppression that can be transferred by spleen cells. 
6.2.4 Alternative strategies to deplete LC and establish an 
immunosuppressive environment 
As DMBA treatment caused non-specific suppression an alternative 
strategy was required to deplete LC without causing generalised suppression. 
The contact sensitiser TNCB was selected because at a high dose it is able to 
deplete epidermal LC in normal mice; when a second antigen is applied 
through this skin antigen specific suppression results (Woods et al., 1996). 
6.2.4.1 LC density in 3dnTx mice following TNCB-treatment 
The ability of TNCB to deplete LC from 3dnTx mice was evaluated to 
confirm that LC depletion also occurred in 3dnTx mice and that the mice did 
not suffer any stress or discomfort. Results shown in Figure 6.5 demonstrate 
that topical application of 2% TNCB caused a significant reduction in LC 
density compared to acetone treated controls. The mice did not exhibit any 
undue distress or discomfort. 
6.2.4.2 Effect of 2% TNCB followed by peptide 19 in 3dnTx mice with 
autoimmune gastritis 
Thymectomised mice with autoimmune gastritis and autoantibody 
titres 32 which were treated with 2% TNCB followed by peptide 19 did not 
demonstrate any evidence of antigen specific suppression as there was no 
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Figure 6.5 Number of LC in the epidermis five days after 
TNCB (test) or acetone treatment (control). 
Results represent the mean ± standard 
deviation from at least 6 mice. P value was 
determined by Student's unpaired t-test. 
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Figure 6.6 Autoantibody titres of AIG positive mice after treatment 
with TNCB followed by peptide 19. 
Shaved dorsal trunk skin of 3dnTx mice with AIG was 
treated with either acetone followed by peptide 19 (group 
1), TNCB followed by peptide 19 (group 2), or TNCB 
alone (group 3). The open columns represent the 
autoantibody titres of the 3dnTx mice that were selected 
prior to treatment. The hatched columns represent 
autoantibody titres after 35 days since first treatment and 
the solid columns represent autoantibody titres tested 
after 50 days since first treatment. Results represent mean 
± standard deviation from 6 mice per group. 
Comparisons were made between the different 
treatments at day 35 and day 50, group 1 was compared to 
group 2 and to group 3 using Student's two-tailed, 
unpaired t-test. TNCB followed by peptide 19 or TNCB 
alone did not reduce autoantibody titres. 
Treatment Pathology Autoantibody titre Number 
(Group 1; 6 mice) 
Normal 0 
Acetone followed 
by peptide 19 Stage 1 0 
Stage 2 128 128 2 
Stage 3 128 256 256 1024 4 
(Group 2; 6 mice) Normal 0 
TNCB followed 
by peptide 19 
Stage 1 0 
Stage 2 128 256 2 
Stage 3 256 256 512 512 2 
(Group 3; 6 mice) Normal 0 
TNCB alone Stage 1 0 
Stage 2 128 128 256 3 
Stage 3 256 512 512 3 
Table 6.3 Comparison of autoantibody titres and pathological 
changes of 3dnTx mice with autoimmune gastritis 50 days 
post treatment. 
difference in the autoantibody titres of these mice compared to both 2% 
TNCB treatment alone and acetone treatment groups (Figure 6.6). 
A summary of the histological changes following TNCB treatment is shown 
in Table 6.3. Of the 5 mice treated with TNCB followed by peptide 19, all 6 
mice had evidence for either stage 2 or stage 3 pathological changes which 
was similar to both the acetone followed by peptide 19 treated and TNCB 
alone treated groups. Consequently, the evidence indicates that TNCB 
followed by peptide 19 treatment does not cause antigen specific suppression 
of autoantibody production and has no effect on the pathological changes. 
6.2.5 Prevention of the development of autoimmune gastritis disease by 
treating 3dnTx mice at 4 days of age with peptide 19 
In an associated study undertaken in the Division of Pathology (Mary 
Power-Connon, Advanced Studies Project) it was revealed that the 
epidermis of 4 day old mice contained dendritic cells that appeared 
immature, had yet to form a network, had shortened dendrites and when a 
contact sensitiser was applied through this skin suppression, rather than 
immunity, resulted. As there was a striking resemblance between the 
epidermal Langerhans cells of the 4 day old mice and the epidermal 
Langerhans cells of adult mice following exposure to DMBA, it was 
proposed that these neonatal and immature LC would induce suppression 
in a similar manner to the LC from DMBA-treated skin. Consequently, 
experiments were initiated with the application of peptide 19 through the 
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epidermis of 3dnTx mice at day 4. As shown in Figure 6.7a, 58% mice 
thymectomised at day 3 and treated at day 4 with 101.1g of peptide 19 
dissolved in acetone developed autoantibody titres .. 32. This compared to 
46% mice treated with acetone alone. It thus appeared that application• of 
peptide 19 through neonatal skin did not prevent the development of 
autoimmune gastritis. As peptide 19 was a small self derived peptide it may 
not have provided an appropriate signal (eg. danger signal) to the epidermis 
and was therefore ignored by the immune system. In order to increase the 
signals to the immune system the next stage was to apply peptide 19 
dissolved in the contact sensitiser, TNCB. With this strategy TNCB would 
serve as an adjuvant and cause some minor skin irritation and 
inflammation. This approach provided encouraging evidence that 
autoimmune gastritis could be prevented. As shown in Figure 6.7h, 13 mice 
were thymectomised at day 3 and treated at day 4 with peptide 19 dissolved 
in TNCB and not one of these mice (0%) developed autoantibody titres 32, 
compared to the control group, treated with TNCB alone where 50% mice 
developed autoantibody titres 32. 
The histology is summarised in Table 6.4. There are two important points to 
note. Firstly, there was a consistent correlation of antibody titre with 
pathological stage. It should also be noted that thymectomy does not always 
result in AIG, consequently there are some mice in the control groups which 
failed to develop disease. These mice were not cured but simply failed to 
develop disease. Secondly, and more importantly, none of mice treated with 
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Figure 6.7a Autoantibody titres of 3dnTx mice after treatment with 
peptide 19. 
Dorsal trunk skin of 3dnTx mice was treated at day 4 
following birth with either acetone or peptide 19. In the 
acetone alone group, 45% of 3dnTx mice developed 
autoantibody titres 32. In the peptide 19 alone group, 
58% of 3dnTx mice developed autoantibody titres 32. 
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Figure 6.7b Autoantibody titres of 3dnTx mice after treatment with 
peptide 19 dissolved in TNCB. 
Dorsal trunk skin of 3dnTx mice was treated with either 
TNCB or peptide 19 dissolved in TNCB at day 4. In the 
TNCB alone treated group, 50% of 3dnTx mice 
developed autoantibody titres ?.. 32. In the TNCB + 
peptide 19 treated group, 0% of 3dnTx mice developed 
autoantibody titres ?. 32. 
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Treatment Pathology Autoantibody titre Number 
(Group 1; 11 mice) Normal 0 8 2 
Acetone alone Stage 1 0 0 0 8 4 
Stage 2 32 32 64 64 128 5 
Stage 3 
(Group 2; 12 mice) Normal 0 0 2 
Peptide 19 Stage 1 0 0 16 3 
Stage 2 32 64 128 3 
Stage 3 64 256 1024 1024 4 
(Group 3; 14 mice) Normal 0 0 2 
TNCB alone Stage 1 0 0 0 16 64 64 6 
Stage 2 0 64 64 3 
Stage 3 128 128 512 3 
(Group 4; 13 mice) Normal 0 0 0 0 0 0 6 
Peptide 19 dissolved 
in TNCB 
Stage 1 0 0 0 0 4 
Stage 2 0 16 16 3 
Stage 3 
Table 6.4 Comparison of the autoantibody titres and the stomach 
pathology of 2dnTx mice treated at day 4 with acetone (group1) 
or peptide 19 (group2), TNCB (group3),or peptide 19 dissolved in 
TNCB (group4). 
peptide 19 dissolved in TNCB developed stage 3 pathological changes and 
only 23% showed signs of stage 2 changes, which also had very low (<32) 
autoantibody titres. This compares to the acetone alone treatment group 
where 46% of the mice developed stage 2 or stage 3 changes, the peptide 19 
treatment group were 58% developed stage 2 or stage 3, and 43% TNCB 
alone treatment group developed stage 2 or stage 3 changes and all of these 
mice developed relatively high titre 32). 
Consequently, application of peptide 19 dissolved in TNCB through day 4 
neonatal skin of mice thymectomised on day 3 not only significantly 
inhibited the development of autoantibodies, but also prevented the 
infiltration of lymphocytes and prevented pathological changes. 
6.3 Discussion 
BALB/c mice thymectomised 3 days after birth are prone to 
developing autoimmune gastritis, presumably due to an alteration in the 
balance of immunoregulatory T cells (Sakaguchi et al., 1996). In this chapter, 
3dnTx mice with the symptoms of autoimmune gastritis were treated with 
DMBA to deplete the epidermal LC, followed by the gastric 1-1+/K+ ATPase 
autoantigen or the immunogenic epitope, referred to as peptide 19 to induce 
antigen specific suppression. The justification for this strategy was based on 
earlier observations that application of antigen through LC-depleted skin 
could downregulate an established CHS response (Chapter 3) and that 3dnTx 
mice retain their capacity to generate antigen specific suppression (Chapter 
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5). As an established immune response could be downregulated and as 
3dnTx mice could generate antigen specific suppression, it was reasonable to 
propose that antigen specific suppression could be generated with this 
treatment. This suppression could therefore be directed against the 
autoreactive cells responsible for causing the tissue damage which leads to 
autoimmune gastritis. 
The strategy of applying autoantigen through skin previously exposed to 
DMBA did result in a downregulation of autoantibody levels, however, this 
appeared to be primarily due to a direct effect of DMBA which caused non-
specific immune suppression. This non-specific suppression following 
exposure to DMBA had not been observed with the contact sensitivity 
experiments outlined in Chapter 3 nor had it been observed by Halliday et al. 
(1986) who performed the early work on DMBA-induced antigen specific 
suppression of contact sensitivity. In these experiments, when DMBA was 
applied through the dorsal skin and a contact sensitiser applied through the 
ventral skin, there was no evidence for a reduction in contact sensitivity, 
hence no evidence for non-specific suppression (Halliday and Muller, 1986). 
Nonetheless, there are other reports suggesting that DMBA can be 
immunosuppressive. Thurmond and colleagues showed that mice injected 
intravenously with a low dose of DMBA and then immunised with sheep 
erythrocytes failed to produce antibody forming cells in a plaque-forming 
assay (Thurmond et al., 1987). They also showed that splenic lymphocytes 
had a reduced ability to proliferate in vitro when they were cultured in the 
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presence of DMBA (Ward et al., 1984; Thurmond et al., 1988). This reduced 
proliferative ability may have been due to a suppressed production of IL-2 as 
Con A stimulated splenic lymphocytes have a reduced ability to produce IL-2 
when the cells have been exposed to DMBA (Thurmond et al., 1988). Thus it 
appears that in certain circumstances DMBA can cause non-specific 
immunosuppressive effects. 
A contact sensitivity response is an efficient cell mediated immune response 
as a low dose of contact sensitiser can induce an optimal immune response 
(Sullivan et al., 1990) and consequently the non-specific suppression caused 
by DMBA might be insufficient to overcome the strength of this response. In 
contrast, intact proteins are generally weak immunogens when applied 
through the skin and it has been reported that protein antigens often require 
the assistance of some form of adjuvant to induce an optimal immune 
response (Ada, 1993). The ability of TNCB to cause non-specific suppression 
may be observed with less effective immune responses. 
Peptides may also require the addition of cytokines or repeated applications 
to produce an effective immune response (Berzofsky and Berkower, 1993), 
therefore, induction of antigen specific suppression in this system may 
require modification such as the inclusion of adjuvant or repeated 
applications. As antibody responses appear to be sensitive to DMBA, 
evidenced by reduced plaque-forming cells (Thurmond et al., 1987), and as 
FIVIC ATPase and its peptide are self antigens and therefore unlikely to 
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elicit an efficient immune response, it is highly plausible that the 
suppression induced by DMBA at the level of antibody mediated immunity 
might be sufficient on its own to reduce the level of autoantibodies. The 
stomach pathology supports this conclusion as there was no evidence for a 
reduced lymphocyte infiltration. The encouraging aspect from this reduction 
in autoantibody titres was that autoantibody production could at least be 
downregulated. With this in mind, the next strategy to induce auto-antigen 
specific suppression required procedures that did not involve exposure to 
DMBA. 
The requirement for depleting epidermal LC without causing non-specific 
immune suppression in the 3dnTx mice, led to the concept of applying 
TNCB through the skin which not only results in LC depletion, but an 
immunosuppressive environment is established such that a second antigen 
applied through this skin results in antigen specific suppression (Woods et 
al., 1996). The approach of applying autoantigen through LC-depleted skin 
following TNCB application did overcome the problem of non-specific 
suppression, however there was still no evidence for specific suppression at 
the autoantigen level. It is possible that the amount of peptide used in this 
study was not optimal to induce tolerance. Evidence for this comes from a 
related study which suggested that a large antigen dose is required to induce 
immune tolerance when introduced intravenously (Critchfield et al., 1994). 
Another possible explanation may be that peptide 19 is not sufficiently 
immunogenic and therefore would be unable to produce a negative signal 
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when applied through LC-depleted skin. Downregulation of autoimmunity 
would not result as the strength of the suppressive signal could not compete 
effectively with the established autoimmune response. To increase the 
immunogenicity, and therefore produce a more effective 
immunosuppressive response, it may be appropriate to modify peptide 19 or 
use another peptide derived from the parent protein H+10 ATPase. This 
strategy has been successful in studies involving mice with experimental 
autoimmune encephalomyelitis (EAE). In this autoimmune disease it has 
been shown that myelin basic protein, like FIVIC ATPase in autoimmune 
gastritis, is the autoantigen target of EAE. Experimental autoimmune 
encephalomyelitis can be prevented by administering myelin basic protein 
through oral (Miller et al., 1993), nasal (Bai et al., 1997), or intravenous 
routes (Gaur et al., 1992). However, to suppress established EAE (eg. after 
clinical symptoms have developed) the normal myelin basic protein 
requires modification. Brocke and colleagues discovered that by altering 
peptides derived from myelin basic protein the symptoms of established 
EAE could be downregulated, whereas the normal peptide derived from 
myelin basic protein could not treat established EAE (Brocke et al., 1996). 
Consequently, it would appear that to treat established autoimmune disease 
a modification of the immunising autoantigen is required whereas 
prevention of disease requires the native conformation of the autoantigen. 
This does not imply that autoimmune gastritis can not be treated by 
applying autoantigen via modified dendritic cells, but it does suggest that 
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further manipulation of this system would be required to achieve optimal 
results. 
The ability to prevent development of autoimmunity has been 
demonstrated in other disease such as experimental autoimmune 
encephalomyelitis (Hauser et al., 1984; Bai et al., 1997), type 1 diabetes of non-
obese mice (Harada et al., 1990; Muir et al., 1995; Daniel and Wegmann, 
1996b), experimental arthritis (Thompson et al., 1993), and experimental 
uveitis (Sasamoto et al., 1992; Gregerson et al., 1993). Consequently it was 
reassuring that the induction of autoimmune gastritis could be prevented by 
immunising neonatal mice with peptide 19 dissolved in TNCB. The 
requirement for simultaneous administration of TNCB was a different 
approach from the earlier experiments where the aim in these experiments 
was to treat established disease. For the previous experiments, the 
application of TNCB or DMBA to the skin of adult mice with autoimmune 
gastritis was designed to cause LC depletion and the cells that were present 
in the treated area 5 days later induced antigen specific suppression. Results 
from collaborative work in the Department of Pathology revealed a 
similarity between the LC in the epidermis of adult mice treated with DMBA 
and the LC in the epidermis of neonatal mice. The similarity was that both 
populations appeared to be immature. Furthermore, application of TNCB 
through neonatal skin failed to induce immunity (Mary Power Connon and 
Kathleen Doherty, personal communication). Consequently, application of 
antigen through neonatal skin, and therefore immature LC, is more likely to 
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result in tolerance than immunity. The results from this chapter indicated 
that application of peptide 19 through neonatal skin did not prevent the 
development of autoimmune gastritis, however, when peptide 19 and 
TNCB were combined there was a remarkable reduction in both 
autoantibody production and pathological changes. The requirement for 
TNCB is unlikely to be due to the need to cause LC depletion (as in adult 
suppression experiments) but to serve as an adjuvant for the self peptide, 
peptide 19, thus making this peptide more visible to the immune system. In 
addition, inflammatory changes associated with the effect of TNCB may also 
contribute to the increased immune response. Consequently future 
strategies at either the prevention or treatment stages may benefit from the 
simultaneous administration of peptides ( either unmodified for prevention 
strategies, or modified for the treatment strategies) and some form of 
adjuvant that will allow the peptide to be recognised by the residual antigen-
presenting cells. 
The preventative immunisation strategy of peptide 19 dissolved in TNCB 
not only prevented autoantibody titres from developing, but also 
significantly reduced, and in most cases prevented, the lymphocyte 
infiltration towards the base of the glands and the destruction of both 
parietal and chief cells. As there was no lymphocyte infiltration, there was 
no damage to the stomach mucosa and therefore no opportunity for 
autoantigen to be released and therefore there was no evidence for 
autoantibodies. Consequently, the preventative phase of this approach 
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successfully targeted the disease process and therefore provides a potential 
strategy for immunological manipulation of autoimmune disease. 
) 
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Chapter Seven 
General Discussion 
Autoimmunity is one of the major medical problems in today's 
society with approximately 5% of the population suffering from some form 
of autoimmune disease (Peakman and Vergani, 1994). Most of these 
conditions are chronic (eg. diabetes, rheumatoid arthritis, and multiple 
sclerosis), and therefore in both medical and social terms, autoimmune 
disease is a high-cost disorder. To reduce the medical and social cost related 
to autoimmune disease, efficient and cost-effective treatment strategies are 
required that target the disease process and reduce the associated symptoms. 
Current methods of treating autoimmune diseases are successful in 
reducing the symptoms but are more palliative, rather than curative, as 
most treatments are aimed at non-specific reduction of the immune 
response. A more desirable way to treat autoimmune disease would be to 
target the treatment against the cause of the disease without producing 
detrimental side effects. It was the aim of this thesis to design and evaluate a 
strategy for antigen specific treatment of autoimmune disease. 
One way of achieving antigen specific immunosuppression is by 
immunising through skin that has been modified. In normal situations the 
application of a contact sensitiser through skin induces an immune 
response against the contact sensitiser (Stingl et al., 1980; Katz et al., 1985; 
Katz, 1988; Streilein and Grammer, 1989). This is primarily due to the 
Langerhans cells which transport the antigen to the local lymph nodes 
119 
where it is presented to antigen specific T cells (Silberberg and Thorbecke, 
1980). Application of a complete carcinogen such as DMBA or exposure to a 
physical carcinogen such as UVB irradiation can significantly reduce the 
density and alter the morphology of the epidermal LC population (Greene et 
al., 1979; Bergstresser et al., 1980; Kripke, 1984; Dandie et al., 1992; Muller et 
al., 1993). When a contact sensitiser is applied through this modified skin 
environment, contact sensitivity is not induced but antigen specific 
suppression results. The ability to prevent the development of an immune 
response through a modified skin environment provides an ideal 
opportunity to manipulate the immune system to induce antigen specific 
immunosuppression and avoid the induction of an inappropriate immune 
response, such as autoimmunity. 
Central to the induction of antigen specific immunosuppression is the 
depletion, and/or modification, of LC from the skin as well as exposure to 
the antigen. To utilise the skin to induce immunosuppression against 
autoimmune disease, the skin needs to be depleted of LC and autoantigen 
applied through this modified skin. For this approach to be successful, in an 
animal model of autoimmune disease, the autoantigen must be 
characterised. It would also be necessary to be able to effectively monitor 
these animals for evidence of disease by evaluating autoantibody titres and 
pathological changes. Autoimmune gastritis was selected because the animal 
model closely resembles the human disease and therefore a direct 
comparison could be made (Toh et al., 1997) and the autoantigen has also 
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been identified as the Fr/K+ ATPase (proton pump). More specifically it is 
the n-chain of the 'proton pump' that is the major target autoantigen 
(Alderuccio et al., 1997) and peptide mapping analysis has identified an 
epitope (peptide 19) which reacts with the autoreactive T cells (B-H Toh, 
personal communication). Furthermore AIG is the underlying cause of 
pernicious anaemia, a disease that affects 0.1% of the general western 
population. However, above the age of 60 it affects 1% of the population, and 
is a representative organ specific autoimmune disease (McGee et al., 1992). 
As autoimmune disease is the result of an established immune response, 
and as the previous work on skin-induced tolerance involved naive mice, 
prior to the induction of contact sensitivity, the initial experiments in this 
thesis were designed to determine if an established contact sensitivity 
response could be downregulated. In chapters 3 and 4, an established 
immune response to TNCB was shown to be effectively downregulated by 
treating skin with DMBA or UVB irradiation followed by TNCB. This 
downregulation was observed for both contact sensitivity and antibody 
production following DMBA treatment, whereas only contact sensitivity 
was downregulated following UVB irradiation. The observation that 
downregulation was not a complete suppression of immunity, may have 
been due to a number of factors. These include the possibilities that memory 
cells, or previously activated cells, are more difficult to regulate than non-
activated T cells or that an established contact sensitivity response, which is 
a potent response, would be difficult to suppress due to its intensity (Gray, 
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1992; Ahmed and Gray, 1996). Nonetheless, downregulation was observed 
and consequently a similar DMBA treatment protocol could prove to be 
effective in downregulating an autoimmune response. The next stage of the 
study was to evaluate this possibility. 
Thymectomy of BALB/c mice at day 3 following birth is a well established 
and reliable procedure for inducing AIG and therefore provides an effective 
animal model for studying an autoimmune disease (Toh et al., 1993). The 
removal of the thymus at such an early age means that the full repertoire of 
T cells would not have fully developed and the question of the ability of 
these mice to generate regulatory T cells to either prevent, or downregulate, 
an already established immune response was evaluated in chapter 5. It has 
been suggested that a population of CD4+ T cells regulates the development 
of autoreactive T cells that contribute to the prevention of AIG (Fukuma et 
al., 1988; Fowell et al., 1991; Mason, 1993; Nishio et al., 1994). The proposal is 
that a failure of these regulatory CD4+ T cells to develop allows autoreactive 
T cells to be activated, and/or expand, resulting in damage to the parietal 
cells eventually causing AIG. The CD4+ T cell population has been proposed 
to belong to a CD5high or CD45RB/C 1' T cell subset because elimination of 
either of these populations in normal mice resulted in the development of 
AIG and their reconstitution prevented autoimmune development (Powrie 
and Mason, 1990; Mason and Fowell, 1992; Fowell et al., 1995). 
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Further analysis revealed that a CD25+ subpopulation of CD4+ cells was more 
effective in regulating AIG development as adoptive transfer of these cells 
from normal mice to 3dnTx mice prevented the induction of AIG 
(Sakaguchi et al., 1995; Asano et al., 1996). Consequently it would appear that 
these regulatory CD25+ T cells, or at least their precursors, developed at, or 
after 3 days following birth, whereas the autoreactive T cells were exported 
to the periphery before day 3, thus explaining why thymectomy at this time 
predisposes to autoimmunity. This is consistent with the observation that 
the CD4+ CD25+ cell are not detected in peripheral lymphoid organs of 
normal mice within 3 days following birth (Sakaguchi et al., 1995). 
It is unlikely that these same regulatory T cells also regulate contact 
sensitivity responses as 3dnTx mice, which still produced an effective 
contact sensitivity response, could also produce regulatory T cells that 
suppressed this contact sensitivity response. Thus the precursor cells that 
can regulate a contact sensitivity response were produced within 3 days 
following birth whereas the CD4+ CD25+ regulatory cells, which regulate the 
T cells that contribute to autoimmune gastritis, were exported at, or after 3 
days following birth. It is attractive to consider that the CD25+ T cells, which 
are specific for AIG prevention, and exported from the thymus after 3 days 
following birth, contribute to 'central' tolerance. In contrast the precursor 
cells to the regulatory T cells that are induced following inappropriate 
antigen presentation when a antigen is applied through DMBA-treated skin, 
have been exported from the thymus within 3 days following birth. It is this 
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population of cells that contributes to 'peripheral' tolerance. The nature of 
these cells has yet to be determined, however, they exhibited similar 
characteristics to the regulatory T cells from normal mice as they were 
present in the spleen and adoptive transfer prevented the induction of a 
contact sensitivity response. In preliminary work it appears that these cells 
belong to a population of CD4+ T cells that express CD11b (Rist personal 
communication). As 3dnTx mice could still generate cells capable of 
preventing a contact sensitivity response, the application of autoantigen 
through DMBA-treated skin may produce a similar population of T cells 
that regulate autoreactive T cells via peripheral tolerance mechanisms. 
The experiments undertaken in chapter 6 evaluated this possibility and it 
was shown that established autoimmune gastritis was not downregulated in 
an antigen specific manner. This was different to contact sensitivity induced 
immunity where both contact sensitivity and antibody production were 
specifically downregulated by applying contact sensitiser via DMBA 
modified skin. This may be a consequence of the different mechanisms 
involved in the induction of immunity via immunisation and 
autoimmunity induced via thymectomy. Thymectomy does not expose the 
mice to new antigen but is likely to alter immunoregulatory T cell balance 
(Heath et al., 1996) whereas contact sensitisation involves the exposure to a 
foreign antigen and therefore is a reactive immune response. The concept 
proposed is that when an exogenous antigen is involved, downregulation 
can be achieved but when T cell immunoregulation is affected, an 
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established immune response is difficult to downregulate. This proposal 
gains support from studies of other autoimmune diseases such as EAE, 
which require an immunising antigen and can be downregulated once the 
disease has been established (Sun et al., 1996). Autoimmune diseases that 
occur spontaneously in genetically susceptible mice such as diabetes in NOD 
mice, have yet to be downregulated, when the disease has been established. 
An additional explanation may also relate to the nature of the antigen. In 
autoimmune gastritis, the autoantigen is continuously present whereas 
with the contact sensitivity experiment the immunising antigen was only 
present for a short term. Hence, the downregulation of an established 
immune response may be made more difficult due to the continued 
presence of antigen. It is possible that the downregulation method may be 
useful for the treatment for autoimmune disease that develops following 
exposure to autoantigen. 
Although suppression of established AIG was not achieved, this same 
autoimmune disease was successfully prevented by treating neonatal mice 
with antigen dissolved in a contact sensitiser. Two important elements lead 
to this prevention. Firstly, adjuvant assistance in the form of TNCB was 
required. Peptide 19, being a self peptide was not highly immunogenic on its 
own, therefore an adjuvant, such as contact sensitiser, which is a powerful 
antigen, could assist the skin to respond to the antigen. This approach has 
also been successful in delivering antigen through the skin when antigen 
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was combined with cholera toxin (Glenn et al., 1998). In this situation 
bovine serum albumin alone did not produce an effective immune 
response, however when cholera toxin was used as an adjuvant the 
immune response was boosted and immunity developed. The second 
element leading to successful immunisation against AIG was the nature of 
neonatal skin which was comprised of an immunosuppressive 
environment. As previously discussed it is most likely that the immature 
LC in neonatal skin are responsible for producing the immunosuppressive 
signal. Neonatal mice can accept allografts from adult mice (Jamshidi et al., 
1991) and a combined transplant of (neonatal and adult) skin can prolong 
the survival of adult skin allografts and induce long-term tolerance in 
recipients given short-term immunosuppression (Markees et al., 1989; 
Markees et al., 1992; De Fazio et al., 1992). Thus neonatal skin can provide a 
tolerising environment which, in the experiments performed in this thesis, 
appeared to generate a population of regulatory cells. These cells protected 
against AIG development when peptide 19 (antigen) and TNCB were 
simultaneously applied through the skin of mice thymectomised on day 3 
and immunised on day 4. These cells belong to a different population to the 
CD25+ T cells that regulate against autoimmune gastritis as these cells were 
not present in the 3dnTx mice (Asano et al., 1996). It would therefore appear 
that two separate populations of regulatory cells can prevent the 
development of AIG. The precursor to one population is the CD25+ 
population that did not arise until at least 3 days after birth and contributes 
to 'central' thymic derived tolerance. The precursor to the other population 
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develops within 3 days following birth and can be induced following 
exposure to antigen via modified LC. It is likely to belong to a similar 
population of regulatory cells that suppress a contact sensitivity response 
and contribute to peripheral tolerance. While this population of cells can be 
induced by immunisation, further challenges will be to adapt these cells, and 
their counterparts, to downregulate an established disease. 
Other immunological approaches to specifically target autoimmune disease 
have induced tolerance via the oral, nasal, or intravenous routes. These 
procedures have all induced a form of peripheral tolerance via various 
mechanisms. For example, the induction of Th2 (IL-4/IL-10) regulatory cells 
was achieved by oral feeding of a low dose of antigen (Weiner et al., 1994); 
deletion or anergy of both Th1 and Th2 cells has been achieved by oral 
feeding of a high dose of antigen (Weiner, 1997b); induction of regulatory 
CD4+ (Fuller et al., 1993) or CD8+ (Mukasa et al., 1994) T cells was achieved by 
intravenous injection of autoantigen or its associated antigen. Dendritic cells 
cultured in vitro and incubated with IL-10 have a greatly reduced capacity to 
stimulate CD4+ T cells (Steinbrink et al., 1997). It was proposed that these IL-
10 pulsed dendritic cells induced alloantigen-specific anergy in CD4+ T cells 
and also induced peptide-specific anergy in the influenza haemagglutinin-
specific T cell clone HA1.7 (Steinbrink et al., 1997). 
In this thesis, application of antigen through skin depleted of LC by prior 
carcinogen treatment was used to downregulate an established contact 
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sensitivity response whereas immunisation of an autoantigen peptide 
through neonatal skin could be used to prevent the spontaneous 
development of autoimmune gastritis. The combined interpretation of 
these result provides evidence that modified Langerhans cells, (or modified 
dendritic cells), produce signals that can alter the outcome of an immune 
response such that potentially damaging responses can be avoided. 
Although the risk of cancer development limits the use of carcinogen the 
information gained from this thesis provides potential as it is not the 
carcinogen that is necessary but the depletion of LC which can occur by other 
treatments (eg. by TNCB) (Woods et al., 1996) that results in the generation 
of antigen specific suppression. The results outlined in the previous 
paragraph indicate that immunisation through oral, nasal, or intravenous 
routes protect against damaging immunity and it is most likely a 
consequence of the interaction of the dendritic cell populations found in 
these areas. Consequently the results are more compelling that modified 
dendritic cells can be used to alter the direction of an immune response, and 
the appropriate use of such knowledge could provide therapeutic strategies. 
In summary, the insight gained from this thesis provides encouraging 
evidence that detrimental immune responses, as well as established 
immunity, can be manipulated in an antigen specific manner. This implies 
that immunotherapy protocols targeted at specific antigens could provide 
potential therapeutic strategies. The future challenges will be to determine 
the most appropriate antigens, (or preferably peptides), the best 
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immunisation routes and the nature of modified dendritic cells that 
establish the immunosuppressive response. 
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